# Basic Survey (Radiation Dose Estimates) 

Reported on 30 November 2015

## 1. Response Rates and Radiation Dose Estimates

### 1.1 Response Rates of Residents

The overall effective response rate to the Basic Survey (radiation dose estimates), for the entire population of Fukushima Prefecture, was $27.3 \%$ ( 561,966 of $2,055,328$ ) as of 30 September 2015. Response rate for the simplified questionnaire was $3.4 \%$ ( 69,100 of $2,055,328$ ). (See Table 1.)
Thanks to instructions for filling out the survey form at thyroid ultrasound examination venues and venues for check-ups and health exams organized by municipalities, we continue to receive responses from participants.

| Table 1 R | Response rates to the Basic Survey |  |  |
| :---: | :---: | :---: | :---: |
| Survey | population | 2,055,328 |  |
| Responses | Original questionnaire | 492,866 | 24.0\% |
|  | Simplified questionnaire* | 69,100 | 3.4\% |
|  | Total | 561,966 | 27.3\% |

*Preliminary figures
Fractions have been rounded.

* Tables 2 and 3 show the results of the original and simplified questionnaires combined.


### 1.2 Radiation Dose Estimates

Doses have been estimated for 544,714 of 561,966 respondents ( $96.9 \%$ ) as of 30 September 2015, and results have been returned to 542,463 respondents. (See Table 2.)

| Table 2 | Response rates to the Basic Survey |  |  |  |  | As of 30 September 2015 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Area (preceding and full-scale surveys) | Survey population | Responses <br> b | Response rate $\mathrm{c}=\mathrm{b} / \mathrm{a}$ | Completed dose estimates d | Proportion $\mathrm{e}=\mathrm{d} / \mathrm{b}$ | Returned results <br> f | Proportion $g=f / b$ |
| Kempoku | 504,042 | 151,182 | 30.0\% | 148,028 | 97.9\% | 147,645 | 97.7\% |
| Kenchu | 557,238 | 135,488 | 24.3\% | 131,494 | 97.1\% | 130,590 | 96.4\% |
| Kennan | 152,225 | 34,528 | 22.7\% | 33,177 | 96.1\% | 33,005 | 95.6\% |
| Aizu | 267,203 | 56,731 | 21.2\% | 54,066 | 95.3\% | 53,780 | 94.8\% |
| Minami-aizu | 30,789 | 6,321 | 20.5\% | 5,951 | 94.1\% | 5,893 | 93.2\% |
| Soso | 195,605 | 89,887 | 46.0\% | 86,768 | 96.5\% | 86,430 | 96.2\% |
| Iwaki | 348,226 | 87,829 | 25.2\% | 85,230 | 97.0\% | 85,120 | 96.9\% |
| Total | 2,055,328 | 561,966 | 27.3\% | 544,714 | 96.9\% | 542,463 | 96.5\% |

[^0]We have been estimating doses for non-residents who were visiting or staying in Fukushima Prefecture at the time of the accident. (See Table 3.)

| Table 3 | Response rates to the Basic Survey |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | (Visitors) |  |  |  | As of 30 September 2015 |  |
| Number of requests | Responses | Response rate | Completed dose estimates | Proportion | Returned results | Proportion |
| a | b | $\mathrm{c}=\mathrm{b} / \mathrm{a}$ | d | $\mathrm{e}=\mathrm{d} / \mathrm{b}$ | f | $g=f / b$ |
| 3,936 | 2,185 | 55.5\% | 1,941 | 88.8\% | 1,935 | 88.6\% |

* Table 2, 3, and Appendix 1 include the data in the estimation period less than four months.


## 2. Results of Radiation Dose Estimates

Table 4 shows a breakdown of completed dose estimates (from Table 2), excluding cases of data covering less than four months ${ }^{1}$.

Radiation doses for a total of 466,102 residents have been estimated to date. The results for 457,031 respondents (excluding radiation workers) suggest that the doses for about $87 \%$ of the respondents in Kempoku area and about $92 \%$ in Kenchu area were $<2 \mathrm{mSv}$. The doses for approximately $88 \%$ of the respondents in Kennan area and more than $99 \%$ of those in Aizu and Minami-aizu areas were $<1 \mathrm{mSv}$. Doses for about $77 \%$ of respondents in the Soso area and more than $99 \%$ of respondents in Iwaki were also <1 mSv.

1) There was a change in tallying procedures. Previously, when we returned the results to participants, estimated dose had been rounded (values less than 10 mSv were rounded to the nearest tenth, and radiation doses of 10 mSv or more were rounded to the nearest one) and then tallied. However, the values before rounding were used in some of the preceding surveys. This time, we standardized the method by using the values after rounding. There was no change in the results sent to the participants.


## 3. Evaluation of the results

The latest effective radiation dose estimates showed similar trends to those observed so far.
Since previous epidemiological studies ${ }^{1}$ indicate no significant health effects at doses $\leq 100 \mathrm{mSv}$, we concluded that radiation doses estimated so far are unlikely to cause adverse effects on health, although this conclusion is based on external radiation doses estimated only for the first four months following the accident.

## References

1) Sources and effects of ionizing radiation, United Nations Scientific Committee on the Effects of Atomic Radiation, UNSCEAR 2008 Report to the General Assembly, with scientific annexes.


## 4. Survey on the representativeness of dose distribution shown in the Basic Survey (Interim Report)

In order to investigate whether people who have responded to the Basic Survey represent the whole population in regard to external dose estimates and dose distribution, we have been conducting a survey. This report presents progress and results gathered so far.

### 4.1 Progress Report

Listed below are the projects that we have been working on. Some of them were completed as of 30 September 2015 (4.1-1 and 4.1-3).
4.1-1

In order to find out if what has already been reported is an accurate and unbiased assessment of dose distribution for the whole population of Fukushima Prefecture, we visit randomly selected nonrespondents and encourage their cooperation.
4.1-2

We compare by region the dose distribution of the respondents from the door-to-door survey and those who responded previously by mail. In the Soso area, where the residents experienced a wide range of exposure levels, more samples are selected.
4.1-3

By visiting the nonrespondents, we ask them why they did not answer the questionnaire.

### 4.2 Results

4.2-1 Results of the door-to-door survey

There were 2,645 people to be interviewed in this survey, and 990 of them responded (four of them responded spontaneously). The number of respondents by region was: Kempoku (177), Kenchu (227), Kennan (71), Aizu (34), Minami-aizu (49), Soso (407) and Iwaki (25).

We found that the number of responses was enough to compare the dose distribution. We are estimating the doses for all respondents to make comparisons.

A more detailed breakdown of the response (e.g. responded, denied, or could not be visited) can be found in a chart shown on the next page.

## 4.2-2 Reasons for not having answered the questionnaire

We used multiple choice questions and asked the participants why they did not answer the questionnaire previously.
The most common reasons gathered were "I put off responding because it seemed time consuming," followed by "I could not remember enough to fill out the questionnaire," and then "I felt I needed someone to help filling out the survey form."

## 4.2-3 Details of the results

## a. Results of the door-to-door survey

The table below describes the results of 2,645 participants.

| Results | Number | (\%) |
| :--- | ---: | ---: |
| Responded | 990 | 37 |
| Contacted, but no response <br> was received | 327 | 12 |
| Could not be contacted | 664 | 25 |
| Could not be visited | 212 | 8 |
| Denied | 452 | 17 |
| Total | 2,645 | 100 |



Description of the results

- Contacted, but no response was received:

We handed out questionnaires and asked the participants or their family to cooperate, but did not get their responses.

- Could not be contacted:

We visited the participants twice and left a notice but could not contact them.

- Could not be visited:

We visited the participants to find out that they had moved to a different place.

## b. Reasons for not answering the questionnaire

Respondents were allowed to select multiple answers from the list of choices below when asked why they did not answer the questionnaire previously.
A total of 1,094 responses were gathered and tallied.

|  | Choice |
| :--- | ---: |
| A. I could not remember enough to fill out the questionnaire. | 393 |
| B. I did not understand the purpose of the survey. | 161 |
| C. I did not want to remember the disaster. | 77 |
| D. I put off responding because it seemed time consuming. | 594 |
| E. I felt I needed someone to help filling out the survey form. | 217 |
| F.Judging by the previous results, it seemed unnecessary to <br> know a radiation dose. | 191 |
| G. Other | 104 |



Response rates to the Basic Survey by district
Preceding and full-scale surveys
As of 30 September 2015

| Preceding and full-scale surveys |  |  |  |  |  | As of 30 September 2015 |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Area | District | Survey population | Responses b | Response rate $\mathrm{c}=\mathrm{b} / \mathrm{a}$ | Completed dose estimates | Proportion $\mathrm{e}=\mathrm{d} / \mathrm{b}$ | Returned results | Proportion $g=f / b$ |
| Kempoku | Fukushima | 295,645 | 93,516 | 31.6\% | 91,882 | 98.3\% | 91,749 | 98.1\% |
|  | Nihonmatsu | 60,857 | 16,550 | 27.2\% | 16,157 | 97.6\% | 16,128 | 97.5\% |
|  | Date | 67,577 | 18,226 | 27.0\% | 17,749 | 97.4\% | 17,702 | 97.1\% |
|  | Motomiya | 31,762 | 8,932 | 28.1\% | 8,703 | 97.4\% | 8,569 | 95.9\% |
|  | Kori | 13,207 | 3,879 | 29.4\% | 3,769 | 97.2\% | 3,769 | 97.2\% |
|  | Kunimi | 10,316 | 3,023 | 29.3\% | 2,935 | 97.1\% | 2,934 | 97.1\% |
|  | Kawamata | 15,885 | 5,145 | 32.4\% | 4,966 | 96.5\% | 4,927 | 95.8\% |
|  | Otama | 8,793 | 1,911 | 21.7\% | 1,867 | 97.7\% | 1,867 | 97.7\% |
|  | Subtotal | 504,042 | 151,182 | 30.0\% | 148,028 | 97.9\% | 147,645 | 97.7\% |
| Kenchu | Koriyama | 339,720 | 86,361 | 25.4\% | 84,413 | 97.7\% | 83,700 | 96.9\% |
|  | Sukagawa | 80,163 | 17,072 | 21.3\% | 16,291 | 95.4\% | 16,249 | 95.2\% |
|  | Tamura | 41,723 | 10,485 | 25.1\% | 9,803 | 93.5\% | 9,712 | 92.6\% |
|  | Kagamiishi | 13,109 | 2,881 | 22.0\% | 2,793 | 96.9\% | 2,791 | 96.9\% |
|  | Tenei | 6,470 | 1,225 | 18.9\% | 1,180 | 96.3\% | 1,175 | 95.9\% |
|  | Ishikawa | 17,487 | 4,167 | 23.8\% | 4,065 | 97.6\% | 4,064 | 97.5\% |
|  | Tamakawa | 7,337 | 1,474 | 20.1\% | 1,425 | 96.7\% | 1,420 | 96.3\% |
|  | Hirata | 7,053 | 1,646 | 23.3\% | 1,588 | 96.5\% | 1,577 | 95.8\% |
|  | Asakawa | 7,163 | 1,479 | 20.6\% | 1,443 | 97.6\% | 1,443 | 97.6\% |
|  | Furudono | 6,319 | 1,296 | 20.5\% | 1,261 | 97.3\% | 1,261 | 97.3\% |
|  | Miharu | 18,993 | 4,855 | 25.6\% | 4,748 | 97.8\% | 4,718 | 97.2\% |
|  | Ono | 11,701 | 2,547 | 21.8\% | 2,484 | 97.5\% | 2,480 | 97.4\% |
|  | Subtotal | 557,238 | 135,488 | 24.3\% | 131,494 | 97.1\% | 130,590 | 96.4\% |
| Kennan | Shirakawa | 65,428 | 15,767 | 24.1\% | 14,918 | 94.6\% | 14,780 | 93.7\% |
|  | Nishigo | 20,088 | 4,945 | 24.6\% | 4,821 | 97.5\% | 4,813 | 97.3\% |
|  | Izumizaki | 6,931 | 1,370 | 19.8\% | 1,329 | 97.0\% | 1,317 | 96.1\% |
|  | Nakajima | 5,306 | 965 | 18.2\% | 939 | 97.3\% | 939 | 97.3\% |
|  | Yabuki | 18,341 | 4,024 | 21.9\% | 3,920 | 97.4\% | 3,919 | 97.4\% |
|  | Tanagura | 15,384 | 2,961 | 19.2\% | 2,884 | 97.4\% | 2,873 | 97.0\% |
|  | Yamatsuri | 6,489 | 1,436 | 22.1\% | 1,386 | 96.5\% | 1,386 | 96.5\% |
|  | Hanawa | 10,062 | 2,261 | 22.5\% | 2,209 | 97.7\% | 2,209 | 97.7\% |
|  | Samegawa | 4,196 | 799 | 19.0\% | 771 | 96.5\% | 769 | 96.2\% |
|  | Subtotal | 152,225 | 34,528 | 22.7\% | 33,177 | 96.1\% | 33,005 | 95.6\% |
| Aizu | Aizuwakamatsu | 127,815 | 29,175 | 22.8\% | 28,169 | 96.6\% | 28,007 | 96.0\% |
|  | Kitakata | 53,202 | 10,536 | 19.8\% | 9,766 | 92.7\% | 9,724 | 92.3\% |
|  | Kitashiobara | 3,276 | 597 | 18.2\% | 572 | 95.8\% | 572 | 95.8\% |
|  | Nishiaizu | 7,725 | 1,437 | 18.6\% | 1,335 | 92.9\% | 1,332 | 92.7\% |
|  | Bandai | 3,888 | 791 | 20.3\% | 738 | 93.3\% | 733 | 92.7\% |
|  | Inawashiro | 16,271 | 3,639 | 22.4\% | 3,471 | 95.4\% | 3,465 | 95.2\% |
|  | Aizubange | 17,881 | 3,235 | 18.1\% | 3,090 | 95.5\% | 3,064 | 94.7\% |
|  | Yugawa | 3,513 | 708 | 20.2\% | 673 | 95.1\% | 672 | 94.9\% |
|  | Yanaizu | 4,077 | 716 | 17.6\% | 681 | 95.1\% | 679 | 94.8\% |
|  | Mishima | 2,031 | 373 | 18.4\% | 338 | 90.6\% | 338 | 90.6\% |
|  | Kaneyama | 2,544 | 629 | 24.7\% | 568 | 90.3\% | 563 | 89.5\% |
|  | Showa | 1,569 | 344 | 21.9\% | 317 | 92.2\% | 317 | 92.2\% |
|  | Aizumisato | 23,411 | 4,551 | 19.4\% | 4,348 | 95.5\% | 4,314 | 94.8\% |
|  | Subtotal | 267,203 | 56,731 | 21.2\% | 54,066 | 95.3\% | 53,780 | 94.8\% |
| Minami-aizu | Shimogo | 6,650 | 1,242 | 18.7\% | 1,162 | 93.6\% | 1,162 | 93.6\% |
|  | Hinoemata | 614 | 142 | 23.1\% | 133 | 93.7\% | 133 | 93.7\% |
|  | Tadami | 5,030 | 1,139 | 22.6\% | 1,063 | 93.3\% | 1,032 | 90.6\% |
|  | Minami-aizu | 18,495 | 3,798 | 20.5\% | 3,593 | 94.6\% | 3,566 | 93.9\% |
|  | Subtotal | 30,789 | 6,321 | 20.5\% | 5,951 | 94.1\% | 5,893 | 93.2\% |
| Soso | Soma | 37,371 | 13,251 | 35.5\% | 12,580 | 94.9\% | 12,511 | 94.4\% |
|  | Minami-soma | 70,013 | 30,147 | 43.1\% | 29,246 | 97.0\% | 29,119 | 96.6\% |
|  | Hirono | 5,165 | 2,215 | 42.9\% | 2,128 | 96.1\% | 2,119 | 95.7\% |
|  | Naraha | 7,963 | 4,177 | 52.5\% | 3,995 | 95.6\% | 3,979 | 95.3\% |
|  | Tomioka | 15,751 | 8,614 | 54.7\% | 8,385 | 97.3\% | 8,363 | 97.1\% |
|  | Kawauchi | 2,996 | 1,538 | 51.3\% | 1,483 | 96.4\% | 1,476 | 96.0\% |
|  | Okuma | 11,474 | 6,069 | 52.9\% | 5,820 | 95.9\% | 5,801 | 95.6\% |
|  | Futaba | 7,051 | 3,944 | 55.9\% | 3,827 | 97.0\% | 3,819 | 96.8\% |
|  | Namie | 21,335 | 12,962 | 60.8\% | 12,644 | 97.5\% | 12,612 | 97.3\% |
|  | Katsurao | 1,541 | 823 | 53.4\% | 759 | 92.2\% | 756 | 91.9\% |
|  | Shinchi | 8,357 | 2,704 | 32.4\% | 2,573 | 95.2\% | 2,568 | 95.0\% |
|  | litate | 6,588 | 3,443 | 52.3\% | 3,328 | 96.7\% | 3,307 | 96.0\% |
|  | Subtotal | 195,605 | 89,887 | 46.0\% | 86,768 | 96.5\% | 86,430 | 96.2\% |
| Iwaki | Iwaki | 348,226 | 87,829 | 25.2\% | 85,230 | 97.0\% | 85,120 | 96.9\% |
| Total |  | 2,055,328 | 561,966 | 27.3\% | 544,714 | 96.9\% | 542,463 | 96.5\% |

Estimated external radiation doses in the first four months (from 11 March through 11 July)
Preceding survey and full-scale survey
As of 30 September 2015

## Estimated external radiation doses by region

| $\begin{aligned} & \text { Effective } \\ & \text { Dose } \\ & \text { (mSv) } \end{aligned}$ | Total | Excluding radiation workers | By region |  |  |  |  |  |  | Proportion (\%) excluding radiation workers |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Kempoku | Kenchu | Kennan | Aizu | Minami-aizu | Soso | Iwaki |  |  |  |
| <1 | 288,927 | 283,286 | 24,824 | 56,998 | 24,988 | 44,231 | 4,828 | 55,312 | 72,105 | 62.0 | 93.8 | 99.8 |
| 1-2 | 147,773 | 145,455 | 82,919 | 45,645 | 3,346 | 298 | 34 | 12,586 | 627 | 31.8 |  |  |
| 2-3 | 25,705 | 25,334 | 15,460 | 8,116 | 17 | 25 | 0 | 1,686 | 30 | 5.5 | 5.9 |  |
| 3-4 | 1,571 | 1,491 | 468 | 423 | 0 | 1 | 0 | 595 | 4 | 0.3 |  |  |
| 4-5 | 547 | 502 | 40 | 5 | 0 | 0 | 0 | 456 | 1 | 0.1 | 0.2 |  |
| 5-6 | 441 | 389 | 19 | 3 | 0 | 0 | 0 | 366 | 1 | 0.1 |  | 0.2 |
| 6-7 | 268 | 230 | 10 | 1 | 0 | 1 | 0 | 218 | 0 | 0.1 | 0.1 |  |
| 7-8 | 152 | 114 | 1 | 0 | 0 | 0 | 0 | 113 | 0 | 0.0 |  |  |
| 8-9 | 118 | 78 | 1 | 0 | 0 | 0 | 0 | 77 | 0 | 0.0 | 0.0 |  |
| 9-10 | 72 | 41 | 0 | 0 | 0 | 0 | 0 | 41 | 0 | 0.0 |  |  |
| 10-11 | 69 | 36 | 0 | 0 | 0 | 0 | 0 | 36 | 0 | 0.0 | 0.0 | 0.0 |
| 11-12 | 52 | 30 | 1 | 0 | 0 | 0 | 0 | 29 | 0 | 0.0 |  |  |
| 12-13 | 37 | 13 | 0 | 0 | 0 | 0 | 0 | 13 | 0 | 0.0 | 0.0 |  |
| 13-14 | 34 | 12 | 0 | 0 | 0 | 0 | 0 | 12 | 0 | 0.0 |  |  |
| 14-15 | 27 | 6 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0.0 | 0.0 |  |
| $\geq 15$ | 309 | 14 | 0 | 0 | 0 | 0 | 0 | 14 | 0 | 0.0 | 0.0 | 0.0 |
| Total | 466,102 | 457,031 | 123,743 | 111,191 | 28,351 | 44,556 | 4,862 | 71,560 | 72,768 | 100.0 | 100.0 | 100.0 |
| Max | 66 | 25 | 11 | 6.3 | 2.6 | 6.0 | 1.9 | 25 | 5.9 |  |  |  |
| Mean value | 0.9 | 0.8 | 1.4 | 1.0 | 0.6 | 0.2 | 0.1 | 0.8 | 0.3 |  |  |  |
| Median | 0.6 | 0.6 | 1.4 | 0.9 | 0.5 | 0.2 | 0.1 | 0.5 | 0.3 |  |  |  |

Percentages have been rounded and may not total to $100 \%$.


## Estimated external radiation dose by age group (excluding radiation workers)

| $\begin{aligned} & \text { Effective } \\ & \text { Dose } \\ & (\mathrm{mSv}) \end{aligned}$ | Age at the time of the disaster |  |  |  |  |  |  |  |  | Total |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 0-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60-69 | 70-79 | 80 |  |
| <1 | 47,355 | 43,612 | 20,848 | 33,471 | 28,097 | 32,250 | 35,376 | 25,236 | 17,041 | 283,286 |
| 1-2 | 22,815 | 21,466 | 9,994 | 18,098 | 16,486 | 18,363 | 19,172 | 12,149 | 6,912 | 145,455 |
| 2-3 | 6,385 | 4,218 | 1,123 | 2,320 | 2,207 | 2,930 | 3,349 | 1,964 | 838 | 25,334 |
| 3-4 | 249 | 157 | 82 | 158 | 153 | 229 | 231 | 163 | 69 | 1,491 |
| 4-5 | 19 | 47 | 35 | 39 | 75 | 95 | 79 | 75 | 38 | 502 |
| 5-6 | 14 | 13 | 29 | 34 | 46 | 86 | 73 | 66 | 28 | 389 |
| 6-7 | 3 | 6 | 10 | 22 | 24 | 45 | 52 | 47 | 21 | 230 |
| 7-8 | 4 | 4 | 8 | 8 | 13 | 35 | 21 | 14 | 7 | 114 |
| 8-9 | 2 | 6 | 2 | 7 | 8 | 16 | 16 | 12 | 9 | 78 |
| 9-10 | 0 | 1 | 2 | 3 | 3 | 12 | 11 | 5 | 4 | 41 |
| 10-11 | 1 | 1 | 1 | 2 | 6 | 11 | 5 | 6 | 3 | 36 |
| 11-12 | 0 | 0 | 1 | 3 | 0 | 5 | 8 | 11 | 2 | 30 |
| 12-13 | 0 | 0 | 0 | 0 | 1 | 6 | 4 | 1 | 1 | 13 |
| 13-14 | 0 | 0 | 1 | 1 | 1 | 4 | 3 | 2 | 0 | 12 |
| 14-15 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 0 | 0 | 6 |
| $\geq 15$ | 0 | 0 | 0 | 0 | 3 | 3 | 5 | 1 | 2 | 14 |
| Total | 76,847 | 69,531 | 32,136 | 54,166 | 47,123 | 54,093 | 58,408 | 39,752 | 24,975 | 457,031 |

Estimated external radiation doses by sex (excluding radiation workers)

| $\begin{aligned} & \text { Effective } \\ & \text { Dose } \\ & (\mathrm{mSv}) \end{aligned}$ | By sex |  |  |  | Total | Proportion <br> (\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Male | Proportion (\%) | Female | Proportion (\%) |  |  |
| <1 | 126,705 | 60.4 | 156,581 | 63.3 | 283,286 | 62.0 |
| 1-2 | 67,458 | 32.2 | 77,997 | 31.5 | 145,455 | 31.8 |
| 2-3 | 13,765 | 6.6 | 11,569 | 4.7 | 25,334 | 5.5 |
| 3-4 | 950 | 0.5 | 541 | 0.2 | 1,491 | 0.3 |
| 4-5 | 281 | 0.1 | 221 | 0.1 | 502 | 0.1 |
| 5-6 | 199 | 0.1 | 190 | 0.1 | 389 | 0.1 |
| 6-7 | 130 | 0.1 | 100 | 0.0 | 230 | 0.1 |
| 7-8 | 62 | 0.0 | 52 | 0.0 | 114 | 0.0 |
| 8-9 | 49 | 0.0 | 29 | 0.0 | 78 | 0.0 |
| 9-10 | 24 | 0.0 | 17 | 0.0 | 41 | 0.0 |
| 10-11 | 22 | 0.0 | 14 | 0.0 | 36 | 0.0 |
| 11-12 | 16 | 0.0 | 14 | 0.0 | 30 | 0.0 |
| 12-13 | 6 | 0.0 | 7 | 0.0 | 13 | 0.0 |
| 13-14 | 8 | 0.0 | 4 | 0.0 | 12 | 0.0 |
| 14-15 | 3 | 0.0 | 3 | 0.0 | 6 | 0.0 |
| $\geq 15$ | 11 | 0.0 | 3 | 0.0 | 14 | 0.0 |
| Total | 209,689 | 100.0 | 247,342 | 100.0 | 457,031 | 100.0 |

Percentages have been rounded and may not total to $100 \%$.

Estimated external radiation doses by region in the first four months (from 11 March through 11 July) excluding radiation workers

| Area/region |  | Effective Doses ( msv ) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Total |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | <1 | 1-2 | 2-3 | 3-4 | 4-5 | 5-6 | 6-7 | 7-8 | 8-9 | 9-10 | 10-11 | 11-12 | 12-13 | 13-14 | 14-15 | $\geq 15$ |  |
| Kempoku | Fukushima | 16,113 | 52,262 | 9,288 | 151 | 13 | 10 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 77,841 |
|  | Nihonmatsu | 1,310 | 8,374 | 3,444 | 88 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13,217 |
|  | Date | 4,371 | 9,029 | 1,130 | 147 | 8 | 2 | 3 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14,692 |
|  | Motomiya | 734 | 5,301 | 1,202 | 22 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7,260 |
|  | Kori | 315 | 2,747 | 66 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3,131 |
|  | Kunimi | 963 | 1,435 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,410 |
|  | Kawamata | 628 | 2,718 | 185 | 56 | 17 | 6 | 3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 3,614 |
|  | Otama | 390 | 1,053 | 133 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,578 |
| Kempoku Subtotal |  | 24,824 | 82,919 | 15,460 | 468 | 40 | 19 | 10 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 123,743 |
| Kenchu | Koriyama | 23,719 | 40,220 | 7,681 | 413 | 5 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 72,042 |
|  | Sukagawa | 10,421 | 3,107 | 326 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13,858 |
|  | Tamura | 7,306 | 670 | 23 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8,002 |
|  | Kagamiishi | 2,307 | 73 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,380 |
|  | Tenei | 384 | 568 | 55 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,008 |
|  | Ishikawa | 3,131 | 38 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3,170 |
|  | Tamakawa | 1,150 | 17 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,170 |
|  | Hirata | 1,281 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,315 |
|  | Asakawa | 1,182 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,197 |
|  | Furudono | 1,046 | 14 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,062 |
|  | Miharu | 3,106 | 806 | 23 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3,937 |
|  | Ono | 1,965 | 83 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,050 |
| Kenchu Subtotal |  | 56,998 | 45,645 | 8,116 | 423 | 5 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 111,191 |
| Kennan | Shirakawa | 11,632 | 1,212 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12,853 |
|  | Nishigo | 2,202 | 1,955 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4,159 |
|  | Izumizaki | 1,091 | 21 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,113 |
|  | Nakajima | 787 | 11 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 799 |
|  | Yabuki | 3,286 | 78 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3,365 |
|  | Tanagura | 2,448 | 28 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,479 |
|  | Yamatsuri | 1,110 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,119 |
|  | Hanawa | 1,802 | 22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,824 |
|  | Samegawa | 630 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 640 |
| Kennan Subtotal |  | 24,988 | 3,346 | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 28,351 |
| Aizu | Aizuwakamatsu | 23,197 | 155 | 13 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23,366 |
|  | Kitakata | 8,044 | 54 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8,102 |
|  | Kitashiobara | 463 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 467 |
|  | Nishiaizu | 997 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 999 |
|  | Bandai | 623 | 9 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 633 |
|  | Inawashiro | 2,801 | 29 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,833 |
|  | Aizubange | 2,587 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,602 |
|  | Yugawa | 573 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 577 |
|  | Yanaizu | 538 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 542 |
|  | Mishima | 245 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 245 |
|  | Kaneyama | 400 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 403 |
|  | Showa | 235 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 236 |
|  | Aizumisato | 3,528 | 20 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3,551 |
| Aizu Subtotal |  | 44,231 | 298 | 25 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 44,556 |
| Minami-aizu | Shimogo | 933 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 938 |
|  | Hinoemata | 103 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 103 |
|  | Tadami | 858 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 862 |
|  | Minami-aizu | 2,934 | 25 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,959 |
| Minami-aizu Subtotal |  | 4,828 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4,862 |
| Soso | Soma | 9,828 | 447 | 87 | 20 | 5 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 10,389 |
|  | Minami-soma | 18,960 | 6,163 | 511 | 99 | 35 | 3 | 7 | 4 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 25,784 |
|  | Hirono | 1,828 | 56 | 2 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,888 |
|  | Naraha | 3,371 | 129 | 13 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3,517 |
|  | Tomioka | 5,808 | 1,099 | 98 | 18 | 3 | 2 | 0 | 3 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 7,034 |
|  | Kawauchi | 961 | 349 | 16 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,330 |
|  | Okuma | 3,348 | 1,272 | 112 | 17 | 6 | 4 | 4 | 3 | 0 | 2 | 2 | 1 | 0 | 4 | 0 | 1 | 4,776 |
|  | Futaba | 2,660 | 464 | 77 | 18 | 6 | 4 | 3 | 6 | 2 | 1 | 0 | 2 | 0 | 0 | 0 | 2 | 3,245 |
|  | Namie | 5,723 | 2,110 | 383 | 68 | 39 | 17 | 12 | 13 | 9 | 6 | 11 | 7 | 5 | 4 | 3 | 7 | 8,417 |
|  | Katsurao | 497 | 161 | 24 | 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 687 |
|  | Shinchi | 2,142 | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,162 |
|  | litate | 186 | 316 | 363 | 348 | 362 | 333 | 189 | 83 | 62 | 30 | 23 | 17 | 8 | 4 | 3 | 4 | 2,331 |
| Soso Subtotal |  | 55,312 | 12,586 | 1,686 | 595 | 456 | 366 | 218 | 113 | 77 | 41 | 36 | 29 | 13 | 12 | 6 | 14 | 71,560 |
| Iwaki | Iwaki | 72,105 | 627 | 30 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 72,768 |
| Total |  | 283,286 | 145,455 | 25,334 | 1,491 | 502 | 389 | 230 | 114 | 78 | 41 | 36 | 30 | 13 | 12 | 6 | 14 | 457,031 |
|  |  | 62.0 | 31.8 | 5.5 | 0.3 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 99.9 |
| Proportion (\%) |  | 93.8 |  | 5.9 |  | 0.2 |  | 0.1 |  | $0.0$ |  | 0.0 |  | 0.0 |  | 0.0 |  | 100.0 |
|  |  | 99.8 |  |  |  |  | 0.2 |  |  |  |  | 0.0 |  |  |  |  | 0.0 | 100.0 |
|  | sitors | 1,385 | 270 | 18 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,675 |
| Total | +Visitors | 284,671 | 145,725 | 25,352 | 1,493 | 502 | 389 | 230 | 114 | 78 | 41 | 36 | 30 | 13 | 12 | 6 | 14 | 458,706 |

[^1]
## Thyroid Ultrasound Examination (Full-scale Thyroid Screening Program)

Reported on 30 November 2015

## 1. Summary

### 1.1 Purpose

In order to monitor the long-term health of children, we are now engaged in a Full-scale Thyroid Screening Program to assess the condition of their thyroid glands following Preliminary Baseline Screening (Initial Screening).

### 1.2 Group

Residents of Fukushima Prefecture including visitors who were born between 2 April 1992 and 1 April 2011 (Preliminary Baseline Screening), and those who were born between 2 April 2011 and 1 April 2012.

### 1.3 Implementation Period

Full-scale Screening started 2 April 2014 and will proceed for two years.
Thereafter we will repeat the examination every two years until the age of 20 , and every five years afterwards. We will endeavor to make sure they do not let more than 5 years pass between the exams through age 25 .

### 1.4 Responsible Organizations

Fukushima Prefecture commissioned Fukushima Medical University to conduct the survey in cooperation with institutions inside and outside Fukushima.

As of 30 September 2015, we provide the primary examination at 30 medical institutions under contract, and try to have more institutions inside Fukushima Prefecture.
Ninety-nine institutions outside Fukushima Prefecture have agreed to cooperate as of 30 September 2015.
The confirmatory examination has been conducted in Koriyama and Iwaki in Fukushima Prefecture from July 2013, Aizuwakamatsu from August 2014, and several institutions outside Fukushima Prefecture from November 2013. There are 28 institutions that provide the examination as of 30 September 2015.

### 1.5 Method

## 1.5-1 Primary Examination

We use ultrasonography for examination of the thyroid gland.
Assessments are made by specialists on the basis of the following criteria.
-Diagnostic Criteria: A
Those with A1 and A2 test results are recommended for watchful waiting until they undergo the next screening starting from April 2016.
(A1) No nodules / cysts
(A2) Nodules $\leq 5.0 \mathrm{~mm}$ or cysts $\leq 20.0 \mathrm{~mm}$

## -Diagnostic Criteria: B

Those with B test results are advised to take the confirmatory examination.
(B) Nodules $\geq 5.1 \mathrm{~mm}$ or cysts $\geq 20.1 \mathrm{~mm}$

Some A2 test results may be re-classified as B results when clinically indicated.

## -Diagnostic Criteria: C

Those with C test results are advised to take the confirmatory examination.
(C) Immediate need for confirmatory examination.

## 1.5-2 Confirmatory Examination

We conduct ultrasonography, blood test, urine test, and fine-needle aspiration cytology (FNAC) if needed for those with B or C test results. Priority is given to those in urgent clinical need.

## 1.5-3 Flow chart



Fig. 1 Flow chart

### 1.6 Target Municipalities



Fig. 2 Target Municipalities

## 2. Results of Primary Examination (As of 30 September 2015)

## 2.1-1 Progress Report

The Primary Examination started 2 April 2014, and the participation rate as of 30 September 2015 is $52.6 \%$ (199,772 of 379,952) from 59 municipalities ( 25 municipalities in FY 2014, and 34 in FY 2015). (See Appendix 1 and 2.)

The results have been returned to $91.4 \%(182,547)$ of the participants. (See Appendix 3.)
Those with A1 or A2 test results were $181,064(99.2 \%)$, B were $1,483(0.8 \%)$, and C was 0 .

Table 1. Screening test coverage as of 30 September 2015

|  | Target Population$\underline{\mathbf{a}}$ | Participants |  | Proportion (\%) c (c/b) | Test results |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Proportion (\%) <br> b (b/a) | Screened outside Fukushima |  | Class (\%) |  |  |  |
|  |  |  |  |  | A |  | Requiring confirmatory test |  |
|  |  |  |  |  | A1 d (d/c) | A2 e (e/c) | B f (f/c) | C g (g/c) |
| FY 2014 | 216,793 | 152,907 (70.5) | 9,758 | 151,410 ( 99.0) | 63,131 (41.7) | 87,068 (57.5) | 1,211 (0.8) | 0 (0.0) |
| FY 2015 | 163,159 | 46,865 (28.7) | 587 | 31,137 ( 66.4) | 11,854 (38.1) | 19,011 (61.1) | 272 (0.9) | 0 (0.0) |
| Total | 379,952 | 199,772 (52.6) | 10,345 | 182,547 ( 91.4) | 74,985 (41.1) | 106,079 (58.1) | 1,483 (0.8) | 0 (0.0) |

Table 2. Number and proportion of children with nodules/cysts as of 30 September 2015

|  | Number of confirmed screening results <br> a | Number and proportions of children with nodules/cysts |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Nodules |  | Cysts |  |
|  |  | $\underset{\mathrm{b}(\mathrm{~b} / \mathrm{a})}{\geq 5.1 \mathrm{~mm}}$ | $\begin{gathered} \leq 5.0 \mathrm{~mm} \\ \mathrm{c}(\mathrm{c} / \mathrm{a}) \\ \hline \end{gathered}$ | $\begin{gathered} \geq 20.1 \mathrm{~mm} \\ \mathrm{~d}(\mathrm{~d} / \mathrm{a}) \end{gathered}$ | $\begin{gathered} \leq 20.0 \mathrm{~mm} \\ \mathrm{e}(\mathrm{e} / \mathrm{a}) \end{gathered}$ |
| FY 2014 | 151,410 | 1,207 (0.8) | 945 (0.6) | 2 (0.0) | 87,453 (57.8) |
| FY 2015 | 31,137 | 270 (0.9) | 147 (0.5) | 2 (0.0) | 19,116 (61.4) |
| Total | 182,547 | 1,477 (0.8) | 1,092 (0.6) | 4 (0.0) | 106,569 (58.4) |

Fractions have been rounded and may not total to $100 \%$.
Because some duplicate records were found, numbers may vary slightly from previous reports.

## 2.1-2 Participation rates by age group

Participation rate of age group 18-21 (as of 1 April 2014) in target municipalities for FY 2014 was $24.1 \%$, the lowest among other age groups.

Table 3. Participation rates in target municipalities for FY 2014 by age group
As of 30 September 2015

|  |  | Total | Age group (years) |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | 2-7 | 8-12 | 13-17 | 18-21 |
| FY 2014 target municipalities | Target population (a) | 216,793 | 56,398 | 53,375 | 57,783 | 49,237 |
|  | Participants (b) | 152,907 | 43,131 | 48,851 | 49,067 | 11,858 |
|  | Proportion (\%) (b/a) | 70.5 | 76.5 | 91.5 | 84.9 | 24.1 |

Participation rate for FY 2015 is not yet tabulated in the table.
Ages are as of 1 April 2014.

## 2.1-3 Comparison with the Preliminary Baseline Screening (Initial Screening)

Among 169,029 participants who were diagnosed as A1 or A2 in the Preliminary Baseline Screening, 168,065 (99.4\%) had A1 or A2 results, and 964 ( $0.6 \%$ ) were diagnosed as B from the Full-scale Survey.

Among 817 participants who were diagnosed as B in the Preliminary Baseline Screening, 367 (44.9\%) had A1 or A2 results, and 450 ( $55.1 \%$ ) were diagnosed as B from the Full-scale Thyroid Screening Program.

Table 4. Comparison with the Preliminary Baseline Screening
As of 30 September 2015

|  |  |  | Number of test results of the Preliminary Baseline Screening* (\%) | Results of the Full-scale Thyroid Screening |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | A |  | $\begin{gathered} \mathrm{C} \\ \mathrm{e} \\ \mathrm{e} / \mathrm{a}(\%) \end{gathered}$ |
|  |  |  | $\begin{gathered} \mathrm{A} 1 \\ \mathrm{~b} \\ \mathrm{~b} / \mathrm{a}(\%) \end{gathered}$ |  |  | $\begin{gathered} \mathrm{A} 2 \\ \mathrm{c} \\ \mathrm{c} / \mathrm{a}(\%) \end{gathered}$ |
| Results of the Preliminary Baseline Screening | A | A1 |  | $\begin{aligned} & \hline 92,197 \\ & (100.0) \\ & \hline \end{aligned}$ | $\begin{array}{r} \hline 59,970 \\ (65.0) \\ \hline \end{array}$ | $\begin{aligned} & \hline 31,919 \\ & (34.6) \\ & \hline \end{aligned}$ | $\begin{gathered} \hline 308 \\ (0.3) \\ \hline \end{gathered}$ | $\begin{gathered} \hline 0 \\ (0.0) \\ \hline \end{gathered}$ |
|  |  | A2 |  | $\begin{aligned} & \hline 76,832 \\ & (100.0) \\ & \hline \end{aligned}$ | $\begin{aligned} & 7,073 \\ & (9.2) \\ & \hline \end{aligned}$ | $\begin{array}{r} 69,103 \\ (89.9) \\ \hline \end{array}$ | $\begin{gathered} \hline 656 \\ (0.9) \\ \hline \end{gathered}$ | $\begin{gathered} 0 \\ (0.0) \\ \hline \end{gathered}$ |
|  |  | B | $\begin{gathered} 817 \\ (100.0) \end{gathered}$ | $\begin{gathered} 66 \\ (8.1) \end{gathered}$ | $\begin{gathered} 301 \\ (36.8) \end{gathered}$ | $\begin{gathered} 450 \\ (55.1) \end{gathered}$ | $\begin{gathered} 0 \\ (0.0) \end{gathered}$ |
|  |  | C | $\begin{gathered} 0 \\ (0.0) \\ \hline \end{gathered}$ | $\begin{gathered} 0 \\ (0.0) \\ \hline \end{gathered}$ | $\begin{gathered} 0 \\ (0.0) \\ \hline \end{gathered}$ | $\begin{gathered} 0 \\ (0.0) \\ \hline \end{gathered}$ | $\begin{gathered} 0 \\ (0.0) \\ \hline \end{gathered}$ |
|  |  | rticipants | $\begin{aligned} & \hline 12,701 \\ & (100.0) \\ & \hline \end{aligned}$ | $\begin{array}{r} 7,876 \\ (62.0) \\ \hline \end{array}$ | $\begin{aligned} & \hline 4,756 \\ & (37.4) \\ & \hline \end{aligned}$ | $\begin{gathered} 69 \\ (0.5) \\ \hline \end{gathered}$ | $\begin{gathered} 0 \\ (0.0) \\ \hline \end{gathered}$ |
|  | Tota |  | $\begin{aligned} & \hline 182,547 \\ & (100.0) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 74,985 \\ & (41.1) \\ & \hline \end{aligned}$ | $\begin{gathered} \hline 106,079 \\ (58.1) \end{gathered}$ | $\begin{aligned} & 1,483 \\ & (0.8) \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ (0.0) \end{gathered}$ |

* Results of the participants with confirmed test results of the Full-scale survey.

This is not the breakdown of the total $(300,476)$ of confirmed screening results from the Preliminary Baseline Screening.

### 2.2 Results of Confirmatory Examination

## 2.2-1 Progress Report

The number of those who required further testing (started in June 2014) was 1,483, of whom 1,023 (69.0\%) underwent confirmatory testing. Among them, 879 (85.9\%) have completed the tests. (See Appendix 4.)

Of 879 participants, 242 ( 32 with A1 result and 210 with A2 result from Table 5) were found to be back within the range of A1 and A2, and were advised to take their next regularly scheduled examination (27.5\%).

Those who require 6- or 12-month follow-up provided by health insurance were 637 ( $72.5 \%$ ).
Table 5. Confirmatory testing coverage and results as of 30 September 2015

|  | Number of <br> those <br> requiring <br> confirmatory <br> test <br> a | Participants <br> Proportion (\%) <br> b (b/a) | Confirmatory test coverage (\%)$\mathrm{c}(\mathrm{c} / \mathrm{b})$ | Confirmed test results |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | Next screening advised |  | Follow-up advised |  |
|  |  |  |  | $\begin{array}{r} \mathbf{A 1} \\ \mathrm{d}(\mathrm{~d} / \mathrm{c}) \end{array}$ | $\begin{array}{r} \mathrm{A} 2 \\ \mathrm{e}(\mathrm{e} / \mathrm{c}) \end{array}$ | f (f/c) | Cytology <br> g (g/f) |
| FY 2014 | 1,211 | 932 (77.0) | 849 (91.1) | 32 (3.8) | 205 (24.1) | 612 (72.1) | 120 ( 19.6) |
| FY 2015 | 272 | 91 (33.5) | 30 (33.0) | 0 ( 0.0) | 5 (16.7) | 25 (83.3) | 4 (16.0) |
| Total | 1,483 | 1,023 (69.0) | 879 ( 85.9) | 32 (3.6) | 210 (23.9) | 637 (72.5) | 124 ( 19.5) |

Those confirmed within the range of A1 and A2 (including those with other thyroid conditions) were advised to take their next regularly scheduled examination.

Those who require 6- or 12-month follow-up provided by health insurance and those beyond the specified level of A2 were categorized as "Follow-up advised."

## 2.2-2 Results of Fine Needle Aspiration Biopsy and Cytology (FNAC)

Among those who underwent FNAC, 39 had nodules classified as suspicious or malignant.
Sixteen of them were male, and 23 were female. Age at the time of the confirmatory testing ranged from 10 to 22 years (mean age: $17.1 \pm 3.2$ years). The minimum and maximum tumor size was 5.3-30.1 mm in diameter. Mean tumor diameter was $9.6 \pm 4.6 \mathrm{~mm}$.

Results from the Preliminary Baseline Screening show that 37 of the 39 participants were categorized as A (A1: 19; A2: 18) and 2 as B.

Table 6. Target municipalities in FY 2014-2015

| Suspicious or malignant | $39 *$ |
| :--- | :--- |
| Male to female ratio | $16: 23$ |
| Mean age (SD, min-max) | $17.1(3.2,10-22)$ |
|  | $13.2(3.2,6-18)$ at the time of the disaster |
| Mean tumor size | $9.6 \mathrm{~mm}(4.6 \mathrm{~mm}, 5.3-30.1 \mathrm{~mm})$ |

[^2]2.2-3 Suspicious or malignant cases per FNAC by age and sex


Fig. 3 Age as of 11 March 2011


Fig. 4 Age as the date of confirmatory examination

## 2.2-4 Suspicious or malignant cases per FNAC by estimated radiation dose

Twenty-four ( $61.5 \%$ ) of the 39 people participated in the Basic Survey (radiation dose estimates), and 23 received the results. Among those, 8 had estimated radiation exposure dose below 1 mSv , and the highest effective dose documented was 2.1 mSv .

Table 7. Number of suspicious or malignant cases by age and sex
As of 30 September 2015

| Effective dose (mSv) | Age at the time of the disaster |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 0-5 |  | 6-10 |  | 11-15 |  | 16-18 |  | Total |  |
|  | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female |
| <1 | 0 | 0 | 2 | 0 | 1 | 4 | 1 | 0 | 4 | 4 |
| 1-1.9 | 0 | 0 | 0 | 1 | 3 | 2 | 2 | 3 | 5 | 6 |
| 2-4.9 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 2 | 2 |
| 5-9.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 10-19.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| $\geq 20$ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0 | 0 | 3 | 1 | 4 | 7 | 4 | 4 | 11 | 12 |

[^3]

Fig. 5 Effective dose of the respondents

## 2.2-5 Blood and urinary iodine test results as of 30 September 2015

Table 8. Blood test results Mean $\pm$ SD (Abnormal value)

|  | FT4 1) <br> $(\mathrm{ng} / \mathrm{dL})$ | FT3 2) <br> $(\mathrm{pg} / \mathrm{mL})$ | TSH 3) <br> $(\mu \mathrm{IU} / \mathrm{mL})$ | $\operatorname{Tg} 4)$ <br> $(\mathrm{ng} / \mathrm{mL})$ | $\mathrm{TgAb} 5)$ <br> $(\mathrm{IU} / \mathrm{mL})$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Reference Range | $0.95-1.74$ | $2.13-4.077)$ | $0.340-3.880$ | $<32.7$ | $<28.0$ |
| 39 suspicious or malignant | $1.2 \pm 0.2(7.7 \%)$ | $3.5 \pm 0.4(2.6 \%)$ | $1.7 \pm 0.9(7.7 \%)$ | $42.5 \pm 113.3(23.1 \%)$ | $-(20.5 \%)$ |
| Other 838 | $1.2 \pm 0.2(7.3 \%)$ | $3.6 \pm 0.6(6.2 \%)$ | $1.3 \pm 0.9(9.3 \%)$ | $24.0 \pm 63.6(14.3 \%)$ | $-(8.7 \%)$ |

Table 9. Urinary iodine ( $\mu \mathrm{g} /$ day)

|  | Minimum | 25 th percentile | Median | 75th percentile | Maximum |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 39 suspicious or malignant | 49 | 115 | 182 | 376 | 1,370 |
| Other 834 | 33 | 116 | 184.5 | 338 | 11,800 |

1) FT4: Free Thyroxine; higher among patients with thyrotoxicosis (representative disease: Graves' disease) and lower with hypothyroidism (representative disease: Hashimoto's thyroiditis).
2) FT3: Free Triiodothyronine; higher among patients with thyrotoxicosis (representative disease: Graves' disease) and lower with hypothyroidism (representative disease: Hashimoto's thyroiditis).
3) TSH: Thyroid Stimulating Hormone; higher among patients with Hashimoto's disease and lower with Graves' disease.
4) Tg : Thyroglobulin; higher when thyroid tissue is destroyed or when thyroid cancer produces thyroglobulin.
5) TgAb : Anti-Thyroglobulin Antibody; higher among patients with Hashimoto's disease and Graves' disease.
6) TPOAb: Anti-Thyroid Peroxidase Antibody; higher among patients with Hashimoto's disease or Graves' disease.
7) Reference range differs according to age.
2.2-6 Confirmatory test results by municipality as of 30 September 2015

The proportion of suspicious or malignant diagnoses was $0.02 \%$ in FY 2014 target municipalities (13 municipalities in the nationally designated evacuation zones and 12 towns of the Kempoku area), $0.00 \%$ in FY 2015 target municipalities ( 34 towns of Iwaki, the Kennan and Aizu areas).

Table 10.
Confirmatory test results by municipality in FY 2014

|  | Number of those screened | Participants who required confirmatory test | Proportion who required confirmatory test (\%) | Number who underwent confirmatory test | Suspicious or malignant cases | Proportion of suspicious or malignant cases (\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Kawamata | 1,729 | 20 | 1.2 | 18 | 0 | 0.00 |
| Namie | 2,325 | 27 | 1.2 | 22 | 2 | 0.09 |
| Iitate | 750 | 14 | 1.9 | 11 | 0 | 0.00 |
| Minami-soma | 8,530 | 74 | 0.9 | 62 | 3 | 0.04 |
| Date | 9,004 | 83 | 0.9 | 74 | 7 | 0.08 |
| Tamura | 4,827 | 50 | 1.0 | 40 | 2 | 0.04 |
| Hirono | 623 | 8 | 1.3 | 7 | 0 | 0.00 |
| Naraha | 918 | 4 | 0.4 | 4 | 0 | 0.00 |
| Tomioka | 1,749 | 23 | 1.3 | 16 | 0 | 0.00 |
| Kawauchi | 201 | 2 | 1.0 | 1 | 0 | 0.00 |
| Okuma | 1,554 | 10 | 0.6 | 10 | 1 | 0.06 |
| Futaba | 588 | 2 | 0.3 | 0 | 0 | 0.00 |
| Katsurao | 141 | 2 | 1.4 | 2 | 0 | 0.00 |
| Fukushima | 41,971 | 326 | 0.8 | 270 | 8 | 0.02 |
| Nihonmatsu | 7,664 | 54 | 0.7 | 44 | 1 | 0.01 |
| Motomiya | 4,692 | 31 | 0.7 | 26 | 2 | 0.04 |
| Otama | 1,234 | 4 | 0.3 | 4 | 0 | 0.00 |
| Koriyama | 45,589 | 340 | 0.7 | 231 | 10 | 0.02 |
| Kori | 1,571 | 14 | 0.9 | 9 | 1 | 0.06 |
| Kunimi | 1,197 | 8 | 0.7 | 6 | 0 | 0.00 |
| Tenei | 766 | 11 | 1.4 | 3 | 0 | 0.00 |
| Shirakawa | 9,053 | 55 | 0.6 | 41 | 1 | 0.01 |
| Nishigo | 2,996 | 24 | 0.8 | 17 | 0 | 0.00 |
| Izumizaki | 937 | 2 | 0.2 | 1 | 0 | 0.00 |
| Miharu | 2,298 | 23 | 1.0 | 13 | 0 | 0.00 |
| Subtotal | 152,907 | 1,211 | 0.8 | 932 | 38 | 0.02 |

Confirmatory test results by municipality in FY 2015

|  | Number of those screened | Participants who required confirmatory test | Proportion who required confirmatory test (\%) | Number who underwent confirmatory test | Suspicious or malignant cases | Proportion of suspicious or malignant cases (\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Iwaki | 22,395 | 113 | 0.5 | 14 | 1 | 0.00 |
| Sukagawa | 10,573 | 70 | 0.7 | 29 | 0 | 0.00 |
| Soma | 4,327 | 20 | 0.5 | 14 | 0 | 0.00 |
| Kagamiishi | 1,828 | 12 | 0.7 | 4 | 0 | 0.00 |
| Shinchi | 964 | 13 | 1.3 | 7 | 0 | 0.00 |
| Nakajima | 99 | 3 | 3.0 | 2 | 0 | 0.00 |
| Yabuki | 342 | 9 | 2.6 | 5 | 0 | 0.00 |
| Ishikawa | 150 | 3 | 2.0 | 1 | 0 | 0.00 |
| Yamatsuri | 38 | 0 | 0.0 | 0 | 0 | 0.00 |
| Asakawa | 86 | 3 | 3.5 | 3 | 0 | 0.00 |
| Hirata | 79 | 1 | 1.3 | 0 | 0 | 0.00 |
| Tanagura | 142 | 3 | 2.1 | 1 | 0 | 0.00 |
| Hanawa | 87 | 2 | 2.3 | 2 | 0 | 0.00 |
| Samegawa | 20 | 0 | 0.0 | 0 | 0 | 0.00 |
| Ono | 168 | 3 | 1.8 | 1 | 0 | 0.00 |
| Tamakawa | 126 | 1 | 0.8 | 0 | 0 | 0.00 |
| Furudono | 47 | 0 | 0.0 | 0 | 0 | 0.00 |
| Hinoemata | 49 | 0 | 0.0 | 0 | 0 | 0.00 |
| Minami-aizu | 1,436 | 6 | 0.4 | 4 | 0 | 0.00 |
| Kaneyama | 98 | 0 | 0.0 | 0 | 0 | 0.00 |
| Showa | 57 | 0 | 0.0 | 0 | 0 | 0.00 |
| Mishima | 81 | 0 | 0.0 | 0 | 0 | 0.00 |
| Shimogo | 509 | 0 | 0.0 | 0 | 0 | 0.00 |
| Kitakata | 95 | 0 | 0.0 | 0 | 0 | 0.00 |
| Nishiaizu | 10 | 0 | 0.0 | 0 | 0 | 0.00 |
| Tadami | 414 | 3 | 0.7 | 0 | 0 | 0.00 |
| Inawashiro | 1,405 | 5 | 0.4 | 3 | 0 | 0.00 |
| Bandai | 307 | 0 | 0.0 | 0 | 0 | 0.00 |
| Kitashiobara | 275 | 0 | 0.0 | 0 | 0 | 0.00 |
| Aizumisato | 36 | 1 | 2.8 | 0 | 0 | 0.00 |
| Aizubange | 35 | 0 | 0.0 | 0 | 0 | 0.00 |
| Yanaizu | 272 | 0 | 0.0 | 0 | 0 | 0.00 |
| Aizuwakamatsu | 308 | 1 | 0.3 | 1 | 0 | 0.00 |
| Yugawa | 7 | 0 | 0.0 | 0 | 0 | 0.00 |
| Subtotal | 46,865 | 272 | 0.6 | 91 | 1 | 0.00 |


| Total | 199,772 | 1,483 | 0.7 | 1,023 | 39 | 0.02 |
| :--- | :--- | ---: | ---: | ---: | ---: | ---: |

### 2.3 Mental Health Care

## 2.3-1 For participants of confirmatory examination

We set up a support team for participants of the confirmatory examination to address their anxiety and concerns by offering online support.

Since the full-scale thyroid screening started, 613 participants ( 214 male and 399 female) have received support as of 30 September 2015. The number of consultations given to them was 1,058 in total. Of these, $632(59.7 \%)$ received the support services during the first time of the examination, $396(37.4 \%)$ at the second time and after including $90(8.5 \%)$ when undergoing FNAC, and $30(2.8 \%)$ when giving informed consent.
In cooperation with teams of medical staff at hospitals, we offer similar services to those who are recommended for a follow-up provided by health insurance.

## 2.3-2 Briefing on the result of primary examination

Since July 2015, we offer explanations to participants face to face at the primary examination public venue. After the examination, the briefing is offered by physicians using an online video link at consultation booths on request. As of 30 September 2015, 3,213 (57.6\%) of 5,577 participants visited the consultation booth. When the booth could not be set up at the venues, phone support or briefing sessions are offered at schools as an alternative.

### 2.4 Full-scale Thyroid Screening Program (from the $3^{\text {rd }}$ time onward)

2.4-1 Schedule (Approved by the 20th Prefectural Oversight Committee Meeting)

The residents undergo thyroid examination every 2 years until age 20 in a sequence guided by their municipal address. After that, they take the examination every 5 years regardless of their addresses so that it is easier for them to understand when to undergo the screening. We will endeavor to make sure they do not let more than 5 years pass between the exams through age 25 .

## 2.4-2 Review of the primary examination consent form and notice

We will make sure the notice of the thyroid ultrasound examination explains its purpose in detail. We will also inform individuals that by participating in the examination, they will learn the condition of their thyroid glands, although it might make them feel anxious. In the consent form, we ask them to select either "I agree" or "I disagree" in order to document explicit consent from the participants.
2.4-3 Review of the notification of the primary examination results

Since participants will take the exams periodically from FY 2016, we will provide cumulative survey results with, plain-language explanations. We will ask those recommended to take confirmatory testing if they wish to participate, and also about visits to their doctors.

## Appendix 1

Thyroid Ultrasound Examination (TUE) coverage by municipality

| Target <br> Population | Participants |  | Proportion (\%) | Number and proportion of participants by age group |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Screened outside Fukushima |  |  |  |  |  |
| a | b |  | b/a | 2-7 | 8-12 | 13-17 | 18-23 |

As of 30 September 2015

| $\begin{array}{c}\text { Participants } \\ \text { living outside } \\ \text { Fukushima }\end{array}$ | $\begin{array}{c}\text { Proportion } \\ (\%)\end{array}$ |
| :---: | :---: |
| c | c/b |

Screening coverage by municipality in FY 2014

| Kawamata | 2,460 | 1,729 | 45 | 70.3 | 422 | 572 | 591 | 144 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  | 24.4 | 33.1 | 34.2 | 8.3 |
| Namie | 3,772 | 2,325 | 642 | 61.6 | 620 | 672 | 711 | 322 |
|  |  |  |  |  | 26.7 | 28.9 | 30.6 | 13.8 |
| Iitate | 1,123 | 750 | 32 | 66.8 | 184 | 270 | 237 | 59 |
|  |  |  |  |  | 24.5 | 36.0 | 31.6 | 7.9 |
| Minami-soma | 12,982 | 8,530 | 1,655 | 65.7 | 2,227 | 2,823 | 2,587 | 893 |
|  |  |  |  |  | 26.1 | 33.1 | 30.3 | 10.5 |
| Date | 11,742 | 9,004 | 308 | 76.7 | 2,249 | 2,733 | 2,968 | 1,054 |
|  |  |  |  |  | 25.0 | 30.4 | 33.0 | 11.7 |
| Tamura | 7,321 | 4,827 | 135 | 65.9 | 1,106 | 1,623 | 1,646 | 452 |
|  |  |  |  |  | 22.9 | 33.6 | 34.1 | 9.4 |
| Hirono | 1,108 | 623 | 103 | 56.2 | 160 | 184 | 191 | 88 |
|  |  |  |  |  | 25.7 | 29.5 | 30.7 | 14.1 |
| Naraha | 1,489 | 918 | 126 | 61.7 | 226 | 266 | 298 | 128 |
|  |  |  |  |  | 24.6 | 29.0 | 32.5 | 13.9 |
| Tomioka | 3,101 | 1,749 | 399 | 56.4 | 428 | 469 | 573 | 279 |
|  |  |  |  |  | 24.5 | 26.8 | 32.8 | 16.0 |
| Kawauchi | 360 | 201 | 19 | 55.8 | 48 | 71 | 63 | 19 |
|  |  |  |  |  | 23.9 | 35.3 | 31.3 | 9.5 |
| Okuma | 2,499 | 1,554 | 352 | 62.2 | 488 | 479 | 422 | 165 |
|  |  |  |  |  | 31.4 | 30.8 | 27.2 | 10.6 |
| Futaba | 1,258 | 588 | 214 | 46.7 | 170 | 193 | 161 | 64 |
|  |  |  |  |  | 28.9 | 32.8 | 27.4 | 10.9 |
| Katsurao | 240 | 141 | 14 | 58.8 | 33 | 53 | 45 | 10 |
|  |  |  |  |  | 23.4 | 37.6 | 31.9 | 7.1 |
| Fukushima | 55,734 | 41,971 | 2,176 | 75.3 | 10,849 | 12,638 | 13,240 | 5,244 |
|  |  |  |  |  | 25.8 | 30.1 | 31.5 | 12.5 |
| Nihonmatsu | 10,597 | 7,664 | 254 | 72.3 | 1,857 | 2,463 | 2,652 | 692 |
|  |  |  |  |  | 24.2 | 32.1 | 34.6 | 9.0 |
| Motomiya | 6,343 | 4,692 | 148 | 74.0 | 1,190 | 1,501 | 1,543 | 458 |
|  |  |  |  |  | 25.4 | 32.0 | 32.9 | 9.8 |
| Otama | 1,684 | 1,234 | 20 | 73.3 | 344 | 398 | 382 | 110 |
|  |  |  |  |  | 27.9 | 32.3 | 31.0 | 8.9 |
| Koriyama | 66,751 | 45,589 | 2,583 | 68.3 | 10,444 | 15,197 | 15,125 | 4,823 |
|  |  |  |  |  | 22.9 | 33.3 | 33.2 | 10.6 |
| Kori | 2,137 | 1,571 | 45 | 73.5 | 365 | 503 | 547 | 156 |
|  |  |  |  |  | 23.2 | 32.0 | 34.8 | 9.9 |
| Kunimi | 1,624 | 1,197 | 29 | 73.7 | 224 | 379 | 443 | 151 |
|  |  |  |  |  | 18.7 | 31.7 | 37.0 | 12.6 |
| Tenei | 1,101 | 766 | 22 | 69.6 | 206 | 260 | 246 | 54 |
|  |  |  |  |  | 26.9 | 33.9 | 32.1 | 7.0 |
| Shirakawa | 12,674 | 9,053 | 271 | 71.4 | 2,433 | 2,885 | 2,923 | 812 |
|  |  |  |  |  | 26.9 | 31.9 | 32.3 | 9.0 |
| Nishigo | 4,173 | 2,996 | 100 | 71.8 | 853 | 986 | 887 | 270 |
|  |  |  |  |  | 28.5 | 32.9 | 29.6 | 9.0 |
| Izumizaki | 1,337 | 937 | 20 | 70.1 | 253 | 312 | 284 | 88 |
|  |  |  |  |  | 27.0 | 33.3 | 30.3 | 9.4 |
| Miharu | 3,183 | 2,298 | 46 | 72.2 | 516 | 674 | 797 | 311 |
|  |  |  |  |  | 22.5 | 29.3 | 34.7 | 13.5 |
| Subtotal | 216,793 | 152,907 | 9,758 | 70.5 | 37,895 | 48,604 | 49,562 | 16,846 |
|  |  |  |  |  | 24.8 | 31.8 | 32.4 | 11.0 |


| 62 | 3.6 |
| :---: | :---: |
| 718 | 30.9 |
| 40 | 5.3 |
| 1,831 | 21.5 |
| 304 | 3.4 |
| 126 | 2.6 |
| 92 | 14.8 |
| 136 | 14.8 |
| 436 | 24.9 |
| 21 | 10.4 |
| 385 | 24.8 |
| 228 | 38.8 |
| 13 | 9.2 |
| 2,620 | 6.2 |
| 245 | 3.2 |
| 159 | 3.4 |
| 24 | 1.9 |
| 3,085 | 6.8 |
| 35 | 2.2 |
| 28 | 2.3 |
| 23 | 3.0 |
| 297 | 3.3 |
| 104 | 3.5 |
| 12 | 1.3 |
| 49 | 2.1 |
| 11,073 | 7.2 |

1) Number of participants. 2) Number of participants in the age group/Number of participants.
2) Number of participants who underwent the test outside Fukushima.

Fractions have been rounded and may not total to $100 \%$. Ages are at the time when the participants underwent the testing.
Because some duplicate records were found, numbers may vary slightly from previous reports.

Thyroid Ultrasound Examination (TUE) coverage by municipality

| Target Population | Participants |  | Proportion (\%) | Number and proportion of participants by age group |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | b | Screened outside Fukushima 3) |  |  |  |  |  |
| a |  |  | b/a | 2-7 | 8-12 | 13-17 | 18-23 |

Screening coverage by municipality in FY 2015

| Iwaki | 64,285 | 22,395 | 275 | 34.8 |  |
| :---: | ---: | ---: | ---: | ---: | ---: |
| Sukagawa | 15,877 | 10,573 | 100 | 66.6 |  |
| Soma | 7,086 | 4,327 | 82 | 61.1 |  |
| Kagamiishi | 2,705 | 1,828 | 10 | 67.6 |  |
| Shinchi | 1,476 | 964 | 12 | 65.3 |  |
| Nakajima | 1,115 | 99 | 0 | 8.9 |  |
| Yabuki | 3,419 |  |  |  |  |


| Yabuki | 3,419 | 342 | 6 | 10.0 |  |
| :---: | ---: | ---: | ---: | ---: | ---: |
|  | Ishikawa | 2,951 | 150 | 4 | 5.1 |
|  |  |  |  |  |  |
| Yamatsuri | 1,055 | 38 | 3 |  |  |


| Yamatsuri | 1,055 | 38 | 3 | 3.6 |
| :---: | ---: | ---: | ---: | ---: |
| Asakawa | 1,392 | 86 | 0 | 6.2 |
| Hirata | 1,270 | 79 | 0 | 6.2 |
| Tanagura | 3,085 | 142 | 4 | 4.6 |
| Hanawa | 1,716 | 87 | 4 | 5.1 |


| Samegawa | 723 | 20 | 0 | 2.8 |
| :---: | ---: | ---: | ---: | ---: |
| Ono | 1,986 | 168 | 3 | 8.5 |
| Tamakawa | 1,370 | 126 | 0 | 9.2 |


| Furudono | 1,078 | 47 | 3 | 4.4 |
| :---: | ---: | ---: | ---: | ---: |
| Hinoemata | 110 | 49 | 0 | 44.5 |


| Hinoemata | 110 | 49 | 0 | 44.5 | 7 | 19 | 23 | 0 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  | 14.3 | 38.8 | 46.9 | 0.0 |
| Minami-aizu | 2,913 | 1,436 | 1 | 49.3 | 276 | 555 | 526 | 79 |
|  |  |  |  |  | 19.2 | 38.6 | 36.6 | 5.5 |
| Kaneyama | 203 | 98 | 0 | 48.3 | 13 | 41 | 38 | 6 |
|  |  |  |  |  | 13.3 | 41.8 | 38.8 | 6.1 |
| Showa | 134 | 57 | 0 | 42.5 | 7 | 23 | 23 | 4 |
|  |  |  |  |  | 12.3 | 40.4 | 40.4 | 7.0 |
| Mishima | 195 | 81 | 0 | 41.5 | 10 | 43 | 26 | 2 |
|  |  |  |  |  | 12.3 | 53.1 | 32.1 | 2.5 |
| Shimogo | 1,010 | 509 | 2 | 50.4 | 90 | 203 | 184 | 32 |
|  |  |  |  |  | 17.7 | 39.9 | 36.1 | 6.3 |
| Kitakata | 9,235 | 95 | 9 | 1.0 | 21 | 31 | 26 | 17 |
|  |  |  |  |  | 22.1 | 32.6 | 27.4 | 17.9 |
| Nishiaizu | 1,054 | 10 | 0 | 0.9 | 0 | 2 | 6 | 2 |
|  |  |  |  |  | 0.0 | 20.0 | 60.0 | 20.0 |
| Tadami | 735 | 414 | 1 | 56.3 | 92 | 153 | 142 | 27 |
|  |  |  |  |  | 22.2 | 37.0 | 34.3 | 6.5 |
| Inawashiro | 2,757 | 1,405 | 7 | 51.0 | 317 | 551 | 434 | 103 |
|  |  |  |  |  | 22.6 | 39.2 | 30.9 | 7.3 |
| Bandai | 628 | 307 | 2 | 48.9 | 68 | 140 | 84 | 15 |
|  |  |  |  |  | 22.1 | 45.6 | 27.4 | 4.9 |
| Kitashiobara | 581 | 275 | 0 | 47.3 | 83 | 117 | 59 | 16 |
|  |  |  |  |  | 30.2 | 42.5 | 21.5 | 5.8 |
| Aizumisato | 3,658 | 36 | 6 | 1.0 | 7 | 2 | 16 | 11 |
|  |  |  |  |  | 19.4 | 5.6 | 44.4 | 30.6 |
| Aizubange | 3,081 | 35 | 7 | 1.1 | 6 | 16 | 5 | 8 |
|  |  |  |  |  | 17.1 | 45.7 | 14.3 | 22.9 |
| Yanaizu | 611 | 272 | 0 | 44.5 | 70 | 122 | 65 | 15 |
|  |  |  |  |  | 25.7 | 44.9 | 23.9 | 5.5 |
| Aizuwakamatsu | 22,989 | 308 | 46 | 1.3 | 58 | 88 | 123 | 39 |
|  |  |  |  |  | 18.8 | 28.6 | 39.9 | 12.7 |
| Yugawa | 676 | 7 | 0 | 1.0 | 0 | 1 | 4 | 2 |
|  |  |  |  |  | 0.0 | 14.3 | 57.1 | 28.6 |
| Subtotal | 163,159 | 46,865 | 587 | 28.7 | 9,177 | 15,628 | 16,670 | 5,390 |
|  |  |  |  |  | 19.6 | 33.3 | 35.6 | 11.5 |


| Total | 379,952 | 199,772 | 10,345 | 52.6 | 47,072 | 64,232 | 66,232 | 22,236 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  | 23.6 | 32.2 | 33.2 | 11.1 |

As of 30 September 2015

| $\begin{array}{c}\text { Participants } \\ \text { living outside } \\ \text { Fukushima }\end{array}$ | $\begin{array}{c}\text { Proportion } \\ (\%)\end{array}$ |
| :---: | :---: |
| c | $\mathrm{c} / \mathrm{b}$ |


| 589 | 2.6 |
| ---: | ---: |
| 154 | 1.5 |
| 173 | 4.0 |
| 22 | 1.2 |
| 23 | 2.4 |
| 1 | 1.0 |
| 10 | 2.9 |


| 10 | 2.9 |
| ---: | ---: |
| 12 | 8.0 |
| 3 | 7.9 |


| 1 | 1.2 |
| :--- | :--- |
| 2 | 2.5 |


| 8 | 5.6 |
| ---: | ---: |
| 5 | 5.7 |


| 0 | 0.0 |
| ---: | ---: |
| 9 | 5.4 |
| 0 | 0.0 |


| 4 | 8.5 |
| :--- | :--- |
| 0 | 0.0 |
| 2 | 0.1 |
| 0 | 0.0 |


| 0 | 0.0 |
| :--- | :--- |
| 0 | 0.0 |


| 1 | 1.2 |
| :--- | :--- |
| 2 | 0.4 |


| 2 | 0.4 |
| ---: | ---: |
| 8 | 8.4 |
|  |  |


| 0 | 0.0 |
| :--- | :--- |
| 3 | 0.7 |


| 3 | 0.7 |
| ---: | ---: |
| 13 | 0.9 |
| 1 | 0.3 |


| 0 | 0.0 |
| ---: | ---: |
| 5 | 13.9 |
| 7 | 20.0 |
| 0 | 0.0 |
| 46 | 14.9 |
| 0 | 0.0 |
| 1,104 | 2.4 |


| 12,177 | 6.1 |
| :--- | :--- |

## Appendix 2

Thyroid Ultrasound Examination (TUE) coverage by prefecture

| Prefecture | Number of <br> test venues | Participants* |
| :---: | ---: | ---: |
| Hokkaido | 5 | $\mathbf{2 7 8}$ |
| Aomori | 1 | $\mathbf{1 3 0}$ |
| Iwate | 3 | $\mathbf{2 6 2}$ |
| Miyagi | 2 | $\mathbf{2 , 0 6 1}$ |
| Akita | 1 | $\mathbf{1 9 5}$ |
| Yamagata | 3 | $\mathbf{6 8 7}$ |
| Ibaraki | 4 | $\mathbf{5 4 6}$ |
| Tochigi | 6 | $\mathbf{5 9 1}$ |
| Gunma | 2 | $\mathbf{1 8 7}$ |
| Saitama | 2 | $\mathbf{3 2 4}$ |
| Chiba | 3 | $\mathbf{4 3 1}$ |
| Tokyo | 12 | $\mathbf{1 , 5 5 1}$ |
| Kanagawa | 4 | $\mathbf{1 , 1 0 6}$ |
| Niigata | 2 | $\mathbf{6 8 5}$ |
| Toyama | 1 | $\mathbf{1 2}$ |
| Ishikawa | 1 | $\mathbf{4 4}$ |


| Prefecture | Number of <br> test venues | Participants* |
| :---: | ---: | ---: |
| Fukui | 1 | $\mathbf{8}$ |
| Yamanashi | 2 | $\mathbf{1 0 2}$ |
| Nagano | 2 | $\mathbf{1 0 8}$ |
| Gifu | 1 | $\mathbf{2 6}$ |
| Shizuoka | 2 | $\mathbf{9 4}$ |
| Aichi | 3 | $\mathbf{1 5 1}$ |
| Mie | 1 | $\mathbf{2 3}$ |
| Shiga | 1 | $\mathbf{1 8}$ |
| Kyoto | 3 | $\mathbf{6 0}$ |
| Osaka | 6 | $\mathbf{1 7 5}$ |
| Hyogo | 1 | $\mathbf{1 0 9}$ |
| Nara | 1 | $\mathbf{2 0}$ |
| Wakayama | 1 | $\mathbf{8}$ |
| Tottori | 1 | $\mathbf{7}$ |
| Shimane | 1 | $\mathbf{4}$ |
| Okayama | 3 | $\mathbf{3 6}$ |


| Prefecture | Number of <br> test venues | Participants* |  |
| :---: | ---: | ---: | :---: |
| Hiroshima | 1 | $\mathbf{2 5}$ |  |
| Yamaguchi | 1 | $\mathbf{1 2}$ |  |
| Tokushima | 1 | $\mathbf{8}$ |  |
| Kagawa | 1 | $\mathbf{1 7}$ |  |
| Ehime | 1 | $\mathbf{8}$ |  |
| Kochi | 1 | $\mathbf{1 0}$ |  |
| Fukuoka | 3 | $\mathbf{5 6}$ |  |
| Saga | 1 | $\mathbf{1 5}$ |  |
| Nagasaki | 2 | $\mathbf{2 3}$ |  |
| Kumamoto | 1 | $\mathbf{1 3}$ |  |
| Oita | 1 | $\mathbf{2 7}$ |  |
| Miyazaki | 1 | $\mathbf{2 3}$ |  |
| Kagoshima | 1 | $\mathbf{2 0}$ |  |
| Okinawa | 1 | $\mathbf{4 9}$ |  |
|  |  |  |  |
| Total | 99 | $\mathbf{1 0 , 3 4 5}$ |  |

* Participants who underwent testing at venues outside Fukushima carried out either by Fukushima Medical University staff (once in Niigata and Yamagata, and twice in Kanagawa) or by local specialists.


## Appendix 3

| Results of primary examination by municipality |  |  |  |  |  |  |  |  | As of 30 September 2015 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Participants | $\begin{gathered} \text { Confirmed } \\ \text { results } \\ \quad \text { b } \\ \hline \end{gathered}$ | Number by test results |  |  |  | Nodules |  | Cysts |  |
|  |  |  | Proportion (\%) |  |  |  |  |  |  |  |
|  |  |  | A |  | B | C | Proportion (\%) |  | Proportion (\%) |  |
|  |  | Proportion (\%) $\mathrm{b} / \mathrm{a}(\%)$ | A1 | A2 |  |  | $\geq 5.1 \mathrm{~mm}$ | $\leq 5.0 \mathrm{~mm}$ | $\geq 20.1 \mathrm{~mm}$ | $\leq 20.0 \mathrm{~mm}$ |
| Screening coverage b | unicipality in | FY 2014 |  |  |  |  |  |  |  |  |
| Kawamata | 1,729 | 1,722 764 |  | 938 | 20 | 0 | 19 | 13 | 1 | 946 |
|  |  | 99.6 | 44.4 | 54.5 | 1.2 | 0.0 | 1.1 | 0.8 | 0.1 | 54.9 |
| Namie | 2,325 | 2,233 | 919 | 1,287 | 27 | 0 | 27 | 17 | 0 | 1,298 |
|  |  | 96.0 | 41.2 | 57.6 | 1.2 | 0.0 | 1.2 | 0.8 | 0.0 | 58.1 |
| Iitate | 750 | 747 | 354 | 379 | 14 | 0 | 14 | 3 | 0 | 384 |
|  |  | 99.6 | 47.4 | 50.7 | 1.9 | 0.0 | 1.9 | 0.4 | 0.0 | 51.4 |
| Minami-soma | 8,530 | 8,412 | 3,609 | 4,729 | 74 | 0 | 74 | 57 | 0 | 4,752 |
|  |  | 98.6 | 42.9 | 56.2 | 0.9 | 0.0 | 0.9 | 0.7 | 0.0 | 56.5 |
| Date | 9,004 | 8,974 | 3,898 | 4,993 | 83 | 0 | 83 | 68 | 0 | 5,016 |
|  |  | 99.7 | 43.4 | 55.6 | 0.9 | 0.0 | 0.9 | 0.8 | 0.0 | 55.9 |
| Tamura | 4,827 | 4,804 | 1,976 | 2,778 | 50 | 0 | 50 | 28 | 0 | 2,796 |
|  |  | 99.5 | 41.1 | 57.8 | 1.0 | 0.0 | 1.0 | 0.6 | 0.0 | 58.2 |
| Hirono | 623 | 561 | 239 | 314 | 8 | 0 | 8 | 6 | 0 | 313 |
|  |  | 90.0 | 42.6 | 56.0 | 1.4 | 0.0 | 1.4 | 1.1 | 0.0 | 55.8 |
| Naraha | 918 | 851 | 355 | 492 | 4 | 0 | 4 | 7 | 0 | 492 |
|  |  | 92.7 | 41.7 | 57.8 | 0.5 | 0.0 | 0.5 | 0.8 | 0.0 | 57.8 |
| Tomioka | 1,749 | 1,652 | 686 | 943 | 23 | 0 | 23 | 16 | 0 | 952 |
|  |  | 94.5 | 41.5 | 57.1 | 1.4 | 0.0 | 1.4 | 1.0 | 0.0 | 57.6 |
| Kawauchi | 201 | 192 | 63 | 127 | 2 | 0 | 2 | 1 | 0 | 128 |
|  |  | 95.5 | 32.8 | 66.1 | 1.0 | 0.0 | 1.0 | 0.5 | 0.0 | 66.7 |
| Okuma | 1,554 | 1,476 | 641 | 825 | 10 | 0 | 10 | 11 | 0 | 825 |
|  |  | 95.0 | 43.4 | 55.9 | 0.7 | 0.0 | 0.7 | 0.7 | 0.0 | 55.9 |
| Futaba | 588 | 556 | 236 | 318 | 2 | 0 | 2 | 5 | 0 | 318 |
|  |  | 94.6 | 42.4 | 57.2 | 0.4 | 0.0 | 0.4 | 0.9 | 0.0 | 57.2 |
| Katsurao | 141 | 136 | 69 | 65 | 2 | 0 | 2 | 1 | 0 | 65 |
|  |  | 96.5 | 50.7 | 47.8 | 1.5 | 0.0 | 1.5 | 0.7 | 0.0 | 47.8 |
| Fukushima | 41,971 | 41,382 | 17,485 | 23,571 | 326 | 0 | 324 | 249 | 0 | 23,690 |
|  |  | 98.6 | 42.3 | 57.0 | 0.8 | 0.0 | 0.8 | 0.6 | 0.0 | 57.2 |
| Nihonmatsu | 7,664 | 7,644 | 3,322 | 4,268 | 54 | 0 | 54 | 53 | 0 | 4,275 |
|  |  | 99.7 | 43.5 | 55.8 | 0.7 | 0.0 | 0.7 | 0.7 | 0.0 | 55.9 |
| Motomiya | 4,692 | 4,681 | 2,037 | 2,613 | 31 | 0 | 31 | 16 | 0 | 2,627 |
|  |  | 99.8 | 43.5 | 55.8 | 0.7 | 0.0 | 0.7 | 0.3 | 0.0 | 56.1 |
| Otama | 1,234 | 1,232 | 553 | 675 | 4 | 0 | 4 | 8 | 0 | 674 |
|  |  | 99.8 | 44.9 | 54.8 | 0.3 | 0.0 | 0.3 | 0.6 | 0.0 | 54.7 |
| Koriyama | 45,589 | 45,381 | 18,079 | 26,962 | 340 | 0 | 340 | 265 | 0 | 27,067 |
|  |  | 99.5 | 39.8 | 59.4 | 0.7 | 0.0 | 0.7 | 0.6 | 0.0 | 59.6 |
| Kori | 1,571 | 1,557 | 666 | 877 | 14 | 0 | 14 | 9 | 0 | 882 |
|  |  | 99.1 | 42.8 | 56.3 | 0.9 | 0.0 | 0.9 | 0.6 | 0.0 | 56.6 |
| Kunimi | 1,197 | 1,189 | 475 | 706 | 8 | 0 | 7 | 10 | 1 | 706 |
|  |  | 99.3 | 39.9 | 59.4 | 0.7 | 0.0 | 0.6 | 0.8 | 0.1 | 59.4 |
| Tenei | 766 | 766 | 319 | 436 | 11 | 0 | 11 | 11 | 0 | 444 |
|  |  | 100.0 | 41.6 | 56.9 | 1.4 | 0.0 | 1.4 | 1.4 | 0.0 | 58.0 |
| Shirakawa | 9,053 | 9,034 | 3,890 | 5,089 | 55 | 0 | 55 | 45 | 0 | 5,105 |
|  |  | 99.8 | 43.1 | 56.3 | 0.6 | 0.0 | 0.6 | 0.5 | 0.0 | 56.5 |
| Nishigo | 2,996 | 2,994 | 1,273 | 1,697 | 24 | 0 | 24 | 24 | 0 | 1,704 |
|  |  | 99.9 | 42.5 | 56.7 | 0.8 | 0.0 | 0.8 | 0.8 | 0.0 | 56.9 |
| Izumizaki | 937 | 937 | 342 | 593 | 2 | 0 | 2 | 10 | 0 | 592 |
|  |  | 100.0 | 36.5 | 63.3 | 0.2 | 0.0 | 0.2 | 1.1 | 0.0 | 63.2 |
| Miharu | 2,298 | 2,297 | 881 | 1,393 | 23 | 0 | 23 | 12 | 0 | 1,402 |
|  |  | 100.0 | 38.4 | 60.6 | 1.0 | 0.0 | 1.0 | 0.5 | 0.0 | 61.0 |
| Subtotal | 152,907 | 151,410 | 63,131 | 87,068 | 1,211 | 0 | 1,207 | 945 | 2 | 87,453 |
|  |  | 99.0 | 41.7 | 57.5 | 0.8 | 0.0 | 0.8 | 0.6 | 0.0 | 57.8 |

Fractions have been rounded and may not total to $100 \%$.

| Results of primary examination by municip |  |  |  |  |  |  |  |  | As of 30 September 2015 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Participants | Confirmed results b | Number by test results |  |  |  | Nodules |  | Cysts |  |
|  |  |  | Proportion (\%) |  |  |  |  |  |  |  |
|  |  | $\begin{gathered} \text { Proportion (\%) } \\ \text { b/a (\%) } \\ \hline \end{gathered}$ | A |  | B | C | Proportion (\%) |  | Proportion (\%) |  |
|  |  |  | A1 | A2 |  |  | $\geq 5.1 \mathrm{~mm}$ | $\leq 5.0 \mathrm{~mm}$ | $\geq 20.1 \mathrm{~mm}$ | $\leq 20.0 \mathrm{~mm}$ |

Screening coverage by municipality in FY 2015

| Iwaki | 22,395 | 11,951 | 4,531 | 7,307 | 113 | 0 | 111 | 60 | 2 | 7,349 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | 53.4 | 37.9 | 61.1 | 0.9 | 0.0 | 0.9 | 0.5 | 0.0 | 61.5 |
| Sukagawa | 10,573 | 9,012 | 3,338 | 5,604 | 70 | 0 | 70 | 41 | 0 | 5,630 |
|  |  | 85.2 | 37.0 | 62.2 | 0.8 | 0.0 | 0.8 | 0.5 | 0.0 | 62.5 |
| Soma | 4,327 | 3,857 | 1,557 | 2,280 | 20 | 0 | 20 | 17 | 0 | 2,287 |
|  |  | 89.1 | 40.4 | 59.1 | 0.5 | 0.0 | 0.5 | 0.4 | 0.0 | 59.3 |
| Kagamiishi | 1,828 | 1,655 | 659 | 984 | 12 | 0 | 12 | 8 | 0 | 988 |
|  |  | 90.5 | 39.8 | 59.5 | 0.7 | 0.0 | 0.7 | 0.5 | 0.0 | 59.7 |
| Shinchi | 964 | 935 | 369 | 553 | 13 | 0 | 13 | 1 | 0 | 560 |
|  |  | 97.0 | 39.5 | 59.1 | 1.4 | 0.0 | 1.4 | 0.1 | 0.0 | 59.9 |
| Nakajima | 99 | 99 | 36 | 60 | 3 | 0 | 3 | 2 | 0 | 59 |
|  |  | 100.0 | 36.4 | 60.6 | 3.0 | 0.0 | 3.0 | 2.0 | 0.0 | 59.6 |
| Yabuki | 342 | 339 | 124 | 206 | 9 | 0 | 9 | 0 | 0 | 211 |
|  |  | 99.1 | 36.6 | 60.8 | 2.7 | 0.0 | 2.7 | 0.0 | 0.0 | 62.2 |
| Ishikawa | 150 | 149 | 59 | 87 | 3 | 0 | 3 | 0 | 0 | 89 |
|  |  | 99.3 | 39.6 | 58.4 | 2.0 | 0.0 | 2.0 | 0.0 | 0.0 | 59.7 |
| Yamatsuri | 38 | 37 | 15 | 22 | 0 | 0 | 0 | 0 | 0 | 22 |
|  |  | 97.4 | 40.5 | 59.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 59.5 |
| Asakawa | 86 | 86 | 33 | 50 | 3 | 0 | 3 | 0 | 0 | 53 |
|  |  | 100.0 | 38.4 | 58.1 | 3.5 | 0.0 | 3.5 | 0.0 | 0.0 | 61.6 |
| Hirata | 79 | 78 | 28 | 49 | 1 | 0 | 1 | 0 | 0 | 50 |
|  |  | 98.7 | 35.9 | 62.8 | 1.3 | 0.0 | 1.3 | 0.0 | 0.0 | 64.1 |
| Tanagura | 142 | 140 | 55 | 82 | 3 | 0 | 3 | 0 | 0 | 84 |
|  |  | 98.6 | 39.3 | 58.6 | 2.1 | 0.0 | 2.1 | 0.0 | 0.0 | 60.0 |
| Hanawa | 87 | 85 | 35 | 48 | 2 | 0 | 2 | 2 | 0 | 49 |
|  |  | 97.7 | 41.2 | 56.5 | 2.4 | 0.0 | 2.4 | 2.4 | 0.0 | 57.6 |
| Samegawa | 20 | 20 | 8 | 12 | 0 | 0 | 0 | 1 | 0 | 11 |
|  |  | 100.0 | 40.0 | 60.0 | 0.0 | 0.0 | 0.0 | 5.0 | 0.0 | 55.0 |
| Ono | 168 | 166 | 57 | 106 | 3 | 0 | 3 | 2 | 0 | 107 |
|  |  | 98.8 | 34.3 | 63.9 | 1.8 | 0.0 | 1.8 | 1.2 | 0.0 | 64.5 |
| Tamakawa | 126 | 126 | 48 | 77 | 1 | 0 | 1 | 2 | 0 | 78 |
|  |  | 100.0 | 38.1 | 61.1 | 0.8 | 0.0 | 0.8 | 1.6 | 0.0 | 61.9 |
| Furudono | 47 | 44 | 14 | 30 | 0 | 0 | 0 | 1 | 0 | 29 |
|  |  | 93.6 | 31.8 | 68.2 | 0.0 | 0.0 | 0.0 | 2.3 | 0.0 | 65.9 |
| Hinoemata | 49 | 4 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 2 |
|  |  | 8.2 | 50.0 | 50.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 50.0 |
| Minami-aizu | 1,436 | 598 | 222 | 370 | 6 | 0 | 6 | 2 | 0 | 372 |
|  |  | 41.6 | 37.1 | 61.9 | 1.0 | 0.0 | 1.0 | 0.3 | 0.0 | 62.2 |
| Kaneyama | 98 | 3 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
|  |  | 3.1 | 66.7 | 33.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 33.3 |
| Showa | 57 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
|  |  | 3.5 | 50.0 | 50.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 50.0 |
| Mishima | 81 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  |  | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Shimogo | 509 | 20 | 9 | 11 | 0 | 0 | 0 | 0 | 0 | 11 |
|  |  | 3.9 | 45.0 | 55.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 55.0 |
| Kitakata | 95 | 57 | 20 | 37 | 0 | 0 | 0 | 0 | 0 | 37 |
|  |  | 60.0 | 35.1 | 64.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 64.9 |
| Nishiaizu | 10 | 5 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 3 |
|  |  | 50.0 | 40.0 | 60.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 60.0 |
| Tadami | 414 | 155 | 56 | 96 | 3 | 0 | 3 | 2 | 0 | 97 |
|  |  | 37.4 | 36.1 | 61.9 | 1.9 | 0.0 | 1.9 | 1.3 | 0.0 | 62.6 |
| Inawashiro | 1,405 | 914 | 339 | 570 | 5 | 0 | 5 | 4 | 0 | 573 |
|  |  | 65.1 | 37.1 | 62.4 | 0.5 | 0.0 | 0.5 | 0.4 | 0.0 | 62.7 |
| Bandai | 307 | 183 | 62 | 121 | 0 | 0 | 0 | 0 | 0 | 121 |
|  |  | 59.6 | 33.9 | 66.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 66.1 |
| Kitashiobara | 275 | 95 | 38 | 57 | 0 | 0 | 0 | 0 | 0 | 57 |
|  |  | 34.5 | 40.0 | 60.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 60.0 |
| Aizumisato | 36 | 23 | 9 | 13 | 1 | 0 | 1 | 0 | 0 | 14 |
|  |  | 63.9 | 39.1 | 56.5 | 4.3 | 0.0 | 4.3 | 0.0 | 0.0 | 60.9 |
| Aizubange | 35 | 26 | 11 | 15 | 0 | 0 | 0 | 0 | 0 | 15 |
|  |  | 74.3 | 42.3 | 57.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 57.7 |
| Yanaizu | 272 | 45 | 16 | 29 | 0 | 0 | 0 | 0 | 0 | 29 |
|  |  | 16.5 | 35.6 | 64.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 64.4 |
| Aizuwakamatsu | 308 | 222 | 99 | 122 | 1 | 0 | 1 | 2 | 0 | 121 |
|  |  | 72.1 | 44.6 | 55.0 | 0.5 | 0.0 | 0.5 | 0.9 | 0.0 | 54.5 |
| Yugawa | 7 | 6 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 6 |
|  |  | 85.7 | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 100.0 |
| Subtotal | 46,865 | 31,137 | 11,854 | 19,011 | 272 | 0 | 270 | 147 | 2 | 19,116 |
|  |  | 66.4 | 38.1 | 61.1 | 0.9 | 0.0 | 0.9 | 0.5 | 0.0 | 61.4 |
|  | $199,772$ |  |  |  |  |  |  |  |  |  |
| Total |  | 182,547 | 74,985 | 106,079 | 1,483 | 0 | 1,477 | 1,092 | 4 | 106,569 |
|  |  | 91.4 | 41.1 | 58.1 | 0.8 | 0.0 | 0.8 | 0.6 | 0.0 | 58.4 |

## Appendix 4

1. Thyroid Ultrasound Examination results by age and sex

|  |  |  |  |  |  |  |  |  |  |  |  |  | As of | 30 Septem | er 2015 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | A |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | A1 |  |  | A2 |  |  | B |  |  | C |  |  |  |  |
| Ages | Male | Female | Total | Male | Female | Total | Male | Female | Total | Male | Female | Total | Male | Female | Total |
| 2-7 | 13,356 | 11,875 | 25,231 | 9,071 | 9,228 | 18,299 | 14 | 12 | 26 | 0 | 0 | 0 | 22,441 | 21,115 | 43,556 |
| 8-12 | 11,056 | 9,643 | 20,699 | 19,717 | 19,638 | 39,355 | 75 | 134 | 209 | 0 | 0 | 0 | 30,848 | 29,415 | 60,263 |
| 13-17 | 11,655 | 9,569 | 21,224 | 18,645 | 19,102 | 37,747 | 264 | 513 | 777 | 0 | 0 | 0 | 30,564 | 29,184 | 59,748 |
| 18-23 | 3,840 | 3,991 | 7,831 | 4,841 | 5,837 | 10,678 | 158 | 313 | 471 | 0 | 0 | 0 | 8,839 | 10,141 | 18,980 |
| Total | 39,907 | 35,078 | 74,985 | 52,274 | 53,805 | 106,079 | 511 | 972 | 1,483 | 0 | 0 | 0 | 92,692 | 89,855 | 182,547 |




Percentages have been rounded and may not total to $100 \%$.
Ages are at the time when the participants underwent the testing.

|  |  |  |  | As of 30 September 2015 |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Nodule size | Total |  |  | Class | Proportion |
|  |  | Male | Female |  |  |
| None | 179,978 | 91,765 | 88,213 | A1 | 98.6\% |
| $\leq 3.0 \mathrm{~mm}$ | 211 | 88 | 123 | A2 | $0.6 \%$ |
| $3.1-5.0 \mathrm{~mm}$ | 881 | 331 | 550 | A2 | 0.6\% |
| $5.1-10.0 \mathrm{~mm}$ | 1,068 | 364 | 704 |  |  |
| $10.1-15.0 \mathrm{~mm}$ | 255 | 95 | 160 |  |  |
| $15.1-20.0 \mathrm{~mm}$ | 98 | 33 | 65 | в | 0.8\% |
| $20.1-25.0 \mathrm{~mm}$ | 33 | 7 | 26 |  |  |
| $\geq 25.1 \mathrm{~mm}$ | 23 | 9 | 14 |  |  |
| Total | 182,547 | 92,692 | 89,855 | , |  |



## 3. Cyst size

|  |  |  |  | As of 30 September 2015 |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Cyst size | Total |  |  | Class | Proportion |
|  |  | Male | Female |  |  |
| None | 75,974 | 40,283 | 35,691 | A1 |  |
| $\leq 3.0 \mathrm{~mm}$ | 67,688 | 35,139 | 32,549 |  |  |
| $3.1-5.0 \mathrm{~mm}$ | 34,339 | 15,708 | 18,631 |  |  |
| $5.1-10.0 \mathrm{~mm}$ | 4,453 | 1,534 | 2,919 | A2 | 13\% |
| $10.1-15.0 \mathrm{~mm}$ | 83 | 23 | 60 |  | 1.3\% |
| $15.1-20.0 \mathrm{~mm}$ | 6 | 3 | 3 |  |  |
| $20.1-25.0 \mathrm{~mm}$ | 2 | 1 | 1 | B | 002\% |
| $\geq 25.1 \mathrm{~mm}$ | 2 | 1 | 1 | B | 0.002\% |
| Total | 182,547 | 92,692 | 89,855 | , |  |




## Appendix 5

|  | Number of those screened <br> a | Participants who required confirmatory test <br> b | Number of those who underwent confirmatory test |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Total | Ages 2-7 | Ages 8-12 | Ages 13-17 | Ages 18-23 |
|  |  |  | c | d | e | f | g |
|  |  | Proportion (\%) | Proportion (\%) | Proportion <br> (\%) | Proportion <br> (\%) | Proportion <br> (\%) | Proportion (\%) |


| As of 30 September 2015 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| Number of confirmed results |  |  |  |  |
| Total | Next screening advised |  | Follow-up advised |  |
|  |  |  |  | Aspiration biopsy cytology |
| h | $\begin{gathered} \mathrm{Al} \\ \mathrm{i} \end{gathered}$ | $\stackrel{\substack{\mathrm{A}_{\mathrm{j}} \\ \hline}}{ }$ | k | 1 |
| Proportion (\%) | Proportion <br> (\%) | Proportion <br> (\%) | Proportion (\%) | Proportion (\%) |

Screening coverage by municipality in FY 2014

| Kawamata | 1,729 | 20 | 18 | 0 | 3 | 11 | 4 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | 1.2 | 90.0 | 0.0 | 16.7 | 61.1 | 22.2 |
| Namie | 2,325 | 27 | 22 | 0 | 2 | 9 | 11 |
|  |  | 1.2 | 81.5 | 0.0 | 9.1 | 40.9 | 50.0 |
| litate | 750 | 14 | 11 | 0 | 2 | 6 | 3 |
|  |  | 1.9 | 78.6 | 0.0 | 18.2 | 54.5 | 27.3 |
| Minami-soma | 8,530 | 74 | 62 | 2 | 9 | 26 | 25 |
|  |  | 0.9 | 83.8 | 3.2 | 14.5 | 41.9 | 40.3 |
| Date | 9,004 | 83 | 74 | 1 | 17 | 38 | 18 |
|  |  | 0.9 | 89.2 | 1.4 | 23.0 | 51.4 | 24.3 |
| Tamura | 4,827 | 50 | 40 | 1 | 3 | 28 | 8 |
|  |  | 1.0 | 80.0 | 2.5 | 7.5 | 70.0 | 20.0 |
| Hirono | 623 | 8 | 7 | 0 | 1 | 3 | 3 |
|  |  | 1.3 | 87.5 | 0.0 | 14.3 | 42.9 | 42.9 |
| Naraha | 918 | 4 | 4 | 0 | 0 | 0 | 4 |
|  |  | 0.4 | 100.0 | 0.0 | 0.0 | 0.0 | 100.0 |
| Tomioka | 1,749 | 23 | 16 | 0 | 3 | 3 | 10 |
|  |  | 1.3 | 69.6 | 0.0 | 18.8 | 18.8 | 62.5 |
| Kawauchi | 201 | 2 | 1 | 0 | 0 | 1 | 0 |
|  |  | 1.0 | 50.0 | 0.0 | 0.0 | 100.0 | 0.0 |
| Okuma | 1,554 | 10 | 10 | 0 | 1 | 5 | 4 |
|  |  | 0.6 | 100.0 | 0.0 | 10.0 | 50.0 | 40.0 |
| Futaba | 588 | 2 | 0 | 0 | 0 | 0 | 0 |
|  |  | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Katsurao | 141 | 2 | 2 | 0 | 2 | 0 | 0 |
|  |  | 1.4 | 100.0 | 0.0 | 100.0 | 0.0 | 0.0 |
| Fukushima | 41,971 | 326 | 270 | 5 | 37 | 135 | 93 |
|  |  | 0.8 | 82.8 | 1.9 | 13.7 | 50.0 | 34.4 |
| Nihonmatsu | 7,664 | 54 | 44 | 1 | 6 | 21 | 16 |
|  |  | 0.7 | 81.5 | 2.3 | 13.6 | 47.7 | 36.4 |
| Motomiya | 4,692 | 31 | 26 | 0 | 1 | 15 | 10 |
|  |  | 0.7 | 83.9 | 0.0 | 3.8 | 57.7 | 38.5 |
| Otama | 1,234 | 4 | 4 | 0 | 0 | 3 | 1 |
|  |  | 0.3 | 100.0 | 0.0 | 0.0 | 75.0 | 25.0 |
| Korivama | 45,589 | 340 | 231 | 2 | 28 | 114 | 87 |
|  |  | 0.7 | 67.9 | 0.9 | 12.1 | 49.4 | 37.7 |
| Kori | 1,571 | 14 | 9 | 0 | 1 | 4 | 4 |
|  |  | 0.9 | 64.3 | 0.0 | 11.1 | 44.4 | 44.4 |
| Kunimi | 1,197 | 8 | 6 | 1 | 1 | 0 | 4 |
|  |  | 0.7 | 75.0 | 16.7 | 16.7 | 0.0 | 66.7 |
| Tenei | 766 | 11 | 3 | 0 | 0 | 1 | 2 |
|  |  | 1.4 | 27.3 | 0.0 | 0.0 | 33.3 | 66.7 |
| Shirakawa | 9,053 | 55 | 41 | 1 | 4 | 20 | 16 |
|  |  | 0.6 | 74.5 | 2.4 | 9.8 | 48.8 | 39.0 |
| Nishigo | 2,996 | 24 | 17 | 0 | 2 | 9 | 6 |
|  |  | 0.8 | 70.8 | 0.0 | 11.8 | 52.9 | 35.3 |
| Izumizaki | 937 | 2 | 1 | 0 | 0 | 1 | 0 |
|  |  | 0.2 | 50.0 | 0.0 | 0.0 | 100.0 | 0.0 |
| Miharu | 2,298 | 23 | 13 | 0 | 0 | 10 | 3 |
|  |  | 1.0 | 56.5 | 0.0 | 0.0 | 76.9 | 23.1 |
| Subtotal | 152,907 | 1,211 | 932 | 14 | 123 | 463 | 332 |
|  |  | 0.8 | 77.0 | 1.5 | 13.2 | 49.7 | 35.6 |


| 17 | 3 | 6 | 8 | 1 |
| :---: | :---: | :---: | :---: | :---: |
| 94.4 | 17.6 | 35.3 | 47.1 | 12.5 |
| 21 | 0 | 2 | 19 | 3 |
| 95.5 | 0.0 | 9.5 | 90.5 | 15.8 |
| 10 | 2 | 3 | 5 | 1 |
| 90.9 | 20.0 | 30.0 | 50.0 | 20.0 |
| 59 | 4 | 14 | 41 | 12 |
| 95.2 | 6.8 | 23.7 | 69.5 | 29.3 |
| 72 | 0 | 26 | 46 | 9 |
| 97.3 | 0.0 | 36.1 | 63.9 | 19.6 |
| 39 | 1 | 9 | 29 | 6 |
| 97.5 | 2.6 | 23.1 | 74.4 | 20.7 |
| 7 | 0 | 3 | 4 | 0 |
| 100.0 | 0.0 | 42.9 | 57.1 | 0.0 |
| 4 | 0 | 0 | 4 | 0 |
| 100.0 | 0.0 | 0.0 | 100.0 | 0.0 |
| 12 | 0 | 3 | 9 | 1 |
| 75.0 | 0.0 | 25.0 | 75.0 | 11.1 |
| 1 | 0 | 0 | 1 | 0 |
| 100.0 | 0.0 | 0.0 | 100.0 | 0.0 |
| 9 | 0 | 1 | 8 | 2 |
| 90.0 | 0.0 | 11.1 | 88.9 | 25.0 |
| 0 | 0 | 0 | 0 | 0 |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| 2 | 0 | 2 | 0 | 0 |
| 100.0 | 0.0 | 100.0 | 0.0 | 0.0 |
| 263 | 12 | 51 | 200 | 46 |
| 97.4 | 4.6 | 19.4 | 76.0 | 23.0 |
| 43 | 1 | 9 | 33 | 4 |
| 97.7 | 2.3 | 20.9 | 76.7 | 12.1 |
| 21 | 0 | 4 | 17 | 3 |
| 80.8 | 0.0 | 19.0 | 81.0 | 17.6 |
| 4 | 0 | 2 | 2 | 0 |
| 100.0 | 0.0 | 50.0 | 50.0 | 0.0 |
| 186 | 7 | 38 | 141 | 25 |
| 80.5 | 3.8 | 20.4 | 75.8 | 17.7 |
| 8 | 0 | 2 | 6 | 1 |
| 88.9 | 0.0 | 25.0 | 75.0 | 16.7 |
| 6 | 0 | 0 | 6 | 0 |
| 100.0 | 0.0 | 0.0 | 100.0 | 0.0 |
| 2 | 0 | 1 | 1 | 1 |
| 66.7 | 0.0 | 50.0 | 50.0 | 100.0 |
| 36 | 1 | 17 | 18 | 3 |
| 87.8 | 2.8 | 47.2 | 50.0 | 16.7 |
| 14 | 0 | 6 | 8 | 2 |
| 82.4 | 0.0 | 42.9 | 57.1 | 25.0 |
| 1 | 0 | 0 | 1 | 0 |
| 100.0 | 0.0 | 0.0 | 100.0 | 0.0 |
| 12 | 1 | 6 | 5 | 0 |
| 92.3 | 8.3 | 50.0 | 41.7 | 0.0 |
| 849 | 32 | 205 | 612 | 120 |
| 91.1 | 3.8 | 24.1 | 72.1 | 19.6 |

[^4]Fractions have been rounded and may not total to $100 \%$. Ages are at the time when the participants underwent the testing.


## Appendix 6

Surgical cases for malignancy or suspicion of malignancy

1. Target municipalities in FY 2014-2015

Suspicious or malignant: 39 ( 15 surgical cases: 15 of papillary thyroid carcinoma)

## Progress Report of the Comprehensive Health Check

Reported on 30 November 2015

## 1. The implementation status in FY 2014

- Results of FY 2014

| Progress Report for FY 2011-2014 (Ages 16 and older) |  |  |  | (Unit: person, percentage) |
| :---: | :---: | :---: | :---: | :---: |
|  | FY 2011 | FY 2012 | FY 2013 | FY 2014 |
|  | Revised value as of 11 Sep 2012 | Revised value as of 5 Jul 2013 | Revised value as of 1 Sep 2014 | $\begin{gathered} \text { Revised value } \\ \text { as of } 1 \text { Sep } 2015 \\ \hline \end{gathered}$ |
| Survey population | 182,370 | 184,910 | 186,970 | 188,328 |
| Health Check conducted by municipalities within the prefecture | 8,798 | 23,907 | 25,604 | 25,913 |
| Individual examinations conducted within the prefecture | - | 6,692 | 5,806 | 4,927 |
| Group examinations conducted within the prefecture | 41,949 | 10,603 | 6,767 | 5,808 |
| Individual examinations conducted outside the prefecture | 3,815 | 3,055 | 3,205 | 3,418 |
| Other ${ }^{1,2}$ | 2,045 | 3,206 | 2,017 | 1,846 |
| Number of overlapping examinees within and outside the prefecture | 208 | 454 | 359 | 38 |
| Total (Excluding the number of overlapping examinees) | 56,399 | 47,009 | 43,040 | 41,874 |
| Proportion of participants (\%) | 30.9\% | 25.4\% | 23.0\% | 22.2\% |

1) conducted within the prefecture (cases where the municipality delegated the examination to medical institutions or county/city medical associations)
2) conducted outside the prefecture (cases where the municipality delegated the examination to examination agencies)

| Progress Report for FY | 1-2014 (Ag | 15 and youn |  | (Unit: person, percentage) |
| :---: | :---: | :---: | :---: | :---: |
|  | FY 2011 | FY 2012 | FY 2013 | FY 2014 |
|  | Revised value as of 11 Sep 2012 | Revised value as of 5 Jul 2013 | Revised value as of 1 Sep 2014 | Revised value as of 1 Sep 2015 |
| Survey population | 27,819 | 27,077 | 26,474 | 25,883 |
| Children's health examination within the prefecture | 15,002 | 9,534 | 8,432 | 7,432 |
| Children's health examination outside the prefecture | 2,949 | 2,283 | 1,822 | 1,792 |
| Number of overlapping examinees within and outside the prefecture | 17 | 37 | 6 | 8 |
| Total (excluding the number of overlapping examinees) | 17,934 | 11,780 | 10,248 | 9,216 |
| Proportion of participants (\%) | 64.5\% | 43.5\% | 38.7\% | 35.6\% |

## 【People residing within the prefecture】

For those aged 16 and older，items were added to specific health examinations held by municipalities so that these existing health examinations and the Comprehensive Health Check could be conducted simultaneously．Furthermore，group health examinations were conducted 52 times at 24 locations within the prefecture for those who could not undergo individual check－ups． Also，around the same time period as the group health examinations， 504 facilities cooperated to conduct the Comprehensive Health Check．

For children 15 and under，we requested the cooperation of pediatricians so that children＇s needs could be accommodated，and health examinations were conducted at 101 medical institutions within the prefecture．

## 【People living outside the prefecture】

Taking into account the fact that people had evacuated to various locations in the country， health examinations were conducted with the cooperation of a total of 837 medical institutions outside the prefecture．The breakdown of institutions that cooperated is as follows： 432 medical institutions for those 16 and older，and 124 medical institutions with a pediatric department for those 15 and under，as was the case within the prefecture．Furthermore，we received cooperation from 281 medical institutions that could accommodate both age groups．

## －Proportion of participants

The proportion of participants 16 years and older was $22.2 \%$ in FY 2014．Compared to $23.0 \%$ in FY 2013，it has decreased by 0.8 points．Similarly，the proportion of participants who are 15 and under was 35.6 \％，which has decreased by 3.1 points compared to 38.7 \％in FY 2013.

## 2．Implementation status of FY 2015

Group：215，315 individuals

＊Iitate（from 13 May），Tamura（from 25 May），Katsurao（6， 7 Jun），Kawamata（from 17 Jun），Minami－soma （from 6 Jul），Hirono（from 7 Jul），Kawauchi（from 31 Aug ），Futaba（from 5 Sep），Namie（from 18 Sep），Naraha （from 28 Sep），Tomioka（from 7 Oct），Okuma（from 20 Oct）
（25，296 individuals aged 15 and under，190，019 individuals aged 16 and older）

## －Implementation status of FY 2015

## 【People residing within the prefecture】

For those aged 16 and older，items are added to specific health check－ups held by municipalities as before，so that examinations can be simultaneously conducted in 12 municipalities except Date city．Furthermore，we plan to conduct group health examinations and individual health examinations at medical institutions．The number of examinees who are 16 and older is 18,066 at this point．

For children aged 15 and under，the health exams are being conducted during an approximately 6－month period from Jul to Dec 2015 as was the case in the previous year（Number of cooperating medical institutions is 99）．The number of examinees at this point is 3,469 ．

## 【People living outside the prefecture】

In addition to increasing the number of medical institutions that can conduct health examinations nationwide，we have sequentially sent out notices from mid－July in order to ensure early implementation starting from August．Furthermore，we will make efforts to gain cooperation from medical institutions located near regions where a significant number of people have evacuated．

# FY 2011－2014 Comprehensive Health Check Health Statistics Reports 

Reported on 30 November 2015

## 【Group】

Residents of nationally designated evacuation zones as of 2011 and those who were recommended to have follow－up based on the results of the Basic Survey．

【Evacuation area，etc．】
All of Tamura City，Minami－Soma city，Kawamata Town，Hirono Town，Naraha Town，Tomioka Town，Kawauchi Village，Okuma Town，Futaba Town，Namie Town，Katsurao Village，Iitate Village and parts of Date City（belonging to designated evacuation areas）

【Examination items】

| Age group（years） | Examination Items |
| :---: | :---: |
| 0－6 <br> （Infant before entering school） | Height，weight，CBC（Number of red blood cells，hematocrit，hemoglobin，platelet count， number of white blood cells，differential white blood count．） |
| $7-15$ （From 1st to 9 th grade） | Height，weight，blood pressure， <br> CBC（Number of red blood cells，hematocrit，hemoglobin，platelet count，number of white blood cells，differential white blood count．） <br> ［Additional items on request］ <br> Blood biochemistry（AST，ALT，$\gamma$ GT，TG，HDL－C，LDL－C，HbA1c，plasma glucose，serum creatinine，uric acid） |
| 16 and older | Height，weight，abdominal circumference or BMI，blood pressure <br> CBC（Number of red blood cells，hematocrit，hemoglobin，platelet count，number of white blood cells，differential white blood count．） <br> Urinary test（urine protein，urinary sugar，urine occult blood） <br> Blood biochemistry（AST，ALT，$\gamma$ GT，TG，HDL－C，LDL－C，HbA1c，plasma glucose，serum creatinine，estimated glomerular filtration rate［eGFR］，uric acid） <br> The underlined values are not routinely measured during regular health exams． |

－Medical examination results are divided into general age categories and，due to differences in medical checkup items，also divided into 5 age groups：0－6 years old，7－15 years old，16－39 years old， 40－64 years old，and 65 years old and above．This is further paired with 2 categories resulting in 10 categories，and the results were compiled for each medical checkup item．
－Individuals who received examination at least twice in the same year have been included in the total results．
－Symbols in the tables are represented in the same way as in Vital Statistics of the Ministry of Health， Labour and Welfare：

When there are no figures（－）
When there are no items（no medical checkup items due to age category）（ $\cdot$ ）
When it is not appropriate to express the total（．．．）
When the percentage is small（less than 0．05）（ $0.0 \%$ ）
－A statistical analysis has not been conducted．

- Although there are no significant changes in the survey population of FY 2012-2014 from FY 2011, the participants, the time they received their health exams, and the medical organizations differ. Due to such modifying factors, this is not a strict comparison.

Note: Exam schedule for participants aged 15 years old and under
FY 2011: Jan-Mar 2012
FY 2012: Jul-Dec 2012
FY 2013: Jul-Dec 2013
FY 2014: Jul-Dec 2014

## Height

FY 2011

| Height (cm) (overall) |  |  |  |  |
| ---: | :--- | :--- | :--- | :---: |
| Age | Examinees |  | Average age |  |
|  |  | Average height |  |  |
| $0-6$ | 6,461 | 3.6 | 98.5 |  |
| $7-15$ | 11,479 | 11.0 | 144.1 |  |
| $16-39$ | 14,762 | 28.1 | 163.2 |  |
| $40-64$ | 23,637 | 54.0 | 160.0 |  |
| $65-$ | 16,718 | 73.7 | 153.5 |  |


| Height (cm) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> height | 150 cm and below | 170 cm and above |
| 0-6 | 3,271 | 3.6 | 99.2 | $\ldots$ | $\ldots$ |
| 7-15 | 5,766 | 10.9 | 145.1 | $\ldots$ | $\ldots$ |
| 16-39 | 5,963 | 27.7 | 170.9 | 0.2\% | 57.1\% |
| 40-64 | 9,560 | 54.5 | 167.5 | 0.4\% | 34.2\% |
| 65- | 7,498 | 73.4 | 160.8 | 3.9\% | 6.7\% |


| Height (cm) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> height | 140 cm and below | 160 cm and above |
| 0-6 | 3,190 | 3.6 | 97.7 | $\ldots$ | $\ldots$ |
| 7-15 | 5,713 | 11.0 | 143.0 | $\ldots$ | $\ldots$ |
| 16-39 | 8,799 | 28.3 | 158.0 | 0.1\% | 36.4\% |
| 40-64 | 14,077 | 53.7 | 154.9 | 0.4\% | 18.4\% |
| 65- | 9,220 | 73.8 | 147.6 | 10.7\% | 1.6\% |

FY 2012

| Height (cm) (overall) |  |  |  |  |
| ---: | :--- | :--- | :--- | :---: |
| Age | Examinees |  | Average age |  |
|  |  |  | Average height |  |
|  |  | 4,364 | 3.6 |  |


| Height (cm) (male) |  |  |  |  |  |  |  |
| ---: | ---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> height | $150 \quad \mathrm{~cm}$ <br> below | $170 \quad \mathrm{~cm}$ <br> above | and |  |
| $0-6$ | 2,174 | 3.6 | 97.0 | $\ldots$ | $\ldots$ |  |  |
| $7-15$ | 3,810 | 10.8 | 143.1 | $\ldots$ | $\ldots$ |  |  |
| $16-39$ | 3,230 | 27.9 | 171.3 | $0.3 \%$ | $59.2 \%$ |  |  |
| $40-64$ | 7,716 | 55.4 | 167.5 | $0.3 \%$ | $34.6 \%$ |  |  |
| $65-$ | 8,475 | 73.4 | 161.1 | $3.9 \%$ | $7.6 \%$ |  |  |


| Height (cm) (female) |  |  |  |  |  |  |  |
| ---: | ---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age |  | Average <br> height | $140 \quad \mathrm{~cm}$ <br> below | $160 \quad \mathrm{~cm}$ <br> above |  |
| $0-6$ | 2,190 | 3.6 | 95.5 | $\ldots$ | $\ldots$ |  |  |
| $7-15$ | 3,627 | 10.9 | 141.4 | $\ldots$ | $\ldots$ |  |  |
| $16-39$ | 5,250 | 29.1 | 158.3 | $0.1 \%$ | $38.3 \%$ |  |  |
| $40-64$ | 11,836 | 54.6 | 154.9 | $0.5 \%$ | $18.5 \%$ |  |  |
| $65-$ | 10,157 | 73.6 | 148.0 | $9.5 \%$ | $1.7 \%$ |  |  |

Height
FY 2013

| Height (cm) (overall) |  |  |  |  |
| ---: | :--- | :--- | :--- | :---: |
| Age | Examinees |  | Average age |  |
|  |  |  | Average height |  |
| $0-6$ | 3,801 | 3.7 | 96.5 |  |
| $7-15$ | 6,429 | 10.8 | 141.8 |  |
| $16-39$ | 6,535 | 29.0 | 163.1 |  |
| $40-64$ | 16,922 | 55.3 | 159.8 |  |
| $65-$ | 18,960 | 73.5 | 154.3 |  |


| Height (cm) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average height | 150 cm and below | 170 cm and above |
| 0-6 | 1,950 | 3.7 | 97.0 | $\ldots$ | $\ldots$ |
| 7-15 | 3,291 | 10.9 | 143.0 | $\ldots$ | $\ldots$ |
| 16-39 | 2,480 | 28.3 | 171.1 | 0.4\% | 58.8\% |
| 40-64 | 6,511 | 55.7 | 167.6 | 0.3\% | 34.8\% |
| 65- | 8,636 | 73.4 | 161.4 | 3.4\% | 7.9\% |


| Height (cm) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> height | 140 cm and below | 160 cm and above |
| 0-6 | 1.851 | 3.7 | 95.9 | ... | $\ldots$ |
| 7-15 | 3,138 | 10.8 | 140.6 | $\ldots$ | $\ldots$ |
| 16-39 | 4,055 | 29.5 | 158.2 | 0.2\% | 37.2\% |
| 40-64 | 10,411 | 55.0 | 155.0 | 0.5\% | 19.3\% |
| 65- | 10,324 | 73.5 | 148.4 | 8.6\% | 2.1\% |

FY 2014

| Height (cm) (overall) |  |  |  |
| :---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> height |
| $0-6$ | 3,328 | 3.8 | 96.9 |
| $7-15$ | 5,840 | 10.9 | 141.9 |
| $16-39$ | 5,842 | 29.0 | 163.0 |
| $40-64$ | 15,594 | 55.1 | 160.0 |
| $65-$ | 19,159 | 73.3 | 154.6 |


| Height (cm) (male) |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> height | 150 cm and <br> below | 170 cm and <br> above |
| $0-6$ | 1,691 | 3.8 | 97.5 | $\ldots$ | $\ldots$ |
| $7-15$ | 2,989 | 10.9 | 143.3 | $\ldots$ | $\ldots$ |
| $16-39$ | 2,168 | 28.0 | 171.0 | $0.4 \%$ | $58.4 \%$ |
| $40-64$ | 5,859 | 55.5 | 167.9 | $0.3 \%$ | $37.0 \%$ |
| $65-$ | 8,681 | 73.3 | 161.7 | $3.2 \%$ | $9.3 \%$ |


| Height (cm) (female) |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> height | 140 cm and <br> below | 160 cm and <br> above |
| $0-6$ | 1,637 | 3.8 | 96.4 | $\ldots$ | $\ldots$ |
| $7-15$ | 2,851 | 10.8 | 140.5 | $\ldots$ | $\ldots$ |
| $16-39$ | 3,674 | 29.5 | 158.3 | $0.2 \%$ | $37.6 \%$ |
| $40-64$ | 9,735 | 54.9 | 155.2 | $0.4 \%$ | $19.7 \%$ |
| $65-$ | 10,478 | 73.3 | 148.8 | $7.6 \%$ | $2.3 \%$ |

Weight
FY 2011

| Weight (kg) (overall) |  |  |  |  |
| ---: | ---: | :--- | :--- | :---: |
| Age | Examinees |  | Average age |  |
|  |  |  | Average weight |  |
| $0-6$ | 6,462 | 3.6 | 16.1 |  |
| $7-15$ | 11,481 | 11.0 | 40.2 |  |
| $16-39$ | 14,761 | 28.1 | 60.5 |  |
| $40-64$ | 23,637 | 54.0 | 61.2 |  |
| $65-$ | 16,722 | 73.7 | 56.8 |  |


| Weight (kg) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Number of examinees | Average age | Average <br> weight | $50 \quad \mathrm{~kg} \quad$ and below | $70 \quad \mathrm{~kg} \quad$ and above |
| 0-6 | 3,271 | 3.6 | 16.4 | $\ldots$ | $\ldots$ |
| 7-15 | 5,768 | 10.9 | 41.0 | $\ldots$ | $\ldots$ |
| 16-39 | 5,963 | 27.7 | 68.8 | 3.8\% | 39.8\% |
| 40-64 | 9,560 | 54.5 | 69.0 | 1.9\% | 42.6\% |
| 65- | 7,499 | 73.4 | 62.7 | 8.1\% | 20.2\% |


| Weight (kg) (female) |  |  |  |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: | ---: | ---: | ---: |
| Age | Examinees |  | Average age | Average <br> weight | $45 \quad \mathrm{~kg}$ <br> below | and <br> 65 <br> above | $\mathrm{kg} \quad$ and |
| $0-6$ | 3,191 | 3.6 | 15.8 | $\ldots$ | $\ldots$ |  |  |
| $7-15$ | 5,713 | 11.0 | 39.5 | $\ldots$ | $\ldots$ |  |  |
| $16-39$ | 8,798 | 28.3 | 54.8 | $13.8 \%$ | $14.1 \%$ |  |  |
| $40-64$ | 14,077 | 53.7 | 56.0 | $9.1 \%$ | $15.1 \%$ |  |  |
| $65-$ | 9,223 | 73.8 | 52.1 | $19.9 \%$ | $6.9 \%$ |  |  |

FY 2012

| Weight (kg) (overall) |  |  |  |  |
| ---: | :--- | :--- | :--- | :---: |
| Age | Examinees | Average age | Average weight |  |
|  |  |  |  |  |
| $0-6$ | 4,365 | 3.6 | 15.1 |  |
| $7-15$ | 7,437 | 10.9 | 38.3 |  |
| $16-39$ | 8,478 | 28.6 | 60.3 |  |
| $40-64$ | 19,553 | 55.0 | 61.1 |  |
| $65-$ | 18,638 | 73.5 | 56.9 |  |


| Weight (kg) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> weight | 50 kg and below | 70 kg and above |
| 0-6 | 2,174 | 3.6 | 15.4 | ... | $\ldots$ |
| 7-15 | 3,810 | 10.8 | 39.0 | $\ldots$ | $\ldots$ |
| 16-39 | 3,230 | 27.9 | 69.2 | 4.4\% | 40.9\% |
| 40-64 | 7,717 | 55.4 | 68.8 | 2.2\% | 41.3\% |
| 65- | 8,479 | 73.4 | 62.5 | 8.5\% | 20.1\% |


| Weight (kg) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> weight | 45 kg and below | 65 kg and above |
| 0-6 | 2,191 | 3.6 | 14.8 | $\ldots$ | $\ldots$ |
| 7-15 | 3,627 | 10.9 | 37.5 | ... | .. |
| 16-39 | 5,248 | 29.1 | 54.9 | 14.0\% | 14.3\% |
| 40-64 | 11,836 | 54.6 | 56.1 | 9.4\% | 15.9\% |
| 65- | 10,159 | 73.6 | 52.2 | 20.4\% | 7.3\% |

Weight
FY 2013

| Weight (kg) (overall) |  |  |  |  |
| ---: | :--- | :--- | :--- | :---: |
| Age | Examinees |  | Average age |  |
|  |  |  | Average weight |  |
| $0-6$ | 3,802 | 3.7 | 15.2 |  |
| $7-15$ | 6,429 | 10.8 | 37.9 |  |
| $16-39$ | 6,534 | 29.0 | 60.2 |  |
| $40-64$ | 16,921 | 55.3 | 61.0 |  |
| $65-$ | 18,964 | 73.5 | 57.1 |  |


| Weight (kg) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> weight | $50 \quad \mathrm{~kg} \quad$ and below | $70 \quad \mathrm{~kg} \quad$ and above |
| 0-6 | 1,951 | 3.7 | 15.5 | $\ldots$ | $\ldots$ |
| 7-15 | 3,291 | 10.9 | 38.9 | $\ldots$ | $\ldots$ |
| 16-39 | 2,480 | 28.3 | 69.0 | 4.3\% | 40.6\% |
| 40-64 | 6,511 | 55.7 | 69.0 | 2.1\% | 42.5\% |
| 65- | 8,638 | 73.4 | 62.7 | 8.3\% | 21.0\% |


| Weight (kg) (female) |  |  |  |  |  |  |  |
| ---: | :--- | :--- | :--- | :--- | :--- | :--- | :---: |
| Age | Examinees | Average age | Average <br> weight | $45 \quad \mathrm{~kg}$ <br> below | and | 65 <br> above |  |
| $0-6$ | 1,851 | 3.7 | 14.9 | $\ldots$ | $\ldots$ |  |  |
| $7-15$ | 3,138 | 10.8 | 36.8 | $\ldots$ | $\ldots$ |  |  |
| $16-39$ | 4,054 | 29.5 | 54.9 | $14.6 \%$ | $14.5 \%$ |  |  |
| $40-64$ | 10,410 | 55.0 | 56.1 | $9.6 \%$ | $16.2 \%$ |  |  |
| $65-$ | 10,326 | 73.5 | 52.4 | $19.7 \%$ | $7.6 \%$ |  |  |

FY 2014

| Weight (kg) (overall) |  |  |  |
| :---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> weight |
| $0-6$ | 3,328 | 3.8 | 15.3 |
| $7-15$ | 5,840 | 10.9 | 37.7 |
| $16-39$ | 5,836 | 29.0 | 60.1 |
| $40-64$ | 15,594 | 55.1 | 60.9 |
| $65-$ | 19,166 | 73.3 | 57.1 |


| Weight (kg) (male) |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> weight | 50 kg and <br> below | 70 kg and <br> above |
| $0-6$ | 1,691 | 3.8 | 15.6 | $\ldots$ | $\ldots$ |
| $7-15$ | 2,989 | 10.9 | 38.7 | $\ldots$ | $\ldots$ |
| $16-39$ | 2,168 | 28.0 | 68.7 | $4.4 \%$ | $38.7 \%$ |
| $40-64$ | 5,859 | 55.5 | 68.9 | $2.2 \%$ | $42.0 \%$ |
| $65-$ | 8,684 | 73.3 | 62.8 | $8.0 \%$ | $21.3 \%$ |


| Weight (kg) (female) |  |  |  |  |  |
| :---: | ---: | ---: | ---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> weight | 45 kg and <br> below | 65 kg and <br> above |
| $0-6$ | 1,637 | 3.8 | 15.1 | $\ldots$ | $\ldots$ |
| $7-15$ | 2,851 | 10.8 | 36.7 | $\ldots$ | $\ldots$ |
| $16-39$ | 3,668 | 29.5 | 55.1 | $14.7 \%$ | $14.8 \%$ |
| $40-64$ | 9,735 | 54.9 | 56.0 | $9.8 \%$ | $16.2 \%$ |
| $65-$ | 10,482 | 73.3 | 52.4 | $19.7 \%$ | $7.9 \%$ |

FY 2011

| BMI (weight/height $\left.{ }^{2}\right)($ overall $)$ |  |  |  |  |  |  |
| ---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average BMI | Less than 18 | 25 and above |  |
|  |  |  |  |  |  |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 14,761 | 28.1 | 22.6 | $8.0 \%$ | $22.3 \%$ |  |
| $40-64$ | 23,637 | 54.0 | 23.8 | $2.8 \%$ | $33.7 \%$ |  |
| $65-$ | 16,717 | 73.7 | 24.0 | $2.5 \%$ | $37.1 \%$ |  |


| BMI (weight/height ${ }^{2}$ ) (male) |  |  |  |  |  |  |
| ---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average BMI | Less than 18 | 25 and above |  |
|  |  |  |  |  |  |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 5,963 | 27.7 | 23.5 | $4.7 \%$ | $29.8 \%$ |  |
| $40-64$ | 9,560 | 54.5 | 24.6 | $1.1 \%$ | $41.6 \%$ |  |
| $65-$ | 7,498 | 73.4 | 24.2 | $1.8 \%$ | $39.1 \%$ |  |


| BMI (weight/height $\left.{ }^{2}\right)($ female $)$ |  |  |  |  |  |  |
| ---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average BMI | Less than 18 | 25 and above |  |
|  |  |  |  |  |  |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 8,798 | 28.3 | 21.9 | $10.2 \%$ | $17.2 \%$ |  |
| $40-64$ | 14,077 | 53.7 | 23.3 | $4.0 \%$ | $28.4 \%$ |  |
| $65-$ | 9,219 | 73.8 | 23.9 | $3.1 \%$ | $35.4 \%$ |  |

FY 2012

| BMI (weight/height ${ }^{2}$ ) (overall) |  |  |  |  |  |  |
| ---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average BMI | Less than 18 | 25 and above |  |
|  |  |  |  |  |  |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | . | $\cdot$ |  |
| $16-39$ | 8,478 | 28.6 | 22.5 | $8.9 \%$ | $22.3 \%$ |  |
| $40-64$ | 19,551 | 55.0 | 23.8 | $2.9 \%$ | $33.6 \%$ |  |
| $65-$ | 18,632 | 73.5 | 23.9 | $2.8 \%$ | $35.2 \%$ |  |


| BMI (weight/height ${ }^{2}$ ) (male) |  |  |  |  |  |  |
| ---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age |  | Average BMI | Less than 18 |  |
|  |  |  | 25 and above |  |  |  |
|  |  | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 3,230 | 27.9 | 23.6 | $5.2 \%$ | $30.7 \%$ |  |
| $16-39$ | 7,716 | 55.4 | 24.5 | $1.2 \%$ | $40.3 \%$ |  |
| $40-64$ | 8,475 | 73.4 | 24.0 | $2.0 \%$ | $36.4 \%$ |  |
| $65-$ |  |  |  |  |  |  |


| BMI (weight/height $\left.{ }^{2}\right)($ female $)$ |  |  |  |  |  |  |
| ---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average BMI | Less than 18 | 25 and above |  |
|  |  |  |  |  |  |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 5,248 | 29.1 | 21.9 | $11.1 \%$ | $17.1 \%$ |  |
| $40-64$ | 11,835 | 54.6 | 23.4 | $4.1 \%$ | $29.2 \%$ |  |
| $65-$ | 10,157 | 73.6 | 23.8 | $3.4 \%$ | $34.3 \%$ |  |

## BMI

FY 2013

| BMI (weight/height $\left.{ }^{2}\right)($ overall $)$ |  |  |  |  |  |  |
| ---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average BMI | Less than 18 | 25 and above |  |
|  |  |  |  |  |  |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 6,534 | 29.0 | 22.5 | $9.1 \%$ | $22.1 \%$ |  |
| $40-64$ | 16,921 | 55.3 | 23.8 | $3.1 \%$ | $33.5 \%$ |  |
| $65-$ | 18,960 | 73.5 | 23.9 | $2.9 \%$ | $35.3 \%$ |  |


| BMI $\left(\right.$ weight/height $\left.{ }^{2}\right)($ male $)$ |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | :--- | :--- | :--- |
| Age | Examinees | Average age | Average BMI | Less than 18 | 25 and above |  |
|  |  |  |  |  |  |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 2,480 | 28.3 | 23.5 | $5.3 \%$ | $30.0 \%$ |  |
| $40-64$ | 6,511 | 55.7 | 24.5 | $1.2 \%$ | $40.9 \%$ |  |
| $65-$ | 8,636 | 73.4 | 24.0 | $2.1 \%$ | $36.3 \%$ |  |


| BMI (weight/height ${ }^{2}$ ) (female) |  |  |  |  |  |  |
| ---: | :--- | :--- | :--- | :--- | :--- | :---: |
| Age | Examinees | Average age | Average BMI | Less than 18 | 25 and above |  |
|  |  |  |  |  |  |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 4,054 | 29.5 | 21.9 | $11.3 \%$ | $17.3 \%$ |  |
| $40-64$ | 10,410 | 55.0 | 23.3 | $4.2 \%$ | $28.9 \%$ |  |
| $65-$ | 10,324 | 73.5 | 23.8 | $3.5 \%$ | $34.4 \%$ |  |

FY 2014

| BMI (weight/height ${ }^{2}$ ) (overall) |  |  |  |  |  |
| :---: | :---: | ---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average BMI | Less than 18 | 25 and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $16-39$ | 5,836 | 29.0 | 22.5 | $9.0 \%$ | $21.8 \%$ |
| $40-64$ | 15,594 | 55.1 | 23.7 | $3.6 \%$ | $32.2 \%$ |
| $65-$ | 19,159 | 73.3 | 23.8 | $3.0 \%$ | $34.3 \%$ |


| BMI (weight/height ${ }^{2}$ ) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average BMI | Less than 18 | 25 and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $16-39$ | 2,168 | 28.0 | 23.5 | $5.5 \%$ | $29.0 \%$ |
| $40-64$ | 5,859 | 55.5 | 24.4 | $1.5 \%$ | $39.3 \%$ |
| $65-$ | 8,681 | 73.3 | 24.0 | $2.3 \%$ | $35.8 \%$ |


| BMI (weight/height ${ }^{2}$ ) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average BMI | Less than 18 | 25 and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $16-39$ | 3,668 | 29.5 | 22.0 | $11.1 \%$ | $17.6 \%$ |
| $40-64$ | 9,735 | 54.9 | 23.2 | $4.8 \%$ | $27.9 \%$ |
| $65-$ | 10,478 | 73.3 | 23.7 | $3.6 \%$ | $33.0 \%$ |

## Abdominal circumference (AC)

FY 2011

| AC (cm) (overall) |  |  |  |  |
| ---: | :--- | :--- | :--- | :---: |
| Age | Examinees | Average age | Average AC |  |
|  |  |  |  |  |
| $0-6$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 2,470 | 29.7 | $\cdot$ |  |
| $40-64$ | 23,601 | 54.0 | 78.0 |  |
| $65-$ | 10,264 | 69.9 | 83.8 |  |
|  |  | 85.3 |  |  |


| AC (cm) |  |  |  |  |  |  | (male) |
| ---: | :--- | :--- | :--- | :--- | :--- | :---: | :---: |
| Age | Examinees | Average age | Average AC | 85 cm and above |  |  |  |
|  |  |  |  |  |  |  |  |
| $0-6$ | $\cdot$ | $\cdot$ |  | $\cdot$ |  |  |  |
| $7-15$ | $\cdot$ | $\cdot$ |  | $\cdot$ | $\cdot$ |  |  |
| $16-39$ | 867 | 29.0 | 82.2 | $37.3 \%$ |  |  |  |
| $40-64$ | 9,546 | 54.5 | 86.6 | $56.0 \%$ |  |  |  |
| $65-$ | 4,649 | 69.8 | 86.5 | $58.2 \%$ |  |  |  |


| AC (cm) |  |  |  |  |  |  | (female) |
| ---: | :--- | :--- | :--- | :--- | :--- | :---: | :---: |
| Age | Examinees | Average age | Average | AC | 90 cm and above |  |  |
|  |  |  |  |  |  |  |  |
| $0-6$ | $\cdot$ | $\cdot$ |  | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |  |
| $16-39$ | 1,603 | 30.0 | 75.8 | $9.5 \%$ |  |  |  |
| $40-64$ | 14,055 | 53.7 | 81.9 | $19.5 \%$ |  |  |  |
| $65-$ | 5,615 | 70.1 | 84.4 | $26.7 \%$ |  |  |  |

FY 2012

| AC (cm) (overall) |  |  |  |  |
| ---: | :--- | :--- | :--- | :--- |
| Age | Examinees |  | Average age |  |
|  |  |  | Average AC |  |
| $0-6$ | $\cdot$ |  |  |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 1,971 | $\cdot$ | $\cdot$ |  |
| $40-64$ | 19,506 | 30.0 | 77.6 |  |
| $65-$ | 11,859 | 55.0 | 84.0 |  |


| AC (cm) |  |  |  |  |  |  | (male) |
| ---: | ---: | ---: | :--- | :--- | :---: | :---: | :---: |
| Age | Examinees | Average age | Average AC | 85 cm and above |  |  |  |
|  |  |  |  |  |  |  |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |  |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |  |
| $16-39$ | 732 | 29.4 | 81.4 | $36.3 \%$ |  |  |  |
| $40-64$ | 7,704 | 55.4 | 86.6 | $56.2 \%$ |  |  |  |
| $65-$ | 5,415 | 69.7 | 86.2 | $56.4 \%$ |  |  |  |


| AC (cm) |  |  |  |  |  | (female) |
| ---: | ---: | ---: | ---: | :--- | :---: | :---: |
| Age | Examinees | Average age | Average AC | 90 cm and above |  |  |
|  |  |  |  |  |  |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $16-39$ | 1,239 | 30.4 | 75.4 | $8.6 \%$ |  |  |
| $40-64$ | 11,802 | 54.7 | 82.3 | $20.8 \%$ |  |  |
| $65-$ | 6,444 | 69.9 | 84.3 | $26.6 \%$ |  |  |

## AC

FY 2013

| AC (cm) (overall) |  |  |  |  |
| ---: | :--- | :--- | :--- | :--- |
| Age | Examinees |  | Average age | Average AC |
|  |  |  |  |  |
| $0-6$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 1,561 | 30.0 | $\cdot$ |  |
| $40-64$ | 16,904 | 55.3 | 77.2 |  |
| $65-$ | 11,958 | 69.6 | 83.8 |  |
|  |  | 85.1 |  |  |


| AC (cm) |  |  |  |  |  | (male) |
| ---: | :--- | :--- | :--- | :--- | :---: | :---: |
| Age | Examinees | Average age | Average AC | 85 cm and above |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| $0-6$ | $\cdot$ | $\cdot$ |  | $\cdot$ |  |  |
| $7-15$ | $\cdot$ | $\cdot$ |  | $\cdot$ |  |  |
| $16-39$ | 584 | 29.6 | 80.4 | $\cdot$ |  |  |
| $40-64$ | 6,504 | 55.7 | 86.4 | $31.7 \%$ |  |  |
| $65-$ | 5,454 | 69.5 | 86.1 | $55.6 \%$ |  |  |


| AC (cm) |  |  |  |  |  |
| ---: | :--- | :--- | :--- | :--- | :--- |
| (female) |  |  |  |  |  |
| Age | Examinees | Average age | Average AC | 90 cm and above |  |
|  |  |  |  |  |  |
| $0-6$ | $\cdot$ | $\cdot$ |  | $\cdot$ | $\cdot$ |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 977 | 30.2 | 75.2 | $8.6 \%$ |  |
| $40-64$ | 10,400 | 55.0 | 82.1 | $20.7 \%$ |  |
| $65-$ | 6,504 | 69.7 | 84.2 | $26.9 \%$ |  |

FY 2014

| AC (cm) (overall) |  |  |  |
| :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average AC |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $16-39$ | 1,450 | 29.6 | 77.0 |
| $40-64$ | 15,584 | 55.1 | 83.8 |
| $65-$ | 12,412 | 69.6 | 85.1 |


| AC (cm) (male) |  |  |  |  |  |
| :---: | :---: | :---: | ---: | :---: | :---: |
| Age | Examinees | Average age | Average AC | 85 cm and <br> above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 534 | 29.1 | 80.6 | $32.0 \%$ |  |
| $40-64$ | 5,855 | 55.5 | 86.5 | $55.3 \%$ |  |
| $65-$ | 5,593 | 69.5 | 86.2 | $56.2 \%$ |  |


| AC (cm) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average AC | 90 cm and <br> above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 916 | 29.9 | 74.9 | $8.5 \%$ |  |
| $40-64$ | 9,729 | 54.9 | 82.2 | $20.7 \%$ |  |
| $65-$ | 6,819 | 69.6 | 84.2 | $26.4 \%$ |  |

## Systolic blood pressure

FY 2011

| Systolic blood pressure (mmHg) (overall) |  |  |  |  |  |
| ---: | :--- | :--- | :--- | :--- | :---: |
| Age | Examinees | Average age | Average <br> systolic blood <br> pressure | 140 mmHg and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | 11,414 | 11.0 | 107.4 |  |  |
| $16-39$ | 14,757 | 28.1 | 113.7 | $0.6 \%$ |  |
| $40-64$ | 23,633 | 54.0 | 127.7 | $3.3 \%$ |  |
| $65-$ | 16,726 | 73.7 | 136.6 | $22.5 \%$ |  |


| Systolic blood pressure ( mmHg ) (male) |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> systolic blood pressure | 140 mmHg and above |
| 0-6 | - | - | - |  |
| 7-15 | 5,728 | 10.9 | 108.6 | 0.9\% |
| 16-39 | 5,963 | 27.7 | 118.8 | 5.8\% |
| 40-64 | 9,559 | 54.5 | 130.8 | 27.5\% |
| 65- | 7,497 | 73.4 | 137.2 | 43.1\% |


| Systolic blood pressure (mmHg) (female) |  |  |  |  |
| ---: | :--- | :--- | :--- | :--- |
| Age | Examinees | Average age | Average <br> systolic blood <br> pressure | 140 mmHg and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 5,686 | 11.0 | 106.3 | $\cdot$ |
| $16-39$ | 8,794 | 28.3 | 110.2 | $0.2 \%$ |
| $40-64$ | 14,074 | 53.7 | 125.7 | $1.6 \%$ |
| $65-$ | 9,229 | 73.8 | 136.1 | $19.1 \%$ |

FY 2012

| Systolic blood pressure (mmHg) (overall) |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :---: |
| Age | Examinees | Average age | $\begin{array}{l}\text { Average } \\ \text { systolic blood } \\ \text { pressure }\end{array}$ | 140 mmHg and above |  |$]$.


| Systolic blood pressure (mmHg) (male) |  |  |  |  |  |
| ---: | :--- | :--- | :--- | :--- | :---: |
| Age | Examinees | Average age | $\begin{array}{l}\text { Average } \\ \text { systolic blood } \\ \text { pressure }\end{array}$ | 140 mmHg and above |  |$]$.


| Systolic blood pressure ( mmHg ) (female) |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average systolic blood pressure | 140 mmHg and above |
| 0-6 | - | - | - |  |
| 7-15 | 3,601 | 11.0 | 104.1 | 0.1\% |
| 16-39 | 5,250 | 29.1 | 108.8 | 1.3\% |
| 40-64 | 11,835 | 54.6 | 123.2 | 14.9\% |
| 65- | 10,163 | 73.6 | 132.7 | 31.8\% |

## Systolic blood pressure

FY 2013

| Systolic blood pressure (mmHg) (overall) |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :---: |
| Age | Examinees | Average age | $\begin{array}{l}\text { Average } \\ \text { systolic blood } \\ \text { pressure }\end{array}$ | 140 mmHg and above |  |$]$.


| Systolic blood pressure (mmHg) (male) |  |  |  |  |  |
| ---: | :--- | :--- | :--- | :--- | :---: |
| Age | Examinees | Average age | $\begin{array}{l}\text { Average } \\ \text { systolic blood } \\ \text { pressure }\end{array}$ | 140 mmHg and above |  |$]$.


| Systolic blood pressure ( mmHg ) (female) |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average systolic blood pressure | 140 mmHg and above |
| 0-6 | - | - | - |  |
| 7-15 | 3,128 | 10.8 | 104.1 | 0.1\% |
| 16-39 | 4,056 | 29.5 | 108.1 | 1.0\% |
| 40-64 | 10,409 | 55.0 | 122.1 | 12.9\% |
| 65- | 10,327 | 73.5 | 130.7 | 27.0\% |

FY 2014

| Systolic blood pressure (mmHg) (overall) |  |  |  |  |
| :---: | :---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> systolic blood <br> pressure | 140 mmHg <br> and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | 5,827 | 10.9 | 105.0 | $0.3 \%$ |
| $16-39$ | 5,843 | 29.0 | 110.8 | $2.3 \%$ |
| $40-64$ | 15,590 | 55.1 | 123.2 | $13.7 \%$ |
| $65-$ | 19,164 | 73.3 | 129.7 | $23.8 \%$ |


| Systolic blood pressure (mmHg) (male) |  |  |  |  |
| :---: | :---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> systolic blood <br> pressure | 140 mmHg <br> and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | . |
| $7-15$ | 2,983 | 10.9 | 106.2 | $0.4 \%$ |
| $16-39$ | 2,168 | 28.0 | 116.3 | $4.1 \%$ |
| $40-64$ | 5,858 | 55.5 | 126.3 | $17.4 \%$ |
| $65-$ | 8,683 | 73.3 | 130.2 | $25.1 \%$ |


| Systolic blood pressure (mmHg) (female) |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> systolic blood <br> pressure | 140 mmHg <br> and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | 2,844 | 10.9 | 103.8 | $0.1 \%$ |
| $16-39$ | 3,675 | 29.5 | 107.5 | $1.3 \%$ |
| $40-64$ | 9,732 | 54.9 | 121.3 | $11.5 \%$ |
| $65-$ | 10,481 | 73.3 | 129.3 | $22.7 \%$ |

## Diastolic blood pressure

FY 2011

| Diastolic blood pressure (mmHg) (overall) |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :---: |
| Age | Examinees | Average age | Average diastolic <br> blood pressure | 90 mmHg and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 11,411 | 11.0 | 62.4 | $0.6 \%$ |  |
| $16-39$ | 14,757 | 28.1 | 69.0 | $3.7 \%$ |  |
| $40-64$ | 23,633 | 54.0 | 78.8 | $17.0 \%$ |  |
| $65-$ | 16,726 | 73.7 | 78.6 | $15.0 \%$ |  |


| Diastolic blood pressure (mmHg) (male) |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :---: |
| Age | Examinees |  | Average age | Average diastolic <br> blood pressure |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | . |  |
| $7-15$ | 5,727 | 10.9 | 62.6 | $0.8 \%$ |  |
| $16-39$ | 5,963 | 27.7 | 72.3 | $6.6 \%$ |  |
| $40-64$ | 9,559 | 54.5 | 81.8 | $24.1 \%$ |  |
| $65-$ | 7,497 | 73.4 | 79.7 | $17.9 \%$ |  |


| Diastolic blood pressure (mmHg) (female) |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :---: |
| Age | Examinees | Average age | Average diastolic <br> blood pressure | 90 mmHg and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | . |  |
| $7-15$ | 5,684 | 11.0 | 62.2 | $0.4 \%$ |  |
| $16-39$ | 8,794 | 28.3 | 66.7 | $1.7 \%$ |  |
| $40-64$ | 14,074 | 53.7 | 76.8 | $12.2 \%$ |  |
| $65-$ | 9,229 | 73.8 | 77.7 | $12.6 \%$ |  |

FY 2012

| Diastolic blood pressure (mmHg) (overall) |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :---: |
| Age | Examinees | Average age | Average diastolic <br> blood pressure | 90 mmHg and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | . |  |  |
| $7-15$ | 7,379 | 10.9 | 60.9 | $0.3 \%$ |  |
| $16-39$ | 8,478 | 28.6 | 67.6 | $2.8 \%$ |  |
| $40-64$ | 19,551 | 55.0 | 76.9 | $13.1 \%$ |  |
| $65-$ | 18,642 | 73.5 | 76.3 | $10.5 \%$ |  |


| Diastolic blood pressure (mmHg) (male) |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :---: |
| Age | Examinees | Average age | Average diastolic <br> blood pressure | 90 mmHg and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 3,778 | 10.8 | 61.2 | $0.4 \%$ |  |
| $16-39$ | 3,230 | 27.9 | 70.7 | $4.8 \%$ |  |
| $40-64$ | 7,716 | 55.4 | 79.9 | $18.5 \%$ |  |
| $65-$ | 8,479 | 73.4 | 77.4 | $12.5 \%$ |  |


| Diastolic blood pressure (mmHg) (female) |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :---: |
| Age | Examinees | Average age | Average diastolic <br> blood pressure | 90 mmHg and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 3,601 | 11.0 | 60.6 | $0.3 \%$ |  |
| $16-39$ | 5,248 | 29.1 | 65.8 | $1.5 \%$ |  |
| $40-64$ | 11,835 | 54.6 | 75.0 | $9.6 \%$ |  |
| $65-$ | 10,163 | 73.6 | 75.4 | $8.7 \%$ |  |

## Diastolic blood pressure

FY 2013

| Diastolic blood pressure (mmHg) (overall) |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :---: |
| Age | Examinees | Average age | Average diastolic <br> blood pressure | 90 mmHg and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 6,403 | 10.9 | 61.3 | $0.5 \%$ |  |
| $16-39$ | 6,536 | 29.0 | 67.5 | $2.5 \%$ |  |
| $40-64$ | 16,922 | 55.3 | 76.2 | $11.1 \%$ |  |
| $65-$ | 18,969 | 73.5 | 75.0 | $8.1 \%$ |  |


| Diastolic blood pressure (mmHg) (male) |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :---: |
| Age | Examinees |  | Average age | Average diastolic <br> blood pressure |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | . |  |
| $7-15$ | 3,276 | 10.9 | 61.5 | $0.6 \%$ |  |
| $16-39$ | 2,480 | 28.3 | 70.7 | $4.7 \%$ |  |
| $40-64$ | 6,513 | 55.7 | 79.1 | $16.4 \%$ |  |
| $65-$ | 8,642 | 73.4 | 76.0 | $9.6 \%$ |  |


| Diastolic blood pressure (mmHg) (female) |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :---: |
| Age | Examinees | Average age | Average diastolic <br> blood pressure | 90 mmHg and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 3,127 | 10.8 | 61.2 | $0.4 \%$ |  |
| $16-39$ | 4,056 | 29.5 | 65.5 | $1.2 \%$ |  |
| $40-64$ | 10,409 | 55.0 | 74.3 | $7.7 \%$ |  |
| $65-$ | 10,327 | 73.5 | 74.2 | $6.7 \%$ |  |

FY 2014

| Diastolic blood pressure (mmHg) (overall) |  |  |  |  |
| :---: | :---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> diastolic blood <br> pressure | 90 mmHg and <br> above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | . |
| $7-15$ | 5,827 | 10.9 | 61.0 | $0.5 \%$ |
| $16-39$ | 5,843 | 29.0 | 66.9 | $2.4 \%$ |
| $40-64$ | 15,590 | 55.1 | 75.4 | $9.6 \%$ |
| $65-$ | 19,163 | 73.3 | 74.4 | $6.2 \%$ |


| Diastolic blood pressure (mmHg) (male) |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> diastolic blood <br> pressure | 90 mmHg and <br> above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | . |
| $7-15$ | 2,983 | 10.9 | 61.4 | $0.7 \%$ |
| $16-39$ | 2,168 | 28.0 | 70.2 | $4.3 \%$ |
| $40-64$ | 5,858 | 55.5 | 78.4 | $14.4 \%$ |
| $65-$ | 8,683 | 73.3 | 75.3 | $7.6 \%$ |


| Diastolic blood pressure (mmHg) (female) |  |  |  |  |
| :---: | :---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> diastolic blood <br> pressure | 90 mmHg and <br> above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | 2,844 | 10.9 | 60.6 | $0.2 \%$ |
| $16-39$ | 3,675 | 29.5 | 64.9 | $1.4 \%$ |
| $40-64$ | 9,732 | 54.9 | 73.5 | $6.6 \%$ |
| $65-$ | 10,480 | 73.3 | 73.6 | $5.1 \%$ |

## Urinary sugar

FY 2011

| Urinary sugar (overall) |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: |
| Age | Examinees | Average age | $(1+)$ <br> above | and |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 14,642 | 28.1 | $0.7 \%$ |  |
| $40-64$ | 23,578 | 54.1 | $2.7 \%$ |  |
| $65-$ | 16,678 | 73.7 | $3.2 \%$ |  |


| Urinary sugar (male) |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: |
| Age | Examinees | Average age | $(1+)$ <br> above | and |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 5,963 | 27.7 | $1.1 \%$ |  |
| $40-64$ | 9,558 | 54.5 | $4.9 \%$ |  |
| $65-$ | 7,486 | 73.4 | $5.0 \%$ |  |


| Urinary sugar (female) |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: |
| Age | Examinees | Average age | $(1+)$ <br> above | and |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 8,679 | 28.4 | $0.5 \%$ |  |
| $40-64$ | 14,020 | 53.7 | $1.3 \%$ |  |
| $65-$ | 9,192 | 73.8 | $1.7 \%$ |  |

FY 2012

| Urinary sugar (overall) |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: |
| Age | Examinees | Average age | $(1+)$ <br> above | and |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 8,400 | 28.6 | $0.7 \%$ |  |
| $40-64$ | 19,514 | 55.0 | $2.2 \%$ |  |
| $65-$ | 18,606 | 73.5 | $2.3 \%$ |  |


| Urinary sugar (male) |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: |
| Age | Examinees | Average age | $(1+)$ <br> above | and |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 3,228 | 27.9 | $1.0 \%$ |  |
| $40-64$ | 7,709 | 55.4 | $4.1 \%$ |  |
| $65-$ | 8,463 | 73.4 | $3.7 \%$ |  |


| Urinary sugar (female) |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: |
| Age | Examinees | Average age | $(1+)$ <br> above | and |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 5,172 | 29.1 | $0.5 \%$ |  |
| $40-64$ | 11,805 | 54.7 | $1.0 \%$ |  |
| $65-$ | 10,143 | 73.6 | $1.1 \%$ |  |

Urinary sugar
FY 2013

| Urinary sugar (overall) |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: |
| Age | Examinees | Average age | $(1+)$ <br> above | and |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 6,489 | 29.0 | $0.7 \%$ |  |
| $40-64$ | 16,879 | 55.3 | $1.9 \%$ |  |
| $65-$ | 18,863 | 73.4 | $2.0 \%$ |  |


| Urinary sugar (male) |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: |
| Age | Examinees | Average age | $(1+)$ <br> above | and |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 2,476 | 28.3 | $1.1 \%$ |  |
| $40-64$ | 6,501 | 55.7 | $3.6 \%$ |  |
| $65-$ | 8,595 | 73.4 | $3.3 \%$ |  |


| Urinary sugar (female) |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: |
| Age | Examinees | Average age | $(1+)$ <br> above | and |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 4,013 | 29.5 | $0.4 \%$ |  |
| $40-64$ | 10,378 | 55.0 | $0.9 \%$ |  |
| $65-$ | 10,268 | 73.5 | $1.0 \%$ |  |

FY 2014

| Urinary sugar (overall) |  |  |  |
| :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | $(1+)$ and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $16-39$ | 5,797 | 29.0 | $0.5 \%$ |
| $40-64$ | 15,551 | 55.1 | $2.0 \%$ |
| $65-$ | 19,088 | 73.3 | $1.9 \%$ |


| Urinary sugar (male) |  |  |  |
| :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | $(1+)$ and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $16-39$ | 2,166 | 28.0 | $0.6 \%$ |
| $40-64$ | 5,854 | 55.5 | $3.9 \%$ |
| $65-$ | 8,661 | 73.3 | $3.3 \%$ |


| Urinary sugar (female) |  |  |  |
| :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | $(1+)$ and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $16-39$ | 3,631 | 29.6 | $0.4 \%$ |
| $40-64$ | 9,697 | 54.9 | $0.8 \%$ |
| $65-$ | 10,427 | 73.2 | $0.8 \%$ |

## Urine protein

FY 2011

| Urine protein (overall) |  |  |  |  |
| ---: | ---: | ---: | ---: | ---: |
| Age | Examinees | Average age | $(1+)$ <br> above | and |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 14,642 | 28.1 | $1.1 \%$ |  |
| $40-64$ | 23,577 | 54.1 | $1.4 \%$ |  |
| $65-$ | 16,678 | 73.7 | $2.4 \%$ |  |


| Urine protein (male) |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: |
| Age | Examinees | Average age | $(1+)$ <br> above | and |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 5,963 | 27.7 | $1.1 \%$ |  |
| $40-64$ | 9,557 | 54.5 | $2.2 \%$ |  |
| $65-$ | 7,486 | 73.4 | $3.5 \%$ |  |


| Urine protein (female) |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: |
| Age | Examinees | Average age | $(1+)$ <br> above | and |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 8,679 | 28.4 | $1.1 \%$ |  |
| $40-64$ | 14,020 | 53.7 | $0.8 \%$ |  |
| $65-$ | 9,192 | 73.8 | $1.5 \%$ |  |

FY 2012

| Urine protein (overall) |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: |
| Age | Examinees | Average age | $(1+)$ <br> above | and |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 8,400 | 28.6 | $2.2 \%$ |  |
| $40-64$ | 19,515 | 55.0 | $1.7 \%$ |  |
| $65-$ | 18,606 | 73.5 | $2.7 \%$ |  |


| Urine protein (male) |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: |
| Age | Examinees | Average age | $(1+)$ <br> above | and |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 3,228 | 27.9 | $2.2 \%$ |  |
| $40-64$ | 7,709 | 55.4 | $2.6 \%$ |  |
| $65-$ | 8,463 | 73.4 | $3.8 \%$ |  |


| Urine protein (female) |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: |
| Age | Examinees | Average age | $(1+)$ <br> above | and |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 5,172 | 29.1 | $2.2 \%$ |  |
| $40-64$ | 11,806 | 54.7 | $1.1 \%$ |  |
| $65-$ | 10,143 | 73.6 | $1.8 \%$ |  |

## Urine protein

FY 2013

| Urine protein (overall) |  |  |  |  |
| ---: | ---: | ---: | ---: | ---: |
| Age | Examinees | Average age | $(1+)$ <br> above | and |
| $0-6$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | $\cdot$ | $\cdot$ |  |  |
| $16-39$ | 6,489 | 29.0 | $2.4 \%$ |  |
| $40-64$ | 16,878 | 55.3 | $1.6 \%$ |  |
| $65-$ | 18,863 | 73.4 | $2.6 \%$ |  |


| Urine protein (male) |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: |
| Age | Examinees | Average age | $(1+)$ <br> above | and |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 2,476 | 28.3 | $2.3 \%$ |  |
| $40-64$ | 6,501 | 55.7 | $2.4 \%$ |  |
| $65-$ | 8,595 | 73.4 | $3.8 \%$ |  |


| Urine protein (female) |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: |
| Age | Examinees | Average age | $(1+)$ <br> above | and |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 4,013 | 29.5 | $2.5 \%$ |  |
| $40-64$ | 10,377 | 55.0 | $1.1 \%$ |  |
| $65-$ | 10,268 | 73.5 | $1.6 \%$ |  |

FY 2014

| Urine protein (overall) |  |  |  |
| :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | $(1+)$ and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $16-39$ | 5,797 | 29.0 | $2.5 \%$ |
| $40-64$ | 15,551 | 55.1 | $1.6 \%$ |
| $65-$ | 19,088 | 73.3 | $2.5 \%$ |


| Urine protein (male) |  |  |  |
| :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | $(1+)$ and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $16-39$ | 2,166 | 28.0 | $2.5 \%$ |
| $40-64$ | 5,854 | 55.5 | $2.5 \%$ |
| $65-$ | 8,661 | 73.3 | $3.7 \%$ |


| Urine protein (female) |  |  |  |
| :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | $(1+)$ and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $16-39$ | 3,631 | 29.6 | $2.5 \%$ |
| $40-64$ | 9,697 | 54.9 | $1.0 \%$ |
| $65-$ | 10,427 | 73.2 | $1.4 \%$ |

## Urine occult blood

FY 2011

| Urine occult blood (overall) |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | :--- | :--- | :---: |
| Age | Examinees | Average age | (1+) and <br> above | $(1+)$ and above and during <br> time periods other than <br> menstruation. |  |  |
| $0-6$ |  | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $16-39$ | 14,630 | 28.1 | $6.9 \%$ | $\cdot$ |  |  |
| $40-64$ | 23,571 | 54.1 | $7.1 \%$ | $3.0 \%$ |  |  |
| $65-$ | 16,678 | 73.7 | $7.4 \%$ | $5.6 \%$ |  |  |


| Urine occult blood (male) |  |  |  |  |
| ---: | :--- | :--- | :--- | :---: |
| Age | Examinees | Average age | $(1+)$ <br> above |  |
| $0-6$ | $\cdot$ | $\cdot$ | and |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 5,960 | 27.7 | $1.2 \%$ |  |
| $40-64$ | 9,558 | 54.5 | $3.5 \%$ |  |
| $65-$ | 7,486 | 73.4 | $5.5 \%$ |  |


| Urine occult blood (female) |  |  |  |  |  |  |
| ---: | :--- | :--- | :--- | :--- | :--- | :---: |
| Age | Examinees | Average age | (1+) and <br> above | $(1+)$ and above and during <br> time periods other than <br> menstruation. |  |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $16-39$ | 8,670 | 28.4 | $10.7 \%$ |  |  |  |
| $40-64$ | 14,013 | 53.7 | $9.6 \%$ | $4.2 \%$ |  |  |
| $65-$ | 9,192 | 73.8 | $8.9 \%$ | $7.0 \%$ |  |  |

FY 2012

| Urine occult blood (overall) |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | (1+) and above | (1+) and above and during time periods other than menstruation. |
| 0-6 | - | - | - |  |
| 7-15 | - | - | - | - |
| 16-39 | 8,400 | 28.6 | 7.2\% | 3.2\% |
| 40-64 | 19,510 | 55.0 | 6.8\% | 5.5\% |
| 65- | 18,592 | 73.5 | 6.9\% | 6.9\% |


| Urine occult blood (male) |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: |
| Age | Examinees | Average age | (1+) <br> above | and |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 3,228 | 27.9 | $1.4 \%$ |  |
| $40-64$ | 7,707 | 55.4 | $3.6 \%$ |  |
| $65-$ | 8,459 | 73.4 | $4.9 \%$ |  |


| Urine occult blood (female) |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | (1+) and above | (1+) and above and during time periods other than menstruation. |
| 0-6 | - | - | - |  |
| 7-15 | - | - | - | - |
| 16-39 | 5,172 | 29.1 | 10.9\% | 4.2\% |
| 40-64 | 11,803 | 54.7 | 8.9\% | 6.8\% |
| 65- | 10,133 | 73.6 | 8.5\% | 8.5\% |

## Urine occult blood

FY 2013

| Urine occult blood (overall) |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | (1+) and above | (1+) and above and during time periods other than menstruation. |
| 0-6 | - | - | - |  |
| 7-15 | - | - | - | - |
| 16-39 | 6,488 | 29.0 | 7.0\% | 3.2\% |
| 40-64 | 16,878 | 55.3 | 6.8\% | 5.8\% |
| 65- | 18,863 | 73.4 | 6.4\% | 6.4\% |


| Urine occult blood (male) |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: |
| Age | Examinees | Average age | (1+) <br> above | and |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 2,476 | 28.3 | $1.4 \%$ |  |
| $40-64$ | 6,501 | 55.7 | $3.0 \%$ |  |
| $65-$ | 8,595 | 73.4 | $4.5 \%$ |  |


| Urine occult blood (female) |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | (1+) and above | (1+) and above and during time periods other than menstruation. |
| 0-6 | - | - | - |  |
| 7-15 | - | - | - |  |
| 16-39 | 4,012 | 29.5 | 10.4\% | 4.3\% |
| 40-64 | 10,377 | 55.0 | 9.1\% | 7.5\% |
| 65- | 10,268 | 73.5 | 8.0\% | 7.9\% |

FY 2014

| Urine occult blood (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | $(1+)$ and above | $(1+)$ and above and <br> during time periods <br> other than <br> menstruation. |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 5,796 | 29.0 | $6.9 \%$ | $3.2 \%$ |  |
| $40-64$ | 15,548 | 55.1 | $6.6 \%$ | $5.3 \%$ |  |
| $65-$ | 19,089 | 73.3 | $6.2 \%$ | $6.2 \%$ |  |


| Urine occult blood (male) |  |  |  |
| :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | $(1+)$ and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $16-39$ | 2,166 | 28.0 | $0.8 \%$ |
| $40-64$ | 5,854 | 55.5 | $3.1 \%$ |
| $65-$ | 8,661 | 73.3 | $4.1 \%$ |


| Urine occult blood (female) |  |  |  |  |
| :---: | :---: | ---: | ---: | :---: |
| Age | Examinees | Average age | $(1+$ ) and above | (1+) and above and <br> during time periods <br> other than <br> menstruation. |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | . |
| $16-39$ | 3,630 | 29.6 | $10.6 \%$ | $4.6 \%$ |
| $40-64$ | 9,694 | 54.9 | $8.6 \%$ | $6.6 \%$ |
| $65-$ | 10,428 | 73.2 | $7.9 \%$ | $7.9 \%$ |

## Serum creatinine

FY 2011

| Serum creatinine (mg/dL) (overall) |  |  |  |  |
| ---: | :--- | :--- | :--- | :---: |
| Age | Examinees | Average age | Average <br> serum <br> creatinine |  |
| $0-6$ |  | $\cdot$ | $\cdot$ |  |
| $7-15$ | 11,100 | 11.0 | $\cdot$ |  |
| $16-39$ | 14,755 | 28.1 | 0.47 |  |
| $40-64$ | 23,651 | 54.0 | 0.70 |  |
| $65-$ | 16,724 | 73.7 | 0.73 |  |
|  |  |  | 0.78 |  |


| Serum creatinine (mg/dL) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average serum creatinine | $1.15 \mathrm{mg} / \mathrm{dL}$ and above | $1.35 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 5,588 | 10.9 | 0.49 | 0.0\% | 0.0\% |
| 16-39 | 5,965 | 27.7 | 0.83 | 0.4\% | 0.1\% |
| 40-64 | 9,562 | 54.5 | 0.86 | 2.4\% | 0.8\% |
| 65- | 7,496 | 73.4 | 0.91 | 7.6\% | 2.5\% |


| Serum creatinine (mg/dL) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average serum creatinine | $0.95 \mathrm{mg} / \mathrm{dL}$ and above | $1.15 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 5,512 | 11.0 | 0.45 | - | - |
| 16-39 | 8,790 | 28.3 | 0.62 | 0.2\% | 0.0\% |
| 40-64 | 14,089 | 53.7 | 0.64 | 0.8\% | 0.3\% |
| 65- | 9,228 | 73.8 | 0.69 | 4.4\% | 1.3\% |

FY 2012

| Serum creatinine (mg/dL) (overall) |  |  |  |
| ---: | :--- | :--- | :--- |
| Age | Examinees | Average age | Average <br> serum <br> creatinine |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | 7,212 | 10.9 | 0.48 |
| $16-39$ | 8,478 | 28.6 | 0.70 |
| $40-64$ | 19,549 | 55.0 | 0.73 |
| $65-$ | 18,635 | 73.5 | 0.79 |


| Serum creatinine (mg/dL) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average serum creatinine | $1.15 \mathrm{mg} / \mathrm{dL}$ and above | $1.35 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - | - |
| 7-15 | 3,694 | 10.9 | 0.49 | - | - |
| 16-39 | 3,230 | 27.9 | 0.83 | 0.4\% | 0.1\% |
| 40-64 | 7,717 | 55.4 | 0.86 | 2.7\% | 0.9\% |
| 65- | 8,475 | 73.4 | 0.91 | 8.3\% | 2.9\% |


| Serum creatinine (mg/dL) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average serum creatinine | $0.95 \mathrm{mg} / \mathrm{dL}$ and above | $1.15 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 3,518 | 11.0 | 0.46 | - | - |
| 16-39 | 5,248 | 29.1 | 0.61 | 0.1\% | - |
| 40-64 | 11,832 | 54.6 | 0.65 | 0.8\% | 0.3\% |
| 65- | 10,160 | 73.6 | 0.69 | 4.5\% | 1.6\% |

## Serum creatinine

FY 2013

| Serum creatinine (mg/dL) (overall) |  |  |  |
| ---: | :--- | :--- | :--- |
| Age | Examinees | Average age | Average <br> serum <br> creatinine |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | 6,095 | 10.9 | 0.47 |
| $16-39$ | 6,535 | 29.0 | 0.70 |
| $40-64$ | 16,921 | 55.3 | 0.73 |
| $65-$ | 18,954 | 73.5 | 0.80 |


| Serum creatinine (mg/dL) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average serum creatinine | $1.15 \mathrm{mg} / \mathrm{dL}$ and above | $1.35 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - | - |
| 7-15 | 3,117 | 10.9 | 0.49 | - | - |
| 16-39 | 2,479 | 28.3 | 0.83 | 0.6\% | 0.2\% |
| 40-64 | 6,510 | 55.7 | 0.86 | 2.4\% | 0.6\% |
| 65- | 8,635 | 73.4 | 0.91 | 9.0\% | 3.2\% |


| Serum creatinine (mg/dL) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average serum creatinine | $0.95 \mathrm{mg} / \mathrm{dL}$ and above | $1.15 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 2,978 | 10.9 | 0.45 | - | - |
| 16-39 | 4,056 | 29.5 | 0.62 | 0.1\% | 0.0\% |
| 40-64 | 10,411 | 55.0 | 0.65 | 0.9\% | 0.3\% |
| 65- | 10,319 | 73.5 | 0.70 | 5.1\% | 1.5\% |

FY 2014

| Serum creatinine (mg/dL) (overall) |  |  |  |
| :---: | :---: | :---: | ---: |
| Age | Examinees | Average age | Average serum <br> creatinine |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | 5,703 | 10.9 | 0.49 |
| $16-39$ | 5,843 | 29.0 | 0.70 |
| $40-64$ | 15,591 | 55.1 | 0.74 |
| $65-$ | 19,156 | 73.3 | 0.80 |


| Serum creatinine (mg/dL) (male) |  |  |  |  |  |  |  |
| :---: | :---: | ---: | ---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average serum <br> creatinine | $1.15 \mathrm{mg} / \mathrm{dL}$ and <br> above | $1.35 \mathrm{mg} / \mathrm{dL}$ and <br> above |  |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |  |  |
| $7-15$ | 2,912 | 10.9 | 0.51 | - | - |  |  |
| $16-39$ | 2,168 | 28.0 | 0.84 | $0.5 \%$ | - |  |  |
| $40-64$ | 5,858 | 55.5 | 0.87 | $3.1 \%$ | $0.1 \%$ |  |  |
| $65-$ | 8,677 | 73.3 | 0.92 | $9.9 \%$ | $0.9 \%$ |  |  |


| Serum creatinine (mg/dL) (female) |  |  |  |  |  |  |
| :---: | :---: | ---: | ---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average serum <br> creatinine | $0.95 \mathrm{mg} / \mathrm{dL}$ and <br> above | $1.15 \mathrm{mg} / \mathrm{dL}$ and <br> above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | . |  |
| $7-15$ | 2,791 | 10.9 | 0.47 | - | - |  |
| $16-39$ | 3,675 | 29.5 | 0.62 | $0.1 \%$ | $0.0 \%$ |  |
| $40-64$ | 9,733 | 54.9 | 0.66 | $0.9 \%$ | $0.4 \%$ |  |
| $65-$ | 10,479 | 73.3 | 0.71 | $5.0 \%$ | $1.5 \%$ |  |

FY 2011

| eGFR (mL/min/1.73 m${ }^{2}$ ) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> eGFR | Less than 50 $\mathrm{ml} / \mathrm{min}$. $/ 1.73 \mathrm{~m}^{2}$ | Less than 60 $\mathrm{ml} / \mathrm{min} . / 1.73 \mathrm{~m}^{2}$ |
| 0-6 | - | - | - | - | - |
| 7-15 | - | - | - | - | - |
| 16-39 | 14,753 | 28.1 | 96.2 | 0.1\% | 0.2\% |
| 40-64 | 23,651 | 54.0 | 76.9 | 1.2\% | 6.6\% |
| 65- | 16,724 | 73.7 | 66.6 | 9.0\% | 28.6\% |


| eGFR (mL/min/1.73 m${ }^{2}$ ) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average <br> eGFR | Less than 50 $\mathrm{ml} / \mathrm{min}$. $/ 1.73 \mathrm{~m}^{2}$ | Less than 60 $\mathrm{ml} / \mathrm{min}$. $/ 1.73 \mathrm{~m}^{2}$ |
| 0-6 | - | - | - | - | - |
| 7-15 | - | - | - | - | - |
| 16-39 | 5,964 | 27.7 | 95.1 | 0.1\% | 0.3\% |
| 40-64 | 9,562 | 54.5 | 76.2 | 1.5\% | 7.7\% |
| 65- | 7,496 | 73.4 | 67.1 | 8.7\% | 27.1\% |


| eGFR ( $\mathrm{mL} / \mathrm{min} / 1.73 \mathrm{~m}^{2}$ ) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average eGFR | Less than 50 $\mathrm{ml} / \mathrm{min} . / 1.73 \mathrm{~m}^{2}$ | Less than 60 $\mathrm{ml} / \mathrm{min}$. $/ 1.73 \mathrm{~m}^{2}$ |
| 0-6 | - | - | - | - |  |
| 7-15 | - | - | - | - | - |
| 16-39 | 8,789 | 28.3 | 97.0 | 0.1\% | 0.2\% |
| 40-64 | 14,089 | 53.7 | 77.3 | 0.9\% | 6.0\% |
| 65- | 9,228 | 73.8 | 66.2 | 9.2\% | 29.7\% |

FY 2012

| $\mathrm{eGFR}\left(\mathrm{mL} / \mathrm{min} / 1.73 \mathrm{~m}^{2}\right.$ ) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> eGFR | Less than 50 $\mathrm{ml} / \mathrm{min}$. $/ 1.73 \mathrm{~m}^{2}$ | Less than 60 $\mathrm{ml} / \mathrm{min} . / 1.73 \mathrm{~m}^{2}$ |
| 0-6 | - | - | - | - | - |
| 7-15 | - | - | - | - | - |
| 16-39 | 8,478 | 28.6 | 96.3 | 0.1\% | 0.3\% |
| 40-64 | 19,549 | 55.0 | 75.9 | 1.4\% | 8.5\% |
| 65- | 18,635 | 73.5 | 66.2 | 9.6\% | 30.7\% |


| eGFR (mL/min/1.73 m${ }^{2}$ ) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average eGFR | $\begin{aligned} & \text { Less than } 50 \\ & \mathrm{ml} / \mathrm{min} . / 1.73 \mathrm{~m}^{2} \end{aligned}$ | $\begin{aligned} & \text { Less than } 60 \\ & \mathrm{ml} / \mathrm{min} . / 1.73 \mathrm{~m}^{2} \end{aligned}$ |
| 0-6 | - | - | - | - |  |
| 7-15 | - | - | - | - | - |
| 16-39 | 3,230 | 27.9 | 95.4 | 0.1\% | 0.3\% |
| 40-64 | 7,717 | 55.4 | 76.1 | 1.7\% | 8.6\% |
| 65- | 8,475 | 73.4 | 66.9 | 9.3\% | 28.5\% |


| eGFR ( $\mathrm{mL} / \mathrm{min} / 1.73 \mathrm{~m}^{2}$ ) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average <br> eGFR | Less than 50 $\mathrm{ml} / \mathrm{min}$. $/ 1.73 \mathrm{~m}^{2}$ | Less than 60 $\mathrm{ml} / \mathrm{min}$. $/ 1.73 \mathrm{~m}^{2}$ |
| 0-6 | - | - | - | - |  |
| 7-15 | - | - | - | - | - |
| 16-39 | 5,248 | 29.1 | 96.8 | 0.0\% | 0.2\% |
| 40-64 | 11,832 | 54.6 | 75.8 | 1.1\% | 8.5\% |
| 65- | 10,160 | 73.6 | 65.6 | 9.9\% | 32.4\% |

## eGFR

FY 2013

| eGFR ( $\mathrm{mL} / \mathrm{min} / 1.73 \mathrm{~m}^{2}$ ) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> eGFR | Less than 50 $\mathrm{ml} / \mathrm{min}$. $/ 1.73 \mathrm{~m}^{2}$ | Less than 60 $\mathrm{ml} / \mathrm{min}$. $/ 1.73 \mathrm{~m}^{2}$ |
| 0-6 | - | - | - | - |  |
| 7-15 | - | - | - | - |  |
| 16-39 | 6,535 | 29.0 | 95.5 | 0.1\% | 0.3\% |
| 40-64 | 16,919 | 55.3 | 75.4 | 1.3\% | 9.0\% |
| 65- | 18,954 | 73.5 | 65.5 | 10.5\% | 32.5\% |


| eGFR (mL/min/1.73 m ${ }^{2}$ ) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average <br> eGFR | Less than 50 $\mathrm{ml} / \mathrm{min} . / 1.73 \mathrm{~m}^{2}$ | Less than 60 $\mathrm{ml} / \mathrm{min} . / 1.73 \mathrm{~m}^{2}$ |
| 0-6 | - | - | - | - | - |
| 7-15 | - | - | - | - | - |
| 16-39 | 2,479 | 28.3 | 95.1 | 0.2\% | 0.4\% |
| 40-64 | 6,508 | 55.7 | 75.6 | 1.4\% | 8.8\% |
| 65- | 8,635 | 73.4 | 66.3 | 10.2\% | 30.1\% |


| eGFR (mL/min/1.73 m${ }^{2}$ ) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average eGFR | Less than 50 $\mathrm{ml} / \mathrm{min} . / 1.73 \mathrm{~m}^{2}$ | Less than 60 $\mathrm{ml} / \mathrm{min}$. $/ 1.73 \mathrm{~m}^{2}$ |
| 0-6 | - | - | - | - | - |
| 7-15 | - | - | - | - | - |
| 16-39 | 4,056 | 29.5 | 95.8 | 0.1\% | 0.2\% |
| 40-64 | 10,411 | 55.0 | 75.3 | 1.2\% | 9.1\% |
| 65- | 10,319 | 73.5 | 64.8 | 10.8\% | 34.5\% |

FY 2014

| $\mathrm{eGFR}\left(\mathrm{mL} / \mathrm{min} / 1.73 \mathrm{~m}^{2}\right.$ ) (overall) |  |  |  |  |  |  |
| :---: | :---: | ---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> eGFR | Less than 50 <br> $\mathrm{ml} / \mathrm{min} . / 1.73 \mathrm{~m}^{2}$ | Less than 60 <br> $\mathrm{ml} / \mathrm{min} . / 1.73 \mathrm{~m}^{2}$ |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | . |  |
| $16-39$ | 5,843 | 29.0 | 95.4 | $0.1 \%$ | $0.4 \%$ |  |
| $40-64$ | 15,591 | 55.1 | 74.6 | $1.5 \%$ | $9.9 \%$ |  |
| $65-$ | 19,156 | 73.3 | 64.8 | $11.2 \%$ | $34.0 \%$ |  |


| eGFR (mL/min/1.73 $\left.\mathrm{m}^{2}\right)(\mathrm{male})$ |  |  |  |  |  |  |
| :---: | :---: | ---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> eGFR | Less than 50 <br> $\mathrm{ml} / \mathrm{min} . / 1.73 \mathrm{~m}^{2}$ | Less than 60 <br> $\mathrm{ml} / \mathrm{min} . / 1.73 \mathrm{~m}^{2}$ |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | . |  |
| $16-39$ | 2,168 | 28.0 | 94.9 | $0.1 \%$ | $0.3 \%$ |  |
| $40-64$ | 5,858 | 55.5 | 74.8 | $1.9 \%$ | $10.1 \%$ |  |
| $65-$ | 8,677 | 73.3 | 65.5 | $11.1 \%$ | $32.1 \%$ |  |


| $\mathrm{eGFR}\left(\mathrm{mL} / \mathrm{min} / 1.73 \mathrm{~m}^{2}\right)(\mathrm{female})$ |  |  |  |  |  |  |
| :---: | :---: | ---: | ---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> eGFR | Less than 50 <br> $\mathrm{ml} / \mathrm{min} . / 1.73 \mathrm{~m}^{2}$ | Less than 60 <br> $\mathrm{ml} / \mathrm{min} . / 1.73 \mathrm{~m}^{2}$ |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $16-39$ | 3,675 | 29.5 | 95.7 | $0.1 \%$ | $0.4 \%$ |  |
| $40-64$ | 9,733 | 54.9 | 74.5 | $1.2 \%$ | $9.7 \%$ |  |
| $65-$ | 10,479 | 73.3 | 64.3 | $11.2 \%$ | $35.5 \%$ |  |

## Fasting plasma glucose

FY 2011

| Fasting plasma glucose (mg/dL) (overall) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average fasting plasma glucose | $110 \mathrm{mg} / \mathrm{dL}$ and above | $130 \mathrm{mg} / \mathrm{dL}$ and above | $160 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - | - | - |
| 7-15 | 11,063 | 11.0 | 88.6 | 2.4\% | 0.3\% | 0.1\% |
| 16-39 | 12,929 | 28.0 | 89.0 | 1.9\% | 0.8\% | 0.5\% |
| 40-64 | 21,027 | 54.1 | 99.9 | 15.1\% | 5.7\% | 2.5\% |
| 65- | 14,744 | 73.6 | 105.5 | 26.1\% | 9.4\% | 3.1\% |


| Fasting plasma glucose (mg/dL) (male) |  |  |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: | ---: | ---: | ---: | ---: | ---: |
| Age | Examinees <br> Average <br> age |  | Average fasting <br> plasma glucose | 110 <br> and above | 130 <br> and above | 160 <br> and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | 5,569 | 10.9 | 89.4 | $2.4 \%$ | $0.3 \%$ | $0.1 \%$ |
| $16-39$ | 5,204 | 27.6 | 91.1 | $2.9 \%$ | $1.2 \%$ | $0.7 \%$ |
| $40-64$ | 8,370 | 54.5 | 104.6 | $22.5 \%$ | $9.0 \%$ | $3.8 \%$ |
| $65-$ | 6,575 | 73.4 | 108.2 | $31.7 \%$ | $11.9 \%$ | $3.8 \%$ |


| Fasting plasma glucose ( $\mathrm{mg} / \mathrm{dL}$ ) (female) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average fasting plasma glucose | $110 \mathrm{mg} / \mathrm{dL}$ and above | $130 \mathrm{mg} / \mathrm{dL}$ and above | $160 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - | - | - |
| 7-15 | 5,494 | 11.0 | 87.7 | 2.3\% | 0.3\% | 0.1\% |
| 16-39 | 7,725 | 28.3 | 87.6 | 1.2\% | 0.5\% | 0.3\% |
| 40-64 | 12,657 | 53.8 | 96.8 | 10.3\% | 3.5\% | 1.7\% |
| 65- | 8,169 | 73.7 | 103.3 | 21.6\% | 7.4\% | 2.5\% |

FY 2012

| Fasting plasma glucose (mg/dL) (overall) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average fasting plasma glucose | $110 \mathrm{mg} / \mathrm{dL}$ and above | $130 \mathrm{mg} / \mathrm{dL}$ and above | $160 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - | - |  |
| 7-15 | 5,687 | 11.0 | 86.3 | 0.7\% | 0.1\% | 0.0\% |
| 16-39 | 7,289 | 28.6 | 88.0 | 1.9\% | 0.8\% | 0.5\% |
| 40-64 | 17,040 | 55.0 | 98.5 | 14.2\% | 5.3\% | 2.0\% |
| 65- | 15,855 | 73.4 | 102.7 | 21.8\% | 7.5\% | 2.1\% |


| Fasting plasma glucose (mg/dL) (male) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average fasting plasma glucose | $110 \mathrm{mg} / \mathrm{dL}$ and above | $130 \mathrm{mg} / \mathrm{dL}$ and above | $160 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - | - | . |
| 7-15 | 2,908 | 11.0 | 87.1 | 0.7\% | 0.0\% | 0.0\% |
| 16-39 | 2,744 | 27.8 | 90.0 | 2.7\% | 1.1\% | 0.7\% |
| 40-64 | 6,639 | 55.4 | 103.2 | 21.5\% | 8.7\% | 3.3\% |
| 65- | 7,189 | 73.3 | 105.2 | 26.7\% | 9.7\% | 2.8\% |


| Fasting plasma glucose ( $\mathrm{mg} / \mathrm{dL}$ ) (female) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average fasting <br> plasma glucose | $110 \mathrm{mg} / \mathrm{dL}$ and above | $130 \mathrm{mg} / \mathrm{dL}$ and above | $160 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - | - |  |
| 7-15 | 2,779 | 11.1 | 85.4 | 0.6\% | 0.1\% | - |
| 16-39 | 4,545 | 29.2 | 86.8 | 1.4\% | 0.6\% | 0.5\% |
| 40-64 | 10,401 | 54.7 | 95.5 | 9.5\% | 3.1\% | 1.2\% |
| 65- | 8,666 | 73.4 | 100.6 | 17.8\% | 5.6\% | 1.5\% |

## Fasting plasma glucose

FY 2013

| Fasting plasma glucose ( $\mathrm{mg} / \mathrm{dL}$ ) (o |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average fasting plasma glucose | $110 \mathrm{mg} / \mathrm{dL}$ and above | $130 \mathrm{mg} / \mathrm{dL}$ and above | $160 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - | - |  |
| 7-15 | 4,483 | 11.0 | 86.7 | 0.5\% | 0.0\% | 0.0\% |
| 16-39 | 5,470 | 29.0 | 88.5 | 1.9\% | 0.7\% | 0.5\% |
| 40-64 | 14,749 | 55.3 | 98.7 | 14.6\% | 5.2\% | 1.7\% |
| 65- | 16,158 | 73.2 | 102.7 | 22.4\% | 7.4\% | 1.8\% |


| Fasting plasma glucose (mg/dL) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average fasting <br> plasma glucose | $110 \mathrm{mg} / \mathrm{dL}$ and above | $130 \mathrm{mg} / \mathrm{dL}$ and above | $160 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - | - |  |
| 7-15 | 2,296 | 11.0 | 87.6 | 0.6\% | 0.0\% | 0.0\% |
| 16-39 | 2,032 | 28.1 | 90.8 | 3.0\% | 1.4\% | 0.9\% |
| 40-64 | 5,562 | 55.7 | 103.1 | 22.1\% | 8.5\% | 2.8\% |
| 65- | 7,363 | 73.1 | 105.5 | 28.0\% | 9.6\% | 2.5\% |


| Fasting plasma glucose (mg/dL) (female) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average fasting plasma glucose | $110 \mathrm{mg} / \mathrm{dL}$ and above | $130 \mathrm{mg} / \mathrm{dL}$ and above | $160 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - | - | - |
| 7-15 | 2,187 | 11.0 | 85.9 | 0.5\% | 0.0\% | - |
| 16-39 | 3,438 | 29.5 | 87.2 | 1.3\% | 0.3\% | 0.2\% |
| 40-64 | 9,187 | 55.0 | 95.9 | 10.1\% | 3.2\% | 1.1\% |
| 65- | 8,795 | 73.2 | 100.4 | 17.7\% | 5.5\% | 1.3\% |

FY 2014

| Fasting plasma glucose (mg/dL) (overall) |  |  |  |  |  |  |
| :---: | :---: | :---: | ---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average fasting <br> plasma glucose | $110 \mathrm{mg} / \mathrm{dL}$ <br> and above | $130 \mathrm{mg} / \mathrm{dL}$ <br> and above | $160 \mathrm{mg} / \mathrm{dL}$ <br> and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | 4,261 | 11.0 | 87.2 | $0.4 \%$ | $0.0 \%$ | $0.0 \%$ |
| $16-39$ | 5,129 | 28.9 | 88.4 | $2.0 \%$ | $0.8 \%$ | $0.4 \%$ |
| $40-64$ | 13,911 | 55.1 | 98.9 | $14.5 \%$ | $5.2 \%$ | $1.7 \%$ |
| $65-$ | 16,337 | 73.0 | 103.3 | $23.5 \%$ | $7.6 \%$ | $1.6 \%$ |


| Fasting plasma glucose (mg/dL) (male) |  |  |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average fasting <br> plasma glucose | $110 \mathrm{mg} / \mathrm{dL}$ <br> and above | $130 \mathrm{mg} / \mathrm{dL}$ <br> and above | $160 \mathrm{mg} / \mathrm{dL}$ <br> and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | 2,189 | 11.0 | 88.1 | $0.3 \%$ | - | - |
| $16-39$ | 1,865 | 27.9 | 90.2 | $3.1 \%$ | $0.9 \%$ | $0.5 \%$ |
| $40-64$ | 5,166 | 55.5 | 103.5 | $22.0 \%$ | $8.7 \%$ | $2.7 \%$ |
| $65-$ | 7,372 | 73.1 | 106.2 | $29.9 \%$ | $10.2 \%$ | $2.2 \%$ |


| Fasting plasma glucose (mg/dL) (female) |  |  |  |  |  |  |  |
| :---: | :---: | :---: | ---: | ---: | ---: | :---: | :---: |
| Age | Examinees | Average age | Average fasting <br> plasma glucose | $110 \mathrm{mg} / \mathrm{dL}$ <br> and above | $130 \mathrm{mg} / \mathrm{dL}$ <br> and above | $160 \mathrm{mg} / \mathrm{dL}$ <br> and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 2,072 | 11.0 | 86.2 | $0.5 \%$ | $0.1 \%$ | $0.0 \%$ |  |
| $16-39$ | 3,264 | 29.5 | 87.4 | $1.4 \%$ | $0.7 \%$ | $0.3 \%$ |  |
| $40-64$ | 8,745 | 54.8 | 96.2 | $10.1 \%$ | $3.1 \%$ | $1.1 \%$ |  |
| $65-$ | 8,965 | 73.0 | 101.0 | $18.3 \%$ | $5.4 \%$ | $1.1 \%$ |  |

## HbA1c (NGSP)

FY 2011

| HbA1c (\%) (NGSP) (overall) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> HbA1c | $6.0 \%$ and above | $7.0 \%$ and above | $8.0 \%$ and above |
| 0-6 | - | - | - | - | - |  |
| 7-15 | 11,084 | 11.0 | 5.3 | 1.0\% | 0.1\% | 0.0\% |
| 16-39 | 14,755 | 28.1 | 5.1 | 1.6\% | 0.7\% | 0.4\% |
| 40-64 | 23,650 | 54.0 | 5.5 | 11.8\% | 3.8\% | 1.8\% |
| 65- | 16,723 | 73.7 | 5.6 | 18.7\% | 4.7\% | 1.8\% |


| HbA1c (\%) (NGSP) (male) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> HbA1c | $6.0 \%$ and above | $7.0 \%$ and above | $8.0 \%$ and above |
| 0-6 | - | - | - | - | - |  |
| 7-15 | 5,578 | 10.9 | 5.3 | 1.2\% | 0.1\% | 0.1\% |
| 16-39 | 5,966 | 27.7 | 5.1 | 2.1\% | 1.0\% | 0.7\% |
| 40-64 | 9,562 | 54.5 | 5.5 | 16.1\% | 5.7\% | 2.6\% |
| 65- | 7,496 | 73.4 | 5.7 | 22.4\% | 5.9\% | 2.2\% |


| HbA1c (\%) (NGSP) (female) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> HbA1c | $6.0 \%$ and above | $7.0 \%$ and above | $8.0 \%$ and above |
| 0-6 | - | - | - | - | - | - |
| 7-15 | 5,506 | 11.0 | 5.3 | 0.9\% | 0.1\% | 0.0\% |
| 16-39 | 8,789 | 28.3 | 5.1 | 1.2\% | 0.5\% | 0.3\% |
| 40-64 | 14,088 | 53.7 | 5.4 | 8.9\% | 2.6\% | 1.2\% |
| 65- | 9,227 | 73.8 | 5.6 | 15.8\% | 3.7\% | 1.4\% |

FY 2012

| HbA1c (\%) (NGSP) (overall) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> HbA1c | $6.0 \%$ and above | $7.0 \%$ and above | $8.0 \%$ and above |
| 0-6 | - | - | - | - | - | - |
| 7-15 | 7,283 | 10.9 | 5.3 | 0.6\% | 0.1\% | 0.0\% |
| 16-39 | 8,478 | 28.6 | 5.2 | 2.0\% | 0.7\% | 0.5\% |
| 40-64 | 19,552 | 55.0 | 5.5 | 13.2\% | 3.5\% | 1.5\% |
| 65- | 18,638 | 73.5 | 5.7 | 20.3\% | 3.9\% | 1.3\% |


| HbA1c (\%) (NGSP) (male) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> HbA1c | $6.0 \%$ and above | $7.0 \%$ and above | $8.0 \%$ and above |
| 0-6 | - | - | - | - | - | - |
| 7-15 | 3,711 | 10.9 | 5.3 | 0.8\% | 0.1\% | 0.1\% |
| 16-39 | 3,229 | 27.9 | 5.2 | 2.6\% | 0.7\% | 0.5\% |
| 40-64 | 7,717 | 55.4 | 5.6 | 17.2\% | 5.1\% | 2.3\% |
| 65- | 8,476 | 73.4 | 5.7 | 22.9\% | 5.1\% | 1.6\% |


| HbA1c (\%) (NGSP) (female) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> HbA1c | $6.0 \%$ and above | $7.0 \%$ and above | $8.0 \%$ and above |
| 0-6 | - | - | - | - | - | - |
| 7-15 | 3,527 | 11.0 | 5.3 | 0.5\% | 0.1\% | - |
| 16-39 | 5,249 | 29.1 | 5.2 | 1.6\% | 0.6\% | 0.5\% |
| 40-64 | 11,835 | 54.6 | 5.5 | 10.6\% | 2.4\% | 1.0\% |
| 65- | 10,162 | 73.6 | 5.6 | 18.2\% | 3.0\% | 1.1\% |

HbA1c (NGSP)
FY 2013

| HbA1c (\%) (NGSP) (overall) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average HbA1c | $\begin{array}{\|lr} \hline 6.0 \% & \text { and } \\ \text { above } \end{array}$ | 7.0\% and above | 8.0\% and above |
| 0-6 | - | - | - | - | - | - |
| 7-15 | 6,290 | 10.9 | 5.3 | 0.5\% | 0.0\% | 0.0\% |
| 16-39 | 6,536 | 29.0 | 5.2 | 2.2\% | 0.6\% | 0.4\% |
| 40-64 | 16,919 | 55.3 | 5.6 | 15.4\% | 3.7\% | 1.5\% |
| 65- | 18,956 | 73.5 | 5.8 | 24.0\% | 4.5\% | 1.2\% |


| HbAlc (\%) (NGSP) (male) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average <br> HbA1c | 6.0\% and above | 7.0\% and above | $\begin{array}{ll} 8.0 \% & \text { and } \\ \text { above } \end{array}$ |
| 0-6 | - | - | - | - | - | - |
| 7-15 | 3,218 | 10.9 | 5.3 | 0.4\% | 0.1\% | 0.0\% |
| 16-39 | 2,480 | 28.3 | 5.2 | 2.8\% | 0.8\% | 0.7\% |
| 40-64 | 6,508 | 55.7 | 5.7 | 18.9\% | 5.4\% | 2.2\% |
| $65-$ | 8,637 | 73.4 | 5.8 | 26.7\% | 5.6\% | 1.4\% |


| HbA1c (\%) (NGSP) (female) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average <br> HbAlc | 6.0\% and above | 7.0\% and above | $8.0 \%$ and above |
| 0-6 | - | - | - | - | - |  |
| 7-15 | 3,072 | 10.9 | 5.3 | 0.6\% | - | - |
| 16-39 | 4,056 | 29.5 | 5.2 | 1.8\% | 0.4\% | 0.3\% |
| 40-64 | 10,411 | 55.0 | 5.6 | 13.2\% | 2.7\% | 1.1\% |
| 65- | 10,319 | 73.5 | 5.7 | 21.8\% | 3.5\% | 1.0\% |

FY 2014

| HbA1c (\%) (NGSP) (overall) |  |  |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> HbA1c | $6.0 \%$ and <br> above | $7.0 \%$ and <br> above | $8.0 \%$ and <br> above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | 5,706 | 10.9 | 5.3 | $0.6 \%$ | $0.1 \%$ | $0.0 \%$ |
| $16-39$ | 5,843 | 29.0 | 5.3 | $2.3 \%$ | $0.7 \%$ | $0.3 \%$ |
| $40-64$ | 15,588 | 55.1 | 5.6 | $14.4 \%$ | $3.3 \%$ | $1.2 \%$ |
| $65-$ | 19,152 | 73.3 | 5.7 | $22.9 \%$ | $4.0 \%$ | $1.0 \%$ |


| HbA1c (\%) (NGSP) (male) |  |  |  |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: | ---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> HbA1c | $6.0 \%$ and <br> above | $7.0 \%$ and <br> above | $8.0 \%$ and <br> above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 2,917 | 10.9 | 5.3 | $0.8 \%$ | $0.1 \%$ | $0.0 \%$ |  |
| $16-39$ | 2,168 | 28.0 | 5.3 | $2.6 \%$ | $1.0 \%$ | $0.5 \%$ |  |
| $40-64$ | 5,856 | 55.5 | 5.7 | $18.1 \%$ | $5.1 \%$ | $1.9 \%$ |  |
| $65-$ | 8,675 | 73.3 | 5.7 | $25.3 \%$ | $5.0 \%$ | $1.3 \%$ |  |


| HbA1c (\%) (NGSP) (female) |  |  |  |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: | ---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> HbA1c | $6.0 \%$ and <br> above | $7.0 \%$ and <br> above | $8.0 \%$ and <br> above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 2,789 | 10.9 | 5.3 | $0.5 \%$ | $0.1 \%$ | $0.0 \%$ |  |
| $16-39$ | 3,675 | 29.5 | 5.3 | $2.1 \%$ | $0.5 \%$ | $0.2 \%$ |  |
| $40-64$ | 9,732 | 54.9 | 5.6 | $12.2 \%$ | $2.3 \%$ | $0.8 \%$ |  |
| $65-$ | 10,477 | 73.3 | 5.7 | $21.0 \%$ | $3.1 \%$ | $0.8 \%$ |  |

## HDL-C

FY 2011

| HDL-C (mg/dL) (overall) |  |  |  |  |  |
| ---: | :--- | :--- | :--- | :--- | :---: |
| Age | Examinees | Average age | Average <br> HDL-C | Less than $40 \mathrm{mg} / \mathrm{dL}$ |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | 11,101 | 11.0 | 62.5 |  |  |
| $16-39$ | 14,757 | 28.1 | 62.1 | $2.9 \%$ |  |
| $40-64$ | 23,651 | 54.0 | 61.4 | $4.0 \%$ |  |
| $65-$ | 16,725 | 73.7 | 57.6 | $5.8 \%$ |  |
|  |  |  | $8.5 \%$ |  |  |


| HDL-C (mg/dL) (male) |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :---: |
| Age | Examinees | Average age | Average <br> HDL-C | Less than $40 \mathrm{mg} / \mathrm{dL}$ |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | 5,586 | 10.9 | 62.2 | $3.1 \%$ |  |
| $16-39$ | 5,966 | 27.7 | 56.2 | $7.5 \%$ |  |
| $40-64$ | 9,562 | 54.5 | 55.7 | $10.6 \%$ |  |
| $65-$ | 7,496 | 73.4 | 54.2 | $13.3 \%$ |  |


| HDL-C (mg/dL) (female) |  |  |  |  |  |
| ---: | :--- | :--- | :--- | :--- | :---: |
| Age | Examinees | Average age | Average <br> HDL-C | Less than $40 \mathrm{mg} / \mathrm{dL}$ |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | 5,515 | 11.0 | 62.7 |  |  |
| $16-39$ | 8,791 | 28.3 | 66.1 | $2.8 \%$ |  |
| $40-64$ | 14,089 | 53.7 | 65.3 | $1.7 \%$ |  |
| $65-$ | 9,229 | 73.8 | 60.4 | $2.5 \%$ |  |

FY 2012

| HDL-C (mg/dL) (overall) |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :---: |
| Age | Examinees | Average age | Average <br> HDL-C | Less than $40 \mathrm{mg} / \mathrm{dL}$ |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | 7,243 | 10.9 | 61.3 | . |  |
| $16-39$ | 8,479 | 28.6 | 62.0 | $2.7 \%$ |  |
| $40-64$ | 19,551 | 55.0 | 60.7 | $4.3 \%$ |  |
| $65-$ | 18,638 | 73.5 | 57.2 | $6.4 \%$ |  |


| HDL-C (mg/dL) (male) |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :---: |
| Age | Examinees | Average age | Average <br> HDL-C | Less than $40 \mathrm{mg} / \mathrm{dL}$ |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | 3,711 | 10.9 | 61.4 | $3.1 \%$ |  |
| $16-39$ | 3,230 | 27.9 | 55.9 | $8.1 \%$ |  |
| $40-64$ | 7,716 | 55.4 | 55.6 | $11.6 \%$ |  |
| $65-$ | 8,476 | 73.4 | 54.0 | $13.0 \%$ |  |


| HDL-C (mg/dL) (female) |  |  |  |  |  |
| ---: | ---: | :--- | :--- | :--- | :---: |
| Age | Examinees | Average age | Average <br> HDL-C | Less than $40 \mathrm{mg} / \mathrm{dL}$ |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | 3,532 | 11.0 | 61.1 |  |  |
| $16-39$ | 5,249 | 29.1 | 65.7 | $2.3 \%$ |  |
| $40-64$ | 11,835 | 54.6 | 64.1 | $1.9 \%$ |  |
| $65-$ | 10,162 | 73.6 | 59.8 | $3.0 \%$ |  |

## HDL-C

FY 2013

| HDL-C (mg/dL) (overall) |  |  |  |  |  |
| ---: | :--- | :--- | :--- | :--- | :---: |
| Age | Examinees | Average age | Average <br> HDL-C | Less than $40 \mathrm{mg} / \mathrm{dL}$ |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | 6,291 | 10.9 | 61.5 | $2.9 \%$ |  |
| $16-39$ | 6,536 | 29.0 | 62.2 | $4.1 \%$ |  |
| $40-64$ | 16,921 | 55.3 | 61.7 | $5.5 \%$ |  |
| $65-$ | 18,957 | 73.5 | 58.0 | $7.6 \%$ |  |


| HDL-C (mg/dL) (male) |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :---: |
| Age | Examinees | Average age | Average <br> HDL-C | Less than $40 \mathrm{mg} / \mathrm{dL}$ |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | 3,219 | 10.9 | 61.7 | $3.1 \%$ |  |
| $16-39$ | 2,480 | 28.3 | 56.0 | $8.1 \%$ |  |
| $40-64$ | 6,510 | 55.7 | 56.1 | $10.5 \%$ |  |
| $65-$ | 8,637 | 73.4 | 54.7 | $11.7 \%$ |  |


| HDL-C (mg/dL) (female) |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :---: |
| Age | Examinees | Average age | Average <br> HDL-C | Less than $40 \mathrm{mg} / \mathrm{dL}$ |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | 3,072 | 10.9 | 61.3 | . |  |
| $16-39$ | 4,056 | 29.5 | 65.9 | $2.7 \%$ |  |
| $40-64$ | 10,411 | 55.0 | 65.2 | $1.7 \%$ |  |
| $65-$ | 10,320 | 73.5 | 60.8 | $2.4 \%$ |  |
|  |  |  |  | $4.2 \%$ |  |

FY 2014

| HDL-C (mg/dL) (overall) |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> HDL-C | Less than 40 <br> $\mathrm{mg} / \mathrm{dL}$ |
| $0-6$ | $\cdot$ | $\cdot$ |  | $\cdot$ |
| $7-15$ | 5,708 | 10.9 | 61.6 | $2.4 \%$ |
| $16-39$ | 5,843 | 29.0 | 62.7 | $4.2 \%$ |
| $40-64$ | 15,591 | 55.1 | 62.2 | $4.8 \%$ |
| $65-$ | 19,156 | 73.3 | 58.6 | $7.0 \%$ |


| HDL-C (mg/dL) (male) |  |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> HDL-C | Less than 40 <br> $\mathrm{mg} / \mathrm{dL}$ |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | 2,917 | 10.9 | 61.8 | $2.7 \%$ |  |
| $16-39$ | 2,168 | 28.0 | 56.4 | $8.0 \%$ |  |
| $40-64$ | 5,858 | 55.5 | 56.8 | $9.0 \%$ |  |
| $65-$ | 8,677 | 73.3 | 55.3 | $10.7 \%$ |  |


| HDL-C (mg/dL) (female) |  |  |  |  |  |
| :---: | :---: | ---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> HDL-C | Less than 40 <br> $\mathrm{mg} / \mathrm{dL}$ |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 2,791 | 10.9 | 61.5 | $2.0 \%$ |  |
| $16-39$ | 3,675 | 29.5 | 66.3 | $2.0 \%$ |  |
| $40-64$ | 9,733 | 54.9 | 65.5 | $2.2 \%$ |  |
| $65-$ | 10,479 | 73.3 | 61.3 | $4.0 \%$ |  |

## Triglyceride (TG)

FY 2011

| Triglyceride (TG) (mg/dL) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average triglyceride | $150 \mathrm{mg} / \mathrm{dL}$ and above | $300 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | . | - | - | - |  |
| 7-15 | 11,091 | 11.0 | 76.5 | 7.0\% | 0.6\% |
| 16-39 | 14,757 | 28.1 | 88.5 | 11.4\% | 1.7\% |
| 40-64 | 23,651 | 54.0 | 117.8 | 21.3\% | 3.2\% |
| 65- | 16,725 | 73.7 | 114.7 | 20.3\% | 1.6\% |


| Triglyceride (TG) (mg/dL) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average triglyceride | $150 \mathrm{mg} / \mathrm{dL}$ and above | $300 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | $\cdot$ | - | - |  |
| 7-15 | 5,584 | 10.9 | 75.5 | 7.7\% | 0.6\% |
| 16-39 | 5,966 | 27.7 | 109.3 | 19.0\% | 3.2\% |
| 40-64 | 9,562 | 54.5 | 142.3 | 31.5\% | 6.0\% |
| 65- | 7,496 | 73.4 | 119.6 | 23.1\% | 2.5\% |


| Triglyceride (TG) (mg/dL) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average triglyceride | $150 \mathrm{mg} / \mathrm{dL}$ and above | $300 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 5,507 | 11.0 | 77.5 | 6.3\% | 0.5\% |
| 16-39 | 8,791 | 28.3 | 74.3 | 6.2\% | 0.6\% |
| 40-64 | 14,089 | 53.7 | 101.1 | 14.4\% | 1.3\% |
| 65- | 9,229 | 73.8 | 110.7 | 18.1\% | 1.0\% |

FY 2012

| Triglyceride (TG) (mg/dL) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average triglyceride | $150 \mathrm{mg} / \mathrm{dL}$ and above | $300 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 7,242 | 10.9 | 77.0 | 7.1\% | 0.7\% |
| 16-39 | 8,480 | 28.6 | 89.5 | 11.7\% | 1.6\% |
| 40-64 | 19,552 | 55.0 | 117.0 | 21.5\% | 3.2\% |
| 65- | 18,638 | 73.5 | 110.8 | 17.9\% | 1.6\% |


| Triglyceride (TG) (mg/dL) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average triglyceride | $150 \mathrm{mg} / \mathrm{dL}$ and above | $300 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - | - |
| 7-15 | 3,711 | 10.9 | 75.9 | 7.7\% | 0.6\% |
| 16-39 | 3,230 | 27.9 | 111.7 | 19.9\% | 3.0\% |
| 40-64 | 7,717 | 55.4 | 140.0 | 32.0\% | 5.9\% |
| 65- | 8,476 | 73.4 | 115.3 | 20.5\% | 2.2\% |


| Triglyceride (TG) (mg/dL) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average triglyceride | $150 \mathrm{mg} / \mathrm{dL}$ and above | $300 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 3,531 | 11.0 | 78.1 | 6.5\% | 0.7\% |
| 16-39 | 5,250 | 29.1 | 75.8 | 6.7\% | 0.7\% |
| 40-64 | 11,835 | 54.6 | 102.0 | 14.6\% | 1.4\% |
| 65- | 10,162 | 73.6 | 107.1 | 15.7\% | 1.0\% |

Triglyceride (TG)
FY 2013

| Triglyceride (TG) (mg/dL) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average triglyceride | $150 \mathrm{mg} / \mathrm{dL}$ and above | $300 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - | - |
| 7-15 | 6,290 | 10.9 | 78.7 | 7.3\% | 0.7\% |
| 16-39 | 6,536 | 29.0 | 90.9 | 11.8\% | 2.0\% |
| 40-64 | 16,919 | 55.3 | 117.4 | 21.5\% | 3.3\% |
| 65- | 18,957 | 73.5 | 112.6 | 18.4\% | 1.6\% |


| Triglyceride (TG) (mg/dL) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average triglyceride | $150 \mathrm{mg} / \mathrm{dL}$ and above | $300 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 3,219 | 10.9 | 77.6 | 7.6\% | 0.6\% |
| 16-39 | 2,480 | 28.3 | 115.8 | 20.5\% | 4.2\% |
| 40-64 | 6,509 | 55.7 | 140.8 | 30.9\% | 6.2\% |
| 65- | 8,637 | 73.4 | 116.5 | 20.5\% | 2.2\% |


| Triglyceride (TG) (mg/dL) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average triglyceride | $150 \mathrm{mg} / \mathrm{dL}$ and above | $300 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - | - |
| 7-15 | 3,071 | 10.9 | 79.7 | 7.0\% | 0.7\% |
| 16-39 | 4,056 | 29.5 | 75.7 | 6.4\% | 0.6\% |
| 40-64 | 10,410 | 55.0 | 102.8 | 15.6\% | 1.5\% |
| 65- | 10,320 | 73.5 | 109.4 | 16.6\% | 1.2\% |

FY 2014

| Triglyceride (TG) (mg/dL) (overall) |  |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> triglyceride | $150 \mathrm{mg} / \mathrm{dL}$ <br> and above | $300 \mathrm{mg} / \mathrm{dL}$ <br> and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | 5,705 | 10.9 | 79.0 | $8.2 \%$ | $0.8 \%$ |
| $16-39$ | 5,843 | 29.0 | 90.5 | $11.3 \%$ | $1.8 \%$ |
| $40-64$ | 15,591 | 55.1 | 115.5 | $20.5 \%$ | $2.8 \%$ |
| $65-$ | 19,156 | 73.3 | 112.4 | $18.5 \%$ | $1.7 \%$ |


| Triglyceride (TG) (mg/dL) (male) |  |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> triglyceride | $150 \mathrm{mg} / \mathrm{dL}$ <br> and above | $300 \mathrm{mg} / \mathrm{dL}$ <br> and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | 2,916 | 10.9 | 78.9 | $8.7 \%$ | $0.9 \%$ |
| $16-39$ | 2,168 | 28.0 | 114.6 | $19.2 \%$ | $3.5 \%$ |
| $40-64$ | 5,858 | 55.5 | 138.1 | $30.5 \%$ | $5.4 \%$ |
| $65-$ | 8,677 | 73.3 | 117.0 | $21.1 \%$ | $2.3 \%$ |


| Triglyceride (TG) (mg/dL) (female) |  |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> triglyceride | $150 \mathrm{mg} / \mathrm{dL}$ <br> and above | $300 \mathrm{mg} / \mathrm{dL}$ <br> and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | . |
| $7-15$ | 2,789 | 10.9 | 79.1 | $7.7 \%$ | $0.6 \%$ |
| $16-39$ | 3,675 | 29.5 | 76.3 | $6.6 \%$ | $0.8 \%$ |
| $40-64$ | 9,733 | 54.9 | 101.8 | $14.5 \%$ | $1.3 \%$ |
| $65-$ | 10,479 | 73.3 | 108.5 | $16.4 \%$ | $1.1 \%$ |

## LDL-C

FY 2011

| LDL-C (mg/dL) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> LDL-C | $120 \mathrm{mg} / \mathrm{dL}$ and above | $140 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - | - |
| 7-15 | 11,098 | 11.0 | 94.1 | 13.2\% | 3.5\% |
| 16-39 | 14,757 | 28.1 | 110.1 | 33.9\% | 15.9\% |
| 40-64 | 23,651 | 54.0 | 129.3 | 59.8\% | 35.8\% |
| 65- | 16,725 | 73.7 | 122.9 | 52.8\% | 28.6\% |


| LDL-C (mg/dL) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> LDL-C | $120 \mathrm{mg} / \mathrm{dL}$ and above | $140 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 5,587 | 10.9 | 91.9 | 11.7\% | 3.3\% |
| 16-39 | 5,966 | 27.7 | 114.6 | 40.2\% | 21.0\% |
| 40-64 | 9,562 | 54.5 | 126.9 | 57.8\% | 34.2\% |
| 65- | 7,496 | 73.4 | 118.6 | 48.0\% | 24.6\% |


| LDL-C (mg/dL) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> LDL-C | $120 \mathrm{mg} / \mathrm{dL}$ and above | $140 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - | - |
| 7-15 | 5,511 | 11.0 | 96.3 | 14.8\% | 3.6\% |
| 16-39 | 8,791 | 28.3 | 107.0 | 29.6\% | 12.4\% |
| 40-64 | 14,089 | 53.7 | 130.9 | 61.1\% | 37.0\% |
| 65- | 9,229 | 73.8 | 126.4 | 56.7\% | 31.7\% |

FY 2012

| LDL-C (mg/dL) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> LDL-C | $120 \mathrm{mg} / \mathrm{dL}$ and above | $140 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - | - |
| 7-15 | 7,240 | 10.9 | 93.7 | 12.2\% | 3.4\% |
| 16-39 | 8,479 | 28.6 | 109.3 | 32.7\% | 15.7\% |
| 40-64 | 19,550 | 55.0 | 126.0 | 56.0\% | 31.6\% |
| 65- | 18,638 | 73.5 | 118.0 | 46.7\% | 22.3\% |


| LDL-C (mg/dL) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> LDL-C | $120 \mathrm{mg} / \mathrm{dL}$ and above | $140 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 3,710 | 10.9 | 91.9 | 10.7\% | 3.2\% |
| 16-39 | 3,230 | 27.9 | 114.2 | 39.0\% | 21.2\% |
| 40-64 | 7,716 | 55.4 | 123.7 | 53.6\% | 29.6\% |
| 65- | 8,476 | 73.4 | 113.8 | 41.8\% | 18.4\% |


| LDL-C (mg/dL) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average <br> LDL-C | $120 \mathrm{mg} / \mathrm{dL}$ and above | $140 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 3,530 | 11.0 | 95.6 | 13.9\% | 3.6\% |
| 16-39 | 5,249 | 29.1 | 106.3 | 28.9\% | 12.3\% |
| 40-64 | 11,834 | 54.6 | 127.6 | 57.6\% | 32.9\% |
| 65- | 10,162 | 73.6 | 121.6 | 50.8\% | 25.6\% |

## LDL-C

FY 2013

| LDL-C (mg/dL) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> LDL-C | $120 \mathrm{mg} / \mathrm{dL}$ and above | $140 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - | - |
| 7-15 | 6,291 | 10.9 | 94.1 | 13.8\% | 3.9\% |
| 16-39 | 6,536 | 29.0 | 110.4 | 34.5\% | 15.6\% |
| 40-64 | 16,921 | 55.3 | 126.8 | 57.2\% | 32.6\% |
| 65- | 18,957 | 73.5 | 119.1 | 47.9\% | 23.2\% |


| LDL-C (mg/dL) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> LDL-C | $120 \mathrm{mg} / \mathrm{dL}$ and above | $140 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 3,219 | 10.9 | 92.6 | 12.3\% | 4.2\% |
| 16-39 | 2,480 | 28.3 | 114.1 | 40.0\% | 19.5\% |
| 40-64 | 6,510 | 55.7 | 123.9 | 54.3\% | 30.0\% |
| 65- | 8,637 | 73.4 | 114.6 | 42.8\% | 18.8\% |


| LDL-C (mg/dL) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> LDL-C | $120 \mathrm{mg} / \mathrm{dL}$ and above | $140 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 3,072 | 10.9 | 95.8 | 15.4\% | 3.5\% |
| 16-39 | 4,056 | 29.5 | 108.2 | 31.2\% | 13.2\% |
| 40-64 | 10,411 | 55.0 | 128.6 | 59.1\% | 34.1\% |
| 65- | 10,320 | 73.5 | 122.9 | 52.3\% | 26.9\% |

FY 2014

| LDL-C (mg/dL) (overall) |  |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> LDL-C | $120 \mathrm{mg} / \mathrm{dL}$ <br> and above | $140 \mathrm{mg} / \mathrm{dL}$ <br> and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | 5,705 | 10.9 | 93.6 | $12.9 \%$ | $3.5 \%$ |
| $16-39$ | 5,843 | 29.0 | 110.9 | $35.0 \%$ | $16.6 \%$ |
| $40-64$ | 15,591 | 55.1 | 127.6 | $58.3 \%$ | $33.8 \%$ |
| $65-$ | 19,156 | 73.3 | 118.9 | $46.8 \%$ | $23.5 \%$ |


| LDL-C (mg/dL) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> LDL-C | $120 \mathrm{mg} / \mathrm{dL}$ <br> and above | $140 \mathrm{mg} / \mathrm{dL}$ <br> and above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | 2,914 | 10.9 | 91.7 | $11.7 \%$ | $3.4 \%$ |
| $16-39$ | 2,168 | 28.0 | 114.8 | $41.1 \%$ | $21.2 \%$ |
| $40-64$ | 5,858 | 55.5 | 125.4 | $55.8 \%$ | $31.8 \%$ |
| $65-$ | 8,677 | 73.3 | 114.2 | $41.4 \%$ | $19.4 \%$ |


| LDL-C (mg/dL) (female) |  |  |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> LDL-C | $120 \mathrm{mg} / \mathrm{dL}$ <br> and above | $140 \mathrm{mg} / \mathrm{dL}$ <br> and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 2,791 | 10.9 | 95.7 | $14.3 \%$ | $3.5 \%$ |  |
| $16-39$ | 3,675 | 29.5 | 108.6 | $31.3 \%$ | $13.9 \%$ |  |
| $40-64$ | 9,733 | 54.9 | 128.9 | $59.8 \%$ | $34.9 \%$ |  |
| $65-$ | 10,479 | 73.3 | 122.7 | $51.3 \%$ | $26.9 \%$ |  |

## AST

FY 2011

| AST (U/L) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average AST | 31 U/L and above | $51 \mathrm{U} / \mathrm{L}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 11,103 | 11.0 | 23.6 | 9.6\% | 0.8\% |
| 16-39 | 14,757 | 28.1 | 20.6 | 8.2\% | 2.0\% |
| 40-64 | 23,651 | 54.0 | 24.2 | 14.5\% | 2.8\% |
| 65- | 16,725 | 73.7 | 25.7 | 17.7\% | 2.8\% |


| AST (U/L) (male) |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | ---: | ---: | :---: |
| Age | Examinees <br> Average <br> age |  | Average <br> AST | 31 U/L and above | 51 U/L and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 5,588 | 10.9 | 25.1 | $12.8 \%$ | $1.3 \%$ |  |
| $16-39$ | 5,966 | 27.7 | 24.2 | $15.3 \%$ | $3.8 \%$ |  |
| $40-64$ | 9,562 | 54.5 | 26.9 | $21.4 \%$ | $4.3 \%$ |  |
| $65-$ | 7,496 | 73.4 | 27.2 | $23.0 \%$ | $3.7 \%$ |  |


| AST (U/L) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average AST | 31 U/L and above | $51 \mathrm{U} / \mathrm{L}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 5,515 | 11.0 | 22.0 | 6.4\% | 0.4\% |
| 16-39 | 8,791 | 28.3 | 18.2 | 3.4\% | 0.8\% |
| 40-64 | 14,089 | 53.7 | 22.3 | 9.7\% | 1.8\% |
| 65- | 9,229 | 73.8 | 24.5 | 13.4\% | 2.2\% |

FY 2012

| AST (U/L) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average AST | 31 U/L and above | $51 \mathrm{U} / \mathrm{L}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 7,243 | 10.9 | 24.1 | 10.6\% | 0.8\% |
| 16-39 | 8,479 | 28.6 | 20.8 | 8.7\% | 1.8\% |
| 40-64 | 19,552 | 55.0 | 24.7 | 15.8\% | 3.0\% |
| 65- | 18,638 | 73.5 | 26.4 | 19.5\% | 2.8\% |


| AST (U/L) (male) |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | :--- | :--- | :---: |
| Age | Examinees <br> Average <br> age |  | Average <br> AST | 31 U/L and above | 51 U/L and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | 3,711 | 10.9 | 25.6 | $14.1 \%$ | $1.2 \%$ |  |
| $16-39$ | 3,229 | 27.9 | 24.6 | $16.6 \%$ | $3.3 \%$ |  |
| $40-64$ | 7,717 | 55.4 | 27.6 | $23.7 \%$ | $4.4 \%$ |  |
| $65-$ | 8,476 | 73.4 | 27.8 | $25.1 \%$ | $3.6 \%$ |  |


| AST (U/L) (female) |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | ---: | ---: | :---: |
| Age | Examinees <br> Average <br> age |  | Average <br> AST | 31 U/L and above | 51 U/L and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | 3,532 | 11.0 | 22.6 | $7.0 \%$ | $0.5 \%$ |  |
| $16-39$ | 5,250 | 29.1 | 18.5 | $3.8 \%$ | $0.9 \%$ |  |
| $40-64$ | 11,835 | 54.6 | 22.8 | $10.6 \%$ | $2.1 \%$ |  |
| $65-$ | 10,162 | 73.6 | 25.2 | $14.8 \%$ | $2.2 \%$ |  |

## AST

FY 2013

| AST (U/L) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average AST | $31 \mathrm{U} / \mathrm{L}$ and above | $51 \mathrm{U} / \mathrm{L}$ and above |
| 0-6 | - | - | - | - | - |
| 7-15 | 6,291 | 10.9 | 24.0 | 10.5\% | 0.7\% |
| 16-39 | 6,536 | 29.0 | 20.6 | 8.4\% | 2.0\% |
| 40-64 | 16,919 | 55.3 | 24.1 | 14.1\% | 2.8\% |
| 65- | 18,957 | 73.5 | 25.6 | 16.8\% | 2.6\% |


| AST (U/L) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average AST | $31 \mathrm{U} / \mathrm{L}$ and above | $51 \mathrm{U} / \mathrm{L}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 3,219 | 10.9 | 25.5 | 14.4\% | 1.1\% |
| 16-39 | 2,480 | 28.3 | 24.1 | 15.7\% | 3.6\% |
| 40-64 | 6,509 | 55.7 | 26.8 | 20.9\% | 4.3\% |
| 65- | 8,637 | 73.4 | 26.8 | 21.4\% | 3.2\% |


| AST (U/L) (female) |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | ---: | ---: | :---: |
| Age | Examinees <br> Average <br> age |  | Average <br> AST | 31 U/L and above | 51 U/L and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | 3,072 | 10.9 | 22.4 | $6.4 \%$ | $0.3 \%$ |  |
| $16-39$ | 4,056 | 29.5 | 18.4 | $3.9 \%$ | $1.0 \%$ |  |
| $40-64$ | 10,410 | 55.0 | 22.4 | $9.8 \%$ | $1.9 \%$ |  |
| $65-$ | 10,320 | 73.5 | 24.6 | $13.0 \%$ | $2.0 \%$ |  |

FY 2014

| AST (U/L) (overall) |  |  |  |  |  |  |
| :---: | :---: | ---: | :---: | ---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> AST | 31 U/L and <br> above | 51 U/L and <br> above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 5,708 | 10.9 | 24.0 | $11.2 \%$ | $0.8 \%$ |  |
| $16-39$ | 5,843 | 29.0 | 20.5 | $8.3 \%$ | $1.7 \%$ |  |
| $40-64$ | 15,591 | 55.1 | 24.0 | $13.7 \%$ | $2.8 \%$ |  |
| $65-$ | 19,156 | 73.3 | 25.7 | $16.8 \%$ | $2.6 \%$ |  |


| AST (U/L) (male) |  |  |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> AST | 31 U/L and <br> above | 51 U/L and <br> above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 2,917 | 10.9 | 25.5 | $14.8 \%$ | $1.3 \%$ |  |
| $16-39$ | 2,168 | 28.0 | 23.9 | $16.1 \%$ | $3.2 \%$ |  |
| $40-64$ | 5,858 | 55.5 | 26.7 | $20.7 \%$ | $4.6 \%$ |  |
| $65-$ | 8,677 | 73.3 | 27.0 | $21.4 \%$ | $3.5 \%$ |  |


| AST (U/L) (female) |  |  |  |  |  |  |
| :---: | :---: | ---: | :---: | ---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> AST | 31 U/L and <br> above | 51 U/L and <br> above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 2,791 | 10.9 | 22.4 | $7.4 \%$ | $0.3 \%$ |  |
| $16-39$ | 3,675 | 29.5 | 18.4 | $3.7 \%$ | $0.8 \%$ |  |
| $40-64$ | 9,733 | 54.9 | 22.4 | $9.5 \%$ | $1.7 \%$ |  |
| $65-$ | 10,479 | 73.3 | 24.6 | $13.0 \%$ | $1.8 \%$ |  |

## ALT

FY 2011

| ALT (U/L) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average ALT | 31 U/L and above | $51 \mathrm{U} / \mathrm{L}$ and above |
| 0-6 | - | - | - | - | - |
| 7-15 | 11,103 | 11.0 | 15.7 | 4.5\% | 1.6\% |
| 16-39 | 14,757 | 28.1 | 21.8 | 15.9\% | 7.0\% |
| 40-64 | 23,651 | 54.0 | 24.5 | 20.8\% | 6.9\% |
| 65- | 16,725 | 73.7 | 20.9 | 13.6\% | 3.7\% |


| ALT (U/L) (male) |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | ---: | ---: | :---: |
| Age | Examinees <br> Average <br> age |  | Average <br> ALT | 31 U/L and above | 51 U/L and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | 5,588 | 10.9 | 17.8 | $7.0 \%$ | $2.6 \%$ |  |
| $16-39$ | 5,966 | 27.7 | 31.4 | $31.0 \%$ | $14.1 \%$ |  |
| $40-64$ | 9,562 | 54.5 | 30.3 | $32.8 \%$ | $11.3 \%$ |  |
| $65-$ | 7,496 | 73.4 | 23.5 | $18.8 \%$ | $5.2 \%$ |  |


| ALT (U/L) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average ALT | 31 U/L and above | $51 \mathrm{U} / \mathrm{L}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 5,515 | 11.0 | 13.6 | 2.0\% | 0.7\% |
| 16-39 | 8,791 | 28.3 | 15.3 | 5.6\% | 2.2\% |
| 40-64 | 14,089 | 53.7 | 20.5 | 12.7\% | 3.9\% |
| 65- | 9,229 | 73.8 | 18.8 | 9.5\% | 2.6\% |

FY 2012

| ALT (U/L) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average ALT | 31 U/L and above | $51 \mathrm{U} / \mathrm{L}$ and above |
| 0-6 | - | - | - | - | - |
| 7-15 | 7,243 | 10.9 | 15.7 | 4.8\% | 1.4\% |
| 16-39 | 8,480 | 28.6 | 21.8 | 16.9\% | 7.0\% |
| 40-64 | 19,552 | 55.0 | 24.7 | 21.4\% | 7.1\% |
| 65- | 18,638 | 73.5 | 21.6 | 14.2\% | 3.6\% |


| ALT (U/L) (male) |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | ---: | ---: | :---: |
| Age | Examinees <br> Average <br> age |  | Average <br> ALT | 31 U/L and above | 51 U/L and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | 3,711 | 10.9 | 17.8 | $7.4 \%$ |  |  |
| $16-39$ | 3,230 | 27.9 | 31.8 | $33.6 \%$ | $2.2 \%$ |  |
| $40-64$ | 7,717 | 55.4 | 30.7 | $33.8 \%$ | $14.7 \%$ |  |
| $65-$ | 8,476 | 73.4 | 24.0 | $19.5 \%$ | $11.6 \%$ |  |


| ALT (U/L) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average ALT | 31 U/L and above | $51 \mathrm{U} / \mathrm{L}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 3,532 | 11.0 | 13.5 | 2.0\% | 0.5\% |
| 16-39 | 5,250 | 29.1 | 15.7 | 6.5\% | 2.3\% |
| 40-64 | 11,835 | 54.6 | 20.8 | 13.3\% | 4.2\% |
| 65- | 10,162 | 73.6 | 19.5 | 9.8\% | 2.6\% |

## ALT

FY 2013

| ALT (U/L) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average <br> ALT | 31 U/L and above | $51 \mathrm{U} / \mathrm{L}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 6,291 | 10.9 | 15.7 | 4.7\% | 1.6\% |
| 16-39 | 6,536 | 29.0 | 21.8 | 16.1\% | 6.8\% |
| 40-64 | 16,919 | 55.3 | 24.1 | 20.0\% | 6.7\% |
| 65- | 18,957 | 73.5 | 21.0 | 13.0\% | 3.1\% |


| ALT (U/L) (male) |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | ---: | ---: | :---: |
| Age | Examinees <br> Average <br> age |  | Average <br> ALT | 31 U/L and above | 51 U/L and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 3,219 | 10.9 | 18.0 | $7.5 \%$ | $2.6 \%$ |  |
| $16-39$ | 2,480 | 28.3 | 31.3 | $31.6 \%$ | $14.0 \%$ |  |
| $40-64$ | 6,509 | 55.7 | 29.7 | $31.6 \%$ | $11.2 \%$ |  |
| $65-$ | 8,637 | 73.4 | 23.0 | $17.1 \%$ | $4.2 \%$ |  |


| ALT (U/L) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average ALT | 31 U/L and above | $51 \mathrm{U} / \mathrm{L}$ and above |
| 0-6 | - | - | - | - | - |
| 7-15 | 3,072 | 10.9 | 13.3 | 1.8\% | 0.5\% |
| 16-39 | 4,056 | 29.5 | 15.9 | 6.7\% | 2.5\% |
| 40-64 | 10,410 | 55.0 | 20.6 | 12.7\% | 3.9\% |
| 65- | 10,320 | 73.5 | 19.3 | 9.5\% | 2.3\% |

FY 2014

| ALT (U/L) (overall) |  |  |  |  |  |  |
| :---: | :---: | ---: | :---: | ---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> ALT | 31 U/L and <br> above | 51 U/L and <br> above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 5,708 | 10.9 | 15.5 | $4.4 \%$ | $1.4 \%$ |  |
| $16-39$ | 5,843 | 29.0 | 21.4 | $15.5 \%$ | $6.7 \%$ |  |
| $40-64$ | 15,591 | 55.1 | 23.8 | $19.5 \%$ | $6.0 \%$ |  |
| $65-$ | 19,156 | 73.3 | 21.4 | $13.3 \%$ | $3.2 \%$ |  |


| ALT (U/L) (male) |  |  |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> ALT | 31 U/L and <br> above | 51 U/L and <br> above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |  |
| $7-15$ | 2,917 | 10.9 | 17.5 | $6.7 \%$ | $2.4 \%$ |  |
| $16-39$ | 2,168 | 28.0 | 30.8 | $31.0 \%$ | $14.3 \%$ |  |
| $40-64$ | 5,858 | 55.5 | 29.5 | $31.5 \%$ | $10.2 \%$ |  |
| $65-$ | 8,677 | 73.3 | 23.5 | $17.8 \%$ | $4.3 \%$ |  |


| ALT (U/L) (female) |  |  |  |  |  |  |
| :---: | :---: | ---: | :---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> ALT | 31 U/L and <br> above | 51 U/L and <br> above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 2,791 | 10.9 | 13.3 | $2.1 \%$ | $0.3 \%$ |  |
| $16-39$ | 3,675 | 29.5 | 15.8 | $6.4 \%$ | $2.1 \%$ |  |
| $40-64$ | 9,733 | 54.9 | 20.4 | $12.2 \%$ | $3.5 \%$ |  |
| $65-$ | 10,479 | 73.3 | 19.5 | $9.6 \%$ | $2.3 \%$ |  |

## $\gamma$-GT

FY 2011

| $\gamma$-GT (U/L) (overall) |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | :--- | ---: | :---: |
| Age | Examinees | Average <br> age | Average <br> $\gamma$-GT | 51 U/L and above | 101 U/L and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 11,101 | 11.0 | 14.6 | $0.6 \%$ | $0.1 \%$ |  |
| $16-39$ | 14,757 | 28.1 | 25.4 | $8.5 \%$ | $2.5 \%$ |  |
| $40-64$ | 23,651 | 54.0 | 39.7 | $19.9 \%$ | $6.2 \%$ |  |
| $65-$ | 16,725 | 73.7 | 32.8 | $13.4 \%$ | $3.7 \%$ |  |


| $\gamma$-GT (U/L) (male) |  |  |  |  |  |  |
| ---: | :--- | :--- | :--- | :--- | ---: | :---: |
| Age | Examinees | Average <br> age | Average <br> $\gamma$-GT | $51 \mathrm{U} / \mathrm{L}$ and above | $101 \mathrm{U} / \mathrm{L}$ and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 5,587 | 10.9 | 16.0 | $1.0 \%$ | $0.1 \%$ |  |
| $16-39$ | 5,966 | 27.7 | 37.2 | $17.2 \%$ | $5.4 \%$ |  |
| $40-64$ | 9,562 | 54.5 | 58.8 | $35.6 \%$ | $12.3 \%$ |  |
| $65-$ | 7,496 | 73.4 | 44.2 | $22.4 \%$ | $6.9 \%$ |  |


| $\gamma$-GT (U/L) (female) |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | :--- | ---: | :---: |
| Age | Examinees | Average <br> age | Average <br> $\gamma$-GT | 51 U/L and above | 101 U/L and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 5,514 | 11.0 | 13.2 | $0.2 \%$ | $0.0 \%$ |  |
| $16-39$ | 8,791 | 28.3 | 17.3 | $2.5 \%$ | $0.5 \%$ |  |
| $40-64$ | 14,089 | 53.7 | 26.8 | $9.3 \%$ | $2.1 \%$ |  |
| $65-$ | 9,229 | 73.8 | 23.6 | $6.0 \%$ | $1.1 \%$ |  |

FY 2012

| $\gamma$-GT (U/L) (overall) |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | :--- | :--- | :---: |
| Age | Examinees <br> Average <br> age |  | Average <br> $\gamma$-GT | 51 U/L and above | 101 U/L and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | 7,242 | 10.9 | 14.7 | $0.4 \%$ | $0.1 \%$ |  |
| $16-39$ | 8,480 | 28.6 | 25.6 | $8.8 \%$ | $2.5 \%$ |  |
| $40-64$ | 19,552 | 55.0 | 40.5 | $20.4 \%$ | $6.5 \%$ |  |
| $65-$ | 18,638 | 73.5 | 33.4 | $14.0 \%$ | $3.8 \%$ |  |


| $\gamma$-GT (U/L) (male) |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | ---: | ---: | :---: |
| Age | Examinees <br> Average <br> age |  | Average <br> $\gamma$-GT | 51 U/L and above | 101 U/L and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 3,710 | 10.9 | 16.0 | $0.7 \%$ | $0.2 \%$ |  |
| $16-39$ | 3,230 | 27.9 | 38.0 | $18.5 \%$ | $5.4 \%$ |  |
| $40-64$ | 7,717 | 55.4 | 60.7 | $36.9 \%$ | $12.8 \%$ |  |
| $65-$ | 8,476 | 73.4 | 44.1 | $23.1 \%$ | $6.7 \%$ |  |


| $\gamma$-GT (U/L) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average $\gamma \text {-GT }$ | 51 U/L and above | 101 U/L and above |
| 0-6 | - | - | - | - | - |
| 7-15 | 3,532 | 11.0 | 13.3 | 0.1\% | - |
| 16-39 | 5,250 | 29.1 | 17.9 | 2.8\% | 0.6\% |
| 40-64 | 11,835 | 54.6 | 27.3 | 9.7\% | 2.4\% |
| 65- | 10,162 | 73.6 | 24.4 | 6.5\% | 1.5\% |

## $\gamma$-GT

FY 2013

| $\gamma$-GT (U/L) (overall) |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | :--- | :--- | :---: |
| Age | Examinees <br> Average <br> age |  | Average <br> $\gamma$-GT | 51 U/L and above | 101 U/L and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | 6,291 | 10.9 | 14.4 | $0.4 \%$ | $0.0 \%$ |  |
| $16-39$ | 6,535 | 29.0 | 26.0 | $9.1 \%$ | $2.7 \%$ |  |
| $40-64$ | 16,919 | 55.3 | 39.3 | $19.5 \%$ | $6.2 \%$ |  |
| $65-$ | 18,956 | 73.5 | 33.7 | $13.9 \%$ | $3.9 \%$ |  |


| $\gamma$-GT (U/L) (male) |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | ---: | ---: | :---: |
| Age | Examinees <br> Average <br> age |  | Average <br> $\gamma$-GT | 51 U/L and above | 101 U/L and above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |  |
| $7-15$ | 3,219 | 10.9 | 15.7 | $0.8 \%$ | $0.1 \%$ |  |
| $16-39$ | 2,480 | 28.3 | 38.8 | $18.8 \%$ | $5.9 \%$ |  |
| $40-64$ | 6,509 | 55.7 | 58.9 | $35.1 \%$ | $12.3 \%$ |  |
| $65-$ | 8,637 | 73.4 | 44.4 | $22.6 \%$ | $6.8 \%$ |  |


| $\gamma$-GT (U/L) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average $\gamma \text {-GT }$ | $51 \mathrm{U} / \mathrm{L}$ and above | 101 U/L and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 3,072 | 10.9 | 13.0 | 0.1\% | 0.0\% |
| 16-39 | 4,055 | 29.5 | 18.2 | 3.1\% | 0.7\% |
| 40-64 | 10,410 | 55.0 | 27.1 | 9.7\% | 2.4\% |
| 65- | 10,319 | 73.5 | 24.7 | 6.6\% | 1.4\% |

FY 2014

| $\gamma$-GT (U/L) (overall) |  |  |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> $\gamma$-GT | 51 U/L and <br> above | 101 U/L and <br> above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 5,708 | 10.9 | 14.2 | $0.2 \%$ | $0.0 \%$ |  |
| $16-39$ | 5,842 | 29.0 | 25.4 | $8.7 \%$ | $2.4 \%$ |  |
| $40-64$ | 15,591 | 55.1 | 38.3 | $18.9 \%$ | $5.8 \%$ |  |
| $65-$ | 19,156 | 73.3 | 33.0 | $13.5 \%$ | $3.7 \%$ |  |


| $\gamma$-GT (U/L) (male) |  |  |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> $\gamma$-GT | $51 \mathrm{U} / \mathrm{L}$ and <br> above | 101 U/L and <br> above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 2,917 | 10.9 | 15.4 | $0.4 \%$ | $0.0 \%$ |  |
| $16-39$ | 2,168 | 28.0 | 38.5 | $18.5 \%$ | $5.7 \%$ |  |
| $40-64$ | 5,858 | 55.5 | 57.5 | $34.6 \%$ | $11.8 \%$ |  |
| $65-$ | 8,677 | 73.3 | 43.9 | $22.6 \%$ | $6.5 \%$ |  |


| $\gamma$-GT (U/L) (female) |  |  |  |  |  |  |
| :---: | :---: | ---: | :---: | ---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> $\gamma$-GT | 51 U/L and <br> above | 101 U/L and <br> above |  |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |  |
| $7-15$ | 2,791 | 10.9 | 13.0 | $0.0 \%$ | $0.0 \%$ |  |
| $16-39$ | 3,674 | 29.5 | 17.6 | $2.9 \%$ | $0.5 \%$ |  |
| $40-64$ | 9,733 | 54.9 | 26.7 | $9.4 \%$ | $2.2 \%$ |  |
| $65-$ | 10,479 | 73.3 | 23.9 | $6.0 \%$ | $1.3 \%$ |  |

## Uric acid

FY 2011

| Uric acid (mg/dL) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average <br> uric acid | $7.1 \mathrm{mg} / \mathrm{dL}$ and above | $8.0 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 11,091 | 11.0 | 4.5 | 2.5\% | 0.6\% |
| 16-39 | 14,757 | 28.1 | 5.0 | 7.9\% | 2.7\% |
| 40-64 | 23,651 | 54.0 | 5.0 | 8.0\% | 2.7\% |
| $65-$ | 16,725 | 73.7 | 5.1 | 7.6\% | 2.5\% |


| Uric acid (mg/dL) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average <br> uric acid | $7.1 \mathrm{mg} / \mathrm{dL}$ and above | $8.0 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | . | - | . |  |  |
| 7-15 | 5,584 | 10.9 | 4.8 | 4.7\% | 1.2\% |
| 16-39 | 5,966 | 27.7 | 6.0 | 18.5\% | 6.5\% |
| 40-64 | 9,562 | 54.5 | 5.9 | 18.1\% | 6.2\% |
| 65- | 7,496 | 73.4 | 5.7 | 14.4\% | 4.9\% |


| Uric acid (mg/dL) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average uric acid | $7.1 \mathrm{mg} / \mathrm{dL}$ and above | $8.0 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 |  | - | - | - |  |
| 7-15 | 5,507 | 11.0 | 4.3 | 0.3\% | 0.1\% |
| 16-39 | 8,791 | 28.3 | 4.2 | 0.7\% | 0.2\% |
| 40-64 | 14,089 | 53.7 | 4.3 | 1.1\% | 0.3\% |
| 65- | 9,229 | 73.8 | 4.5 | 2.1\% | 0.6\% |

FY 2012

| Uric acid (mg/dL) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average uric acid | $7.1 \mathrm{mg} / \mathrm{dL}$ and above | $8.0 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 7,232 | 10.9 | 4.7 | 3.4\% | 1.1\% |
| 16-39 | 8,480 | 28.6 | 5.0 | 8.2\% | 2.7\% |
| 40-64 | 19,552 | 55.0 | 5.1 | 9.1\% | 3.1\% |
| 65- | 18,637 | 73.5 | 5.1 | 8.7\% | 3.2\% |


| Uric acid (mg/dL) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average uric acid | $7.1 \mathrm{mg} / \mathrm{dL}$ and above | $8.0 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 3,704 | 10.9 | 5.0 | 6.1\% | 2.0\% |
| 16-39 | 3,230 | 27.9 | 6.1 | 20.3\% | 6.8\% |
| 40-64 | 7,717 | 55.4 | 6.0 | 20.9\% | 7.3\% |
| 65- | 8,475 | 73.4 | 5.8 | 16.0\% | 5.9\% |


| Uric acid (mg/dL) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average uric acid | $7.1 \mathrm{mg} / \mathrm{dL}$ and above | $8.0 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - | - |
| 7-15 | 3,528 | 11.0 | 4.4 | 0.6\% | 0.2\% |
| 16-39 | 5,250 | 29.1 | 4.3 | 0.7\% | 0.2\% |
| 40-64 | 11,835 | 54.6 | 4.4 | 1.5\% | 0.4\% |
| 65- | 10,162 | 73.6 | 4.6 | 2.6\% | 0.8\% |

## Uric acid

FY 2013

| Uric acid (mg/dL) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average uric acid | $7.1 \mathrm{mg} / \mathrm{dL}$ and above | $8.0 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 6,290 | 10.9 | 4.5 | 2.6\% | 0.7\% |
| 16-39 | 6,536 | 29.0 | 5.0 | 8.9\% | 3.2\% |
| 40-64 | 16,921 | 55.3 | 5.1 | 8.4\% | 2.7\% |
| 65- | 18,957 | 73.5 | 5.2 | 9.0\% | 2.9\% |


| Uric acid (mg/dL) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average uric acid | $7.1 \mathrm{mg} / \mathrm{dL}$ and above | $8.0 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - | - |
| 7-15 | 3,218 | 10.9 | 4.8 | 4.9\% | 1.5\% |
| 16-39 | 2,480 | 28.3 | 6.1 | 21.8\% | 8.0\% |
| 40-64 | 6,510 | 55.7 | 6.0 | 19.7\% | 6.4\% |
| 65- | 8,637 | 73.4 | 5.8 | 16.3\% | 5.2\% |


| Uric acid (mg/dL) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average uric acid | $7.1 \mathrm{mg} / \mathrm{dL}$ and above | $8.0 \mathrm{mg} / \mathrm{dL}$ and above |
| 0-6 | - | - | - | - |  |
| 7-15 | 3,072 | 10.9 | 4.2 | 0.2\% | - |
| 16-39 | 4,056 | 29.5 | 4.3 | 1.0\% | 0.3\% |
| 40-64 | 10,411 | 55.0 | 4.5 | 1.4\% | 0.4\% |
| 65- | 10,320 | 73.5 | 4.7 | 3.0\% | 0.9\% |

FY 2014

| Uric acid (mg/dL) (overall) |  |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> uric acid | $7.1 \mathrm{mg} / \mathrm{dL}$ and <br> above | $8.0 \mathrm{mg} / \mathrm{dL}$ and <br> above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | 5,707 | 10.9 | 4.5 | $2.7 \%$ | $0.6 \%$ |
| $16-39$ | 5,843 | 29.0 | 5.0 | $8.8 \%$ | $2.7 \%$ |
| $40-64$ | 15,591 | 55.1 | 5.1 | $8.6 \%$ | $2.8 \%$ |
| $65-$ | 19,156 | 73.3 | 5.2 | $8.9 \%$ | $2.9 \%$ |


| Uric acid (mg/dL) (male) |  |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> uric acid | $7.1 \mathrm{mg} / \mathrm{dL}$ and <br> above | $8.0 \mathrm{mg} / \mathrm{dL}$ and <br> above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | 2,916 | 10.9 | 4.8 | $5.0 \%$ | $1.0 \%$ |
| $16-39$ | 2,168 | 28.0 | 6.1 | $22.0 \%$ | $7.0 \%$ |
| $40-64$ | 5,858 | 55.5 | 6.0 | $20.3 \%$ | $6.7 \%$ |
| $65-$ | 8,677 | 73.3 | 5.8 | $16.1 \%$ | $5.4 \%$ |


| Uric acid (mg/dL) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> uric acid | $7.1 \mathrm{mg} / \mathrm{dL}$ and <br> above | $8.0 \mathrm{mg} / \mathrm{dL}$ and <br> above |
| $0-6$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ | $\cdot$ |
| $7-15$ | 2,791 | 10.9 | 4.2 | $0.4 \%$ | $0.1 \%$ |
| $16-39$ | 3,675 | 29.5 | 4.3 | $1.0 \%$ | $0.2 \%$ |
| $40-64$ | 9,733 | 54.9 | 4.5 | $1.6 \%$ | $0.4 \%$ |
| $65-$ | 10,479 | 73.3 | 4.7 | $3.0 \%$ | $0.7 \%$ |

## RBC

FY 2011

| $\mathrm{RBC}\left(10^{6} / \mathrm{LL}\right) \quad$ (overall) |  |  |  |
| ---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> RBC |
| $0-6$ | 6,428 | 3.6 | 4.70 |
| $7-15$ | 11,474 | 11.0 | 4.80 |
| $16-39$ | 14,757 | 28.1 | 4.84 |
| $40-64$ | 23,649 | 54.0 | 4.71 |
| $65-$ | 16,723 | 73.7 | 4.56 |


| $\mathrm{RBC}\left(10^{6} / \mu \mathrm{L}\right)$ |  |  |  |  |  |  |  | (male) |
| ---: | ---: | :--- | :--- | ---: | ---: | ---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average <br> RBC | $3.69 \times 10^{6} / \mu \mathrm{L}$ <br> and below | $3.99 \times 10^{6} / \mu \mathrm{L}$ <br> and below | $5.80 \times 10^{6} / \mu \mathrm{L}$ <br> and above |  |  |
| $0-6$ | 3,253 | 3.6 | 4.72 | $0.0 \%$ | $0.6 \%$ | $0.2 \%$ |  |  |
| $7-15$ | 5,764 | 10.9 | 4.91 | $0.0 \%$ | $0.3 \%$ | $1.1 \%$ |  |  |
| $16-39$ | 5,966 | 27.7 | 5.21 | $0.0 \%$ | $0.1 \%$ | $4.4 \%$ |  |  |
| $40-64$ | 9,562 | 54.5 | 4.96 | $0.4 \%$ | $1.3 \%$ | $1.6 \%$ |  |  |
| $65-$ | 7,495 | 73.4 | 4.74 | $1.5 \%$ | $5.3 \%$ | $1.1 \%$ |  |  |


| $\mathrm{RBC}\left(10^{6} / \mu \mathrm{L}\right)$ |  |  |  |  |  |  |  | (female) |
| ---: | ---: | ---: | :--- | :--- | ---: | ---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average <br> RBC | $3.39 \times 10^{6} / \mu \mathrm{L}$ <br> and below | $3.69 \times 10^{6} / \mu \mathrm{L}$ <br> and below | $5.50 \times 10^{6} / \mu \mathrm{L}$ <br> and above |  |  |
| $0-6$ | 3,175 | 3.6 | 4.68 | $0.1 \%$ | $0.1 \%$ | $0.8 \%$ |  |  |
| $7-15$ | 5,710 | 11.0 | 4.69 | $0.0 \%$ | $0.1 \%$ | $0.8 \%$ |  |  |
| $16-39$ | 8,791 | 28.3 | 4.58 | $0.0 \%$ | $0.7 \%$ | $0.5 \%$ |  |  |
| $40-64$ | 14,087 | 53.7 | 4.54 | $0.2 \%$ | $0.8 \%$ | $0.4 \%$ |  |  |
| $65-$ | 9.228 | 73.8 | 4.42 | $0.8 \%$ | $3.3 \%$ | $0.4 \%$ |  |  |

FY 2012

| $\mathrm{RBC}\left(10^{6} / \mu \mathrm{L}\right) \quad$ (overall) |  |  |  |  |
| ---: | ---: | ---: | :--- | :---: |
| Age | Examinees | Average age | Average <br> RBC |  |
| $0-6$ | 4,342 | 3.6 | 4.69 |  |
| $7-15$ | 7,435 | 10.9 | 4.80 |  |
| $16-39$ | 8,479 | 28.6 | 4.75 |  |
| $40-64$ | 19,552 | 55.0 | 4.61 |  |
| $65-$ | 18,636 | 73.5 | 4.45 |  |


| $\mathrm{RBC}\left(10^{6} / \mu \mathrm{L}\right)$ |  |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | :--- | ---: | ---: | :---: |
| Age | Examinees | Average <br> age |  | Average <br> RBC | $3.69 \times 10^{6} / \mu \mathrm{L}$ <br> and below | $3.99 \times 10^{6} / \mu \mathrm{L}$ <br> and below |  |
| $0-6$ | 2,166 | 3.6 | 4.72 | - | $0.9 \%$ | $5.80 \times 10^{6} / \mu \mathrm{L}$ <br> and above |  |
| $7-15$ | 3,809 | 10.8 | 4.90 | $0.0 \%$ | $0.3 \%$ | $0.4 \%$ |  |
| $16-39$ | 3,230 | 27.9 | 5.17 | - | $0.1 \%$ | $3.5 \%$ |  |
| $40-64$ | 7,717 | 55.4 | 4.88 | $0.7 \%$ | $2.0 \%$ | $1.6 \%$ |  |
| $65-$ | 8,476 | 73.4 | 4.63 | $2.9 \%$ | $8.5 \%$ | $0.9 \%$ |  |


| $\mathrm{RBC}\left(10^{6} / \mu \mathrm{L}\right)$ |  |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | :--- | ---: | ---: | :---: |
| Age | Examinees | Average <br> age |  | Average <br> RBC | $3.39 \times 10^{6} / \mu \mathrm{L}$ <br> and below | $3.69 \times 10^{6} / \mu \mathrm{L}$ <br> and below |  |
| $0-6$ | 2,176 | 3.6 | 4.67 | - | - | $5.50 \times 10^{6} / \mu \mathrm{L}$ <br> and above |  |
| $7-15$ | 3,626 | 10.9 | 4.70 | - | $0.1 \%$ | $0.9 \%$ |  |
| $16-39$ | 5,249 | 29.1 | 4.49 | $0.2 \%$ | $1.0 \%$ | $0.4 \%$ |  |
| $40-64$ | 11,835 | 54.6 | 4.44 | $0.3 \%$ | $1.5 \%$ | $0.4 \%$ |  |
| $65-$ | 10,160 | 73.6 | 4.30 | $1.5 \%$ | $6.7 \%$ | $0.2 \%$ |  |

## RBC

FY 2013

| $\mathrm{RBC}\left(10^{6} / \mu \mathrm{L}\right) \quad$ (overall) |  |  |  |
| ---: | ---: | ---: | :--- |
| Age | Examinees | Average age | Average <br> RBC |
| $0-6$ | 3,781 | 3.7 | 4.70 |
| $7-15$ | 6,421 | 10.8 | 4.81 |
| $16-39$ | 6,536 | 29.0 | 4.75 |
| $40-64$ | 16,920 | 55.3 | 4.62 |
| $65-$ | 18,955 | 73.5 | 4.46 |


| $\operatorname{RBC}\left(10^{6} / \mu \mathrm{L}\right) \quad$ (male) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average RBC | $3.69 \times 10^{6} / \mu \mathrm{L}$ <br> and below | $3.99 \times 10^{6} / \mu \mathrm{L}$ <br> and below | $5.80 \times 10^{6} / \mu \mathrm{L}$ <br> and above |
| 0-6 | 1,942 | 3.7 | 4.73 | 0.1\% | 0.5\% | 0.3\% |
| 7-15 | 3,287 | 10.9 | 4.91 | - | 0.1\% | 0.9\% |
| 16-39 | 2,480 | 28.3 | 5.16 | - | 0.2\% | 3.7\% |
| 40-64 | 6,510 | 55.7 | 4.89 | 0.7\% | 2.0\% | 1.8\% |
| 65- | 8,637 | 73.4 | 4.64 | 2.7\% | 8.5\% | 0.8\% |


| $\operatorname{RBC}\left(10^{6} / \mu \mathrm{L}\right) \quad$ (female) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average RBC | $3.39 \times 10^{6} / \mu \mathrm{L}$ <br> and below | $3.69 \times 10^{6} / \mu \mathrm{L}$ <br> and below | $5.50 \times 10^{6} / \mu \mathrm{L}$ <br> and above |
| 0-6 | 1,839 | 3.7 | 4.68 | 0.1\% | 0.1\% | 0.8\% |
| 7-15 | 3,134 | 10.8 | 4.70 | - | 0.1\% | 0.6\% |
| 16-39 | 4,056 | 29.5 | 4.50 | 0.3\% | 1.1\% | 0.6\% |
| 40-64 | 10,410 | 55.0 | 4.45 | 0.3\% | 1.7\% | 0.3\% |
| 65- | 10,318 | 73.5 | 4.31 | 1.6\% | 6.2\% | 0.3\% |

FY 2014

| RBC $\left(10^{6} / \mu \mathrm{L}\right)$ (overall) |  |  |  |
| :---: | :---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> RBC |
| $0-6$ | 3,295 | 3.8 | 4.67 |
| $7-15$ | 5,832 | 10.9 | 4.80 |
| $16-39$ | 5,843 | 29.0 | 4.77 |
| $40-64$ | 15,591 | 55.1 | 4.63 |
| $65-$ | 19,152 | 73.3 | 4.46 |


|  |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: |
| RBC $\left(10^{6} / \mu \mathrm{L}\right)(\mathrm{male})$ |  |  |  |  |  |  |
| Age | Examinees | Average age | Average <br> RBC | $3.69 \times 10^{6} / \mu \mathrm{L}$ <br> and below | $3.99 \times 10^{6} / \mu \mathrm{L}$ <br> and below | $5.80 \times 10^{6} / \mu \mathrm{L}$ <br> and above |
| $0-6$ | 1,677 | 3.8 | 4.70 | - | $1.0 \%$ | $0.1 \%$ |
| $7-15$ | 2,984 | 10.9 | 4.90 | - | $0.3 \%$ | $0.8 \%$ |
| $16-39$ | 2,168 | 28.0 | 5.19 | $0.1 \%$ | $0.2 \%$ | $5.0 \%$ |
| $40-64$ | 5,858 | 55.5 | 4.91 | $0.6 \%$ | $1.9 \%$ | $2.1 \%$ |
| $65-$ | 8,676 | 73.3 | 4.63 | $2.9 \%$ | $9.1 \%$ | $0.9 \%$ |


| $\mathrm{RBC}\left(10^{6} / \mu \mathrm{L}\right)$ (female) |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> RBC | $3.39 \times 10^{6} / \mu \mathrm{L}$ <br> and below | $3.69 \times 10^{6} / \mu \mathrm{L}$ <br> and below | $5.50 \times 10^{6} / \mu \mathrm{L}$ <br> and above |
| $0-6$ | 1,618 | 3.8 | 4.65 | $0.1 \%$ | $0.2 \%$ | $0.8 \%$ |
| $7-15$ | 2,848 | 10.8 | 4.69 | - | $0.1 \%$ | $0.7 \%$ |
| $16-39$ | 3,675 | 29.5 | 4.52 | $0.2 \%$ | $1.3 \%$ | $0.4 \%$ |
| $40-64$ | 9,733 | 54.9 | 4.47 | $0.2 \%$ | $1.4 \%$ | $0.5 \%$ |
| $65-$ | 10,476 | 73.3 | 4.31 | $1.4 \%$ | $5.8 \%$ | $0.2 \%$ |

## Hemoglobin

FY 2011

| Hemoglobin (g/dL) (overall) |  |  |  |
| ---: | ---: | ---: | :--- |
| Age | Examinees | Average age | Average <br> hemoglobin |
| $0-6$ | 6,428 | 3.6 | 12.6 |
| $7-15$ | 11,475 | 11.0 | 13.6 |
| $16-39$ | 14,757 | 28.1 | 14.3 |
| $40-64$ | 23,649 | 54.0 | 14.3 |
| $65-$ | 16,723 | 73.7 | 14.1 |


| Hemoglobin (g/dL ) (male) |  |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | :--- | :--- | :--- | :--- |
| Age | Examinees |  | Average <br> age |  | Average <br> hemoglobin | 12.0 <br> and below | 13.0 <br> and below |
| $0-6$ | 3,253 | 3.6 | 12.5 | $24.5 \%$ | $74.2 \%$ | 18.0 <br> and above |  |
| $7-15$ | 5,765 | 10.9 | 13.8 | $3.8 \%$ | $24.8 \%$ | $0.0 \%$ |  |
| $16-39$ | 5,966 | 27.7 | 15.9 | $0.3 \%$ | $0.6 \%$ | $1.7 \%$ |  |
| $40-64$ | 9,562 | 54.5 | 15.5 | $0.8 \%$ | $2.4 \%$ | $1.5 \%$ |  |
| $65-$ | 7,495 | 73.4 | 14.9 | $3.1 \%$ | $8.8 \%$ | $1.4 \%$ |  |


| Hemoglobin (g/dL) (female) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average hemoglobin | $11.0 \mathrm{~g} / \mathrm{dL}$ and below | $12.0 \mathrm{~g} / \mathrm{dL}$ and below | $16.0 \mathrm{~g} / \mathrm{dL}$ and above |
| 0-6 | 3,175 | 3.6 | 12.6 | 3.1\% | 23.8\% | - |
| 7-15 | 5,710 | 11.0 | 13.3 | 1.6\% | 7.6\% | 0.1\% |
| 16-39 | 8,791 | 28.3 | 13.3 | 5.7\% | 13.2\% | 0.4\% |
| 40-64 | 14,087 | 53.7 | 13.4 | 5.6\% | 11.4\% | 1.0\% |
| 65- | 9,228 | 73.8 | 13.5 | 2.7\% | 10.5\% | 1.0\% |


| Hemoglobin (g/dL) (overall) |  |  |  |
| ---: | ---: | ---: | :--- |
| Age | Examinees | Average age | Average <br> hemoglobin |
| $0-6$ | 4,342 | 3.6 | 12.6 |
| $7-15$ | 7,435 | 10.9 | 13.6 |
| $16-39$ | 8,479 | 28.6 | 14.1 |
| $40-64$ | 19,552 | 55.0 | 14.0 |
| $65-$ | 18,636 | 73.5 | 13.8 |


| Hemoglobin (g/dL) (male) |  |  |  |  |  |  |  |
| ---: | ---: | ---: | :--- | ---: | ---: | ---: | ---: |
| Age | Examinees |  | Average <br> age |  | Average <br> hemoglobin | 12.0 <br> and below | 13.0 <br> and below |
| $0-6$ | 2,166 | 3.6 | 12.6 | $25.3 \%$ | $71.4 \%$ | 18.0 <br> and above |  |
| $7-15$ | 3,809 | 10.8 | 13.8 | $3.2 \%$ | $21.9 \%$ | - |  |
| $16-39$ | 3,230 | 27.9 | 15.7 | $0.2 \%$ | $0.5 \%$ | $1.0 \%$ |  |
| $40-64$ | 7,717 | 55.4 | 15.2 | $0.9 \%$ | $3.5 \%$ | $1.2 \%$ |  |
| $65-$ | 8,476 | 73.4 | 14.6 | $4.0 \%$ | $12.8 \%$ | $0.8 \%$ |  |


| Hemoglobin (g/dL) (female) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average hemoglobin | $11.0 \mathrm{~g} / \mathrm{dL}$ and below | $12.0 \mathrm{~g} / \mathrm{dL}$ and below | $16.0 \mathrm{~g} / \mathrm{dL}$ and above |
| 0-6 | 2,176 | 3.6 | 12.6 | 3.2\% | 23.1\% | 0.0\% |
| 7-15 | 3,626 | 10.9 | 13.4 | 1.0\% | 6.2\% | 0.2\% |
| 16-39 | 5,249 | 29.1 | 13.1 | 6.0\% | 15.3\% | 0.4\% |
| 40-64 | 11,835 | 54.6 | 13.2 | 5.0\% | 12.5\% | 0.7\% |
| 65- | 10,160 | 73.6 | 13.1 | 3.7\% | 15.4\% | 0.4\% |

## Hemoglobin

FY 2013

| Hemoglobin (g/dL) (overall) |  |  |  |
| ---: | ---: | :--- | :--- |
| Age | Examinees | Average age | Average <br> hemoglobin |
| $0-6$ | 3,781 | 3.7 | 12.6 |
| $7-15$ | 6,421 | 10.8 | 13.6 |
| $16-39$ | 6,536 | 29.0 | 14.1 |
| $40-64$ | 16,920 | 55.3 | 14.1 |
| $65-$ | 18,955 | 73.5 | 13.9 |


| Hemoglobin (g/dL) (male) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average hemoglobin | $12.0 \mathrm{~g} / \mathrm{dL}$ and below | $13.0 \mathrm{~g} / \mathrm{dL}$ and below | $18.0 \mathrm{~g} / \mathrm{dL}$ and above |
| 0-6 | 1,942 | 3.7 | 12.6 | 25.0\% | 71.7\% | - |
| 7-15 | 3,287 | 10.9 | 13.8 | 2.5\% | 23.4\% | 0.0\% |
| 16-39 | 2,480 | 28.3 | 15.7 | 0.2\% | 0.6\% | 0.9\% |
| 40-64 | 6,510 | 55.7 | 15.3 | 1.0\% | 2.8\% | 1.4\% |
| 65- | 8,637 | 73.4 | 14.7 | 3.7\% | 11.3\% | 1.1\% |


| Hemoglobin (g/dL) (female) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> hemoglobin | $11.0 \mathrm{~g} / \mathrm{dL}$ and below | $12.0 \mathrm{~g} / \mathrm{dL}$ and below | $16.0 \mathrm{~g} / \mathrm{dL}$ and above |
| 0-6 | 1,839 | 3.7 | 12.6 | 3.8\% | 22.0\% | - |
| 7-15 | 3,134 | 10.8 | 13.4 | 1.1\% | 5.9\% | 0.1\% |
| 16-39 | 4,056 | 29.5 | 13.2 | 4.9\% | 13.6\% | 0.4\% |
| 40-64 | 10,410 | 55.0 | 13.3 | 4.2\% | 11.0\% | 0.8\% |
| 65- | 10,318 | 73.5 | 13.3 | 3.1\% | 13.4\% | 0.6\% |

FY 2014

| Hemoglobin (g/dL) (overall) |  |  |  |
| :---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> hemoglobin |
| $0-6$ | 3,295 | 3.8 | 12.5 |
| $7-15$ | 5,832 | 10.9 | 13.5 |
| $16-39$ | 5,843 | 29.0 | 14.1 |
| $40-64$ | 15,591 | 55.1 | 14.2 |
| $65-$ | 19,152 | 73.3 | 14.0 |


| Hemoglobin (g/dL) (male) |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> hemoglobin | $12.0 \mathrm{~g} / \mathrm{dL}$ and <br> below | $13.0 \mathrm{~g} / \mathrm{dL}$ and <br> below | $18.0 \mathrm{~g} / \mathrm{dL}$ and <br> above |
| $0-6$ | 1,677 | 3.8 | 12.5 | $27.9 \%$ | $76.1 \%$ | - |
| $7-15$ | 2,984 | 10.9 | 13.8 | $3.9 \%$ | $24.7 \%$ | $0.1 \%$ |
| $16-39$ | 2,168 | 28.0 | 15.7 | $0.1 \%$ | $0.9 \%$ | $1.5 \%$ |
| $40-64$ | 5,858 | 55.5 | 15.4 | $0.8 \%$ | $2.6 \%$ | $1.6 \%$ |
| $65-$ | 8,676 | 73.3 | 14.8 | $3.8 \%$ | $10.7 \%$ | $1.0 \%$ |


| Hemoglobin (g/dL ) (female) |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> hemoglobin | $11.0 \mathrm{~g} / \mathrm{dL}$ and <br> below | $12.0 \mathrm{~g} / \mathrm{dL}$ and <br> below | $16.0 \mathrm{~g} / \mathrm{dL}$ and <br> above |
| $0-6$ | 1,618 | 3.8 | 12.5 | $3.3 \%$ | $26.6 \%$ | - |
| $7-15$ | 2,848 | 10.8 | 13.3 | $0.9 \%$ | $6.1 \%$ | $0.2 \%$ |
| $16-39$ | 3,675 | 29.5 | 13.2 | $5.1 \%$ | $14.6 \%$ | $0.4 \%$ |
| $40-64$ | 9,733 | 54.9 | 13.4 | $4.2 \%$ | $9.9 \%$ | $1.0 \%$ |
| $65-$ | 10,476 | 73.3 | 13.3 | $2.7 \%$ | $11.8 \%$ | $0.7 \%$ |

## Hematocrit

FY 2011

| Hematocrit (\%) (overall) |  |  |  |
| ---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> hematocrit |
| $0-6$ | 6,428 | 3.6 | 37.3 |
| $7-15$ | 11,475 | 11.0 | 40.3 |
| $16-39$ | 14,757 | 28.1 | 42.9 |
| $40-64$ | 23,649 | 54.0 | 42.8 |
| $65-$ | 16,723 | 73.7 | 42.4 |


| Hematocrit (\%) |  | (male) |  |  |  |  |  |  |
| ---: | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Age | Examinees | Average <br> age | Average <br> hematocrit | $35.9 \%$ <br> below | and | $37.9 \%$ <br> below | and | $55.0 \%$ <br> above |
| $0-6$ | 3,253 | 3.6 | 37.2 | $28.4 \%$ | $64.4 \%$ |  |  |  |
| $7-15$ | 5,765 | 10.9 | 40.9 | $5.2 \%$ | $19.0 \%$ | - |  |  |
| $16-39$ | 5,966 | 27.7 | 46.7 | $0.2 \%$ | $0.3 \%$ | $0.1 \%$ |  |  |
| $40-64$ | 9,562 | 54.5 | 45.8 | $0.6 \%$ | $1.3 \%$ | $0.2 \%$ |  |  |
| $65-$ | 7,495 | 73.4 | 44.3 | $2.2 \%$ | $4.8 \%$ | $0.3 \%$ |  |  |


| Hematocrit (\%) |  | (female) |  |  |  |  |  |  |
| ---: | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Age | Examinees | Average <br> age | Average <br> hematocrit | $28.9 \%$ <br> below | and | $32.9 \%$ <br> below | and | $48.0 \%$ <br> above |
| $0-6$ | 3,175 | 3.6 | 37.4 | $0.2 \%$ | $2.1 \%$ | - |  |  |
| $7-15$ | 5,710 | 11.0 | 39.8 | $0.2 \%$ | $0.9 \%$ | $0.1 \%$ |  |  |
| $16-39$ | 8,791 | 28.3 | 40.3 | $0.4 \%$ | $2.3 \%$ | $0.2 \%$ |  |  |
| $40-64$ | 14,087 | 53.7 | 40.7 | $0.6 \%$ | $2.9 \%$ | $0.6 \%$ |  |  |
| $65-$ | 9,228 | 73.8 | 40.8 | $0.2 \%$ | $1.2 \%$ | $0.9 \%$ |  |  |

FY 2012

| Hematocrit (\%) (overall) |  |  |  |
| ---: | ---: | ---: | :--- |
| Age | Examinees | Average age | Average <br> hematocrit |
| $0-6$ | 4,342 | 3.6 | 37.7 |
| $7-15$ | 7,435 | 10.9 | 40.8 |
| $16-39$ | 8,480 | 28.6 | 42.7 |
| $40-64$ | 19,552 | 55.0 | 42.7 |
| $65-$ | 18,636 | 73.5 | 42.2 |


| Hematocrit (\%) (male) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> hematocrit | $35.9 \%$ and below | $37.9 \%$ and below | $55.0 \%$ and above |
| 0-6 | 2,166 | 3.6 | 37.6 | 24.1\% | 56.6\% | - |
| 7-15 | 3,809 | 10.8 | 41.3 | 2.8\% | 12.9\% | - |
| 16-39 | 3,230 | 27.9 | 46.8 | 0.1\% | 0.2\% | 0.2\% |
| 40-64 | 7,717 | 55.4 | 45.8 | 0.6\% | 1.3\% | 0.4\% |
| 65- | 8,476 | 73.4 | 44.2 | 2.6\% | 6.1\% | 0.4\% |


| Hematocrit (\%) |  | (female) |  |  |  |  |  |
| ---: | ---: | :--- | :--- | :--- | :--- | :--- | :--- |
| Age | Examinees | Average <br> age |  | Average <br> hematocrit | $28.9 \%$ <br> below | and | $32.9 \%$ <br> below |
| $0-6$ | 2,176 | 3.6 | 37.9 | $0.1 \%$ | and | $48.0 \%$ <br> above | and |
| $7-15$ | 3,626 | 10.9 | 40.4 | $0.0 \%$ | $0.4 \%$ | $0.0 \%$ |  |
| $16-39$ | 5,250 | 29.1 | 40.2 | $0.3 \%$ | $2.2 \%$ | $0.2 \%$ |  |
| $40-64$ | 11,835 | 54.6 | 40.7 | $0.4 \%$ | $2.2 \%$ | $1.0 \%$ |  |
| $65-$ | 10,160 | 73.6 | 40.5 | $0.3 \%$ | $1.7 \%$ | $0.9 \%$ |  |

## Hematocrit

FY 2013

| Hematocrit (\%) (overall) |  |  |  |
| ---: | ---: | ---: | :--- |
| Age | Examinees | Average age | Average <br> hematocrit |
| $0-6$ | 3,781 | 3.7 | 37.3 |
| $7-15$ | 6,421 | 10.8 | 40.3 |
| $16-39$ | 6,536 | 29.0 | 42.4 |
| $40-64$ | 16,920 | 55.3 | 42.3 |
| $65-$ | 18,955 | 73.5 | 41.8 |


| Hematocrit (\%) (male) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average hematocrit | $35.9 \%$ and below | $37.9 \%$ and below | $55.0 \%$ and above |
| 0-6 | 1,942 | 3.7 | 37.2 | 29.0\% | 62.5\% | - |
| 7-15 | 3,287 | 10.9 | 40.8 | 4.5\% | 18.2\% | - |
| 16-39 | 2,480 | 28.3 | 46.3 | 0.2\% | 0.4\% | 0.1\% |
| 40-64 | 6,510 | 55.7 | 45.4 | 0.7\% | 1.6\% | 0.3\% |
| 65- | 8,637 | 73.4 | 43.7 | 3.2\% | 7.1\% | 0.3\% |


| Hematocrit (\%) (female) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> hematocrit | $28.9 \%$ and below | $32.9 \%$ and below | $48.0 \%$ and above |
| 0-6 | 1,839 | 3.7 | 37.5 | 0.1\% | 2.9\% | - |
| 7-15 | 3,134 | 10.8 | 39.8 | 0.1\% | 0.7\% | 0.1\% |
| 16-39 | 4,056 | 29.5 | 40.0 | 0.4\% | 2.3\% | 0.3\% |
| 40-64 | 10,410 | 55.0 | 40.4 | 0.5\% | 2.3\% | 0.7\% |
| 65- | 10,318 | 73.5 | 40.2 | 0.2\% | 2.0\% | 0.8\% |

FY 2014

| Hematocrit (\%) (overall) |  |  |  |
| :---: | :---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> hematocrit |
| $0-6$ | 3,295 | 3.8 | 37.2 |
| $7-15$ | 5,832 | 10.9 | 40.3 |
| $16-39$ | 5,843 | 29.0 | 42.6 |
| $40-64$ | 15,591 | 55.1 | 42.6 |
| $65-$ | 19,152 | 73.3 | 42.0 |


| Hematocrit (\%) (male) |  |  |  |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: | ---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> hematocrit | $35.9 \%$ and <br> below | $37.9 \%$ and <br> below | $55.0 \%$ and <br> above |  |
| $0-6$ | 1,677 | 3.8 | 37.0 | $32.4 \%$ | $66.0 \%$ | - |  |
| $7-15$ | 2,984 | 10.9 | 40.8 | $4.5 \%$ | $17.9 \%$ | - |  |
| $16-39$ | 2,168 | 28.0 | 46.6 | $0.1 \%$ | $0.4 \%$ | $0.2 \%$ |  |
| $40-64$ | 5,858 | 55.5 | 45.6 | $0.6 \%$ | $1.3 \%$ | $0.3 \%$ |  |
| $65-$ | 8,676 | 73.3 | 43.9 | $3.1 \%$ | $6.8 \%$ | $0.3 \%$ |  |


| Hematocrit (\%) (female) |  |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> hematocrit | $28.9 \%$ and <br> below | $32.9 \%$ and <br> below | $48.0 \%$ and <br> above |  |
| $0-6$ | 1,618 | 3.8 | 37.4 | $0.1 \%$ | $2.6 \%$ | - |  |
| $7-15$ | 2,848 | 10.8 | 39.8 | $0.1 \%$ | $0.6 \%$ | $0.0 \%$ |  |
| $16-39$ | 3,675 | 29.5 | 40.2 | $0.4 \%$ | $2.7 \%$ | $0.4 \%$ |  |
| $40-64$ | 9,733 | 54.9 | 40.7 | $0.5 \%$ | $1.9 \%$ | $0.8 \%$ |  |
| $65-$ | 10,476 | 73.3 | 40.4 | $0.2 \%$ | $1.6 \%$ | $0.7 \%$ |  |

## Platelet count

FY 2011

| Age  Examinees Average <br> age Average <br> platelet <br> count $\left.89 \times 10^{3} / \mu \mathrm{L}\right)$ <br> and below <br> $0-6$ 6,423 3.6 321.9 $0.2 \%$ $129 \times 10^{3} / \mu \mathrm{L}$ <br> and below <br> $7-15$ 11,471 11.0 275.4 $0.0 \%$ $0.5 \%$ <br> and above      |  | $450 \times 10^{3} / \mu \mathrm{L}$ <br> and above |  |  |  |  |  |
| ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| $16-39$ | 14,703 | 28.1 | 263.9 | $0.0 \%$ | $0.2 \%$ | $6.4 \%$ | $6.1 \%$ |
| $40-64$ | 23,479 | 54.0 | 254.2 | $0.2 \%$ | $0.8 \%$ | $3.5 \%$ | $0.9 \%$ |
| $65-$ | 16,535 | 73.7 | 230.9 | $0.3 \%$ | $1.9 \%$ | $1.7 \%$ | $0.6 \%$ |


| Platelet count ( $10^{3} / \mu \mathrm{L}$ ) (male) |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average <br> platelet <br> count | $89 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $129 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $370 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $450 \times 10^{3 /} / \mathrm{L}$ and above |
| 0-6 | 3,251 | 3.6 | 321.2 | 0.3\% | 0.5\% | 22.3\% | 6.4\% |
| 7-15 | 5,763 | 10.9 | 277.4 | - | 0.1\% | 7.2\% | 1.0\% |
| 16-39 | 5,951 | 27.7 | 252.7 | 0.0\% | 0.2\% | 2.4\% | 0.2\% |
| 40-64 | 9,495 | 54.5 | 242.4 | 0.3\% | 1.2\% | 2.1\% | 0.3\% |
| 65- | 7,412 | 73.4 | 220.7 | 0.2\% | 2.7\% | 1.4\% | 0.4\% |


| Platelet count $\left(10^{3} / \mu \mathrm{L}\right)$ |  |  |  |  |  |  |  |  | (female) |  |
| ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average <br> platelet <br> count | $89 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $129 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $370 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $450 \times 10^{3} / \mu \mathrm{L}$ <br> and above |  |  |  |
| $0-6$ | 3,172 | 3.6 | 322.5 | $0.2 \%$ | $0.4 \%$ | $22.7 \%$ | $5.7 \%$ |  |  |  |
| $7-15$ | 5,708 | 11.0 | 273.5 | $0.1 \%$ | $0.3 \%$ | $5.6 \%$ | $0.8 \%$ |  |  |  |
| $16-39$ | 8,752 | 28.3 | 271.6 | $0.0 \%$ | $0.2 \%$ | $5.9 \%$ | $1.0 \%$ |  |  |  |
| $40-64$ | 13,984 | 53.7 | 262.2 | $0.2 \%$ | $0.6 \%$ | $4.9 \%$ | $0.9 \%$ |  |  |  |
| $65-$ | 9,123 | 73.8 | 239.2 | $0.3 \%$ | $1.2 \%$ | $2.0 \%$ | $0.3 \%$ |  |  |  |

FY 2012

| Platelet count (10 ${ }^{3} / \mu \mathrm{L}$ ) (overall) |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average platelet count | $89 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $129 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $370 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $450 \times 10^{3} / \mu \mathrm{L}$ <br> and above |
| 0-6 | 4,336 | 3.6 | 323.3 | 0.2\% | 0.4\% | 23.4\% | 6.3\% |
| 7-15 | 7,431 | 10.9 | 275.0 | 0.0\% | 0.2\% | 5.9\% | 0.6\% |
| 16-39 | 8,467 | 28.6 | 257.0 | 0.1\% | 0.3\% | 3.2\% | 0.5\% |
| 40-64 | 19,485 | 55.0 | 244.9 | 0.3\% | 1.0\% | 2.7\% | 0.4\% |
| 65- | 18,563 | 73.5 | 221.6 | 0.4\% | 2.7\% | 1.2\% | 0.3\% |


| Platelet count $\left(10^{3} / \mu \mathrm{L}\right)$ |  |  |  |  |  |  |  |  |
| :--- | ---: | ---: | :--- | ---: | ---: | ---: | ---: | :--- |
| Age | Examinees | Average <br> age | Average <br> platelet <br> count | $89 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $129 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $370 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $450 \times 10^{3} / \mu \mathrm{L}$ <br> and above |  |
| $0-6$ | 2,164 | 3.6 | 321.1 | $0.0 \%$ | $0.3 \%$ | $22.8 \%$ | $6.0 \%$ |  |
| $7-15$ | 3,807 | 10.8 | 276.3 | - | $0.3 \%$ | $6.1 \%$ | $0.6 \%$ |  |
| $16-39$ | 3,225 | 27.8 | 249.4 | - | $0.3 \%$ | $1.6 \%$ | $0.1 \%$ |  |
| $40-64$ | 7,691 | 55.4 | 237.3 | $0.4 \%$ | $1.4 \%$ | $2.0 \%$ | $0.3 \%$ |  |
| $65-$ | 8,439 | 73.4 | 213.8 | $0.4 \%$ | $3.5 \%$ | $0.9 \%$ | $0.3 \%$ |  |


| Platelet count ( $10^{3} / \mu \mathrm{L}$ ) (female) |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> platelet <br> count | $89 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $129 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $370 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $450 \times 10^{3} / \mu \mathrm{L}$ <br> and above |
| 0-6 | 2,172 | 3.6 | 325.4 | 0.3\% | 0.6\% | 24.0\% | 6.7\% |
| 7-15 | 3,624 | 10.9 | 273.6 | 0.0\% | 0.1\% | 5.7\% | 0.5\% |
| 16-39 | 5,242 | 29.1 | 261.7 | 0.1\% | 0.4\% | 4.2\% | 0.7\% |
| 40-64 | 11,794 | 54.6 | 249.9 | 0.2\% | 0.8\% | 3.1\% | 0.4\% |
| 65- | 10,124 | 73.6 | 228.2 | 0.4\% | 2.1\% | 1.5\% | 0.3\% |

## Platelet count

FY 2013

|  |  | Platelet count $\left(10^{3} / \mu \mathrm{L}\right)$ |  | (overall) |  |  |  |
| ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Age | Examinees | Average <br> age | Average <br> platelet <br> count | $89 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $129 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $370 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $450 \times 10^{3} / \mu \mathrm{L}$ <br> and above |
| $0-6$ | 3,778 | 3.7 | 324.7 | $0.0 \%$ | $0.3 \%$ | $23.9 \%$ | $6.2 \%$ |
| $7-15$ | 6,420 | 10.8 | 279.5 | $0.0 \%$ | $0.1 \%$ | $6.3 \%$ | $0.8 \%$ |
| $16-39$ | 6,528 | 29.0 | 262.6 | $0.1 \%$ | $0.4 \%$ | $4.1 \%$ | $0.5 \%$ |
| $40-64$ | 16,872 | 55.3 | 249.7 | $0.2 \%$ | $0.9 \%$ | $3.3 \%$ | $0.6 \%$ |
| $65-$ | 18,878 | 73.5 | 225.1 | $0.4 \%$ | $2.2 \%$ | $1.3 \%$ | $0.3 \%$ |


| Platelet count ( $10^{3} / \mu \mathrm{L}$ ) (male) |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> platelet <br> count | $89 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $129 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $370 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $450 \times 10^{3} / \mu \mathrm{L}$ <br> and above |
| 0-6 | 1,941 | 3.7 | 324.4 | - | 0.4\% | 24.3\% | 6.6\% |
| 7-15 | 3,287 | 10.9 | 280.5 | - | 0.1\% | 7.0\% | 0.9\% |
| 16-39 | 2,479 | 28.3 | 254.5 | 0.0\% | 0.4\% | 2.7\% | 0.2\% |
| 40-64 | 6,494 | 55.7 | 242.8 | 0.3\% | 1.2\% | 2.5\% | 0.3\% |
| 65- | 8,603 | 73.4 | 217.5 | 0.4\% | 3.0\% | 1.1\% | 0.3\% |


| Platelet count ( $10^{3} / \mu \mathrm{L}$ ) (female) |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> platelet <br> count | $89 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $129 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $370 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $450 \times 10^{3} / \mu \mathrm{L}$ <br> and above |
| 0-6 | 1,837 | 3.7 | 325.0 | 0.1\% | 0.3\% | 23.6\% | 5.8\% |
| 7-15 | 3,133 | 10.8 | 278.5 | 0.0\% | 0.1\% | 5.6\% | 0.8\% |
| 16-39 | 4,049 | 29.5 | 267.6 | 0.2\% | 0.4\% | 4.9\% | 0.7\% |
| 40-64 | 10,378 | 55.0 | 253.9 | 0.2\% | 0.7\% | 3.8\% | 0.7\% |
| 65- | 10,275 | 73.5 | 231.4 | 0.3\% | 1.5\% | 1.4\% | 0.3\% |

FY 2014

| Platelet count $\left(10^{3} / \mu \mathrm{L}\right.$ ) (overall) |  |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> platelet count | $89 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $129 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $370 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $450 \times 10^{3} / \mu \mathrm{L}$ <br> and above |
| $0-6$ | 3,293 | 3.8 | 332.1 | $0.1 \%$ | $0.3 \%$ | $26.8 \%$ | $7.3 \%$ |
| $7-15$ | 5,832 | 10.9 | 280.7 | $0.1 \%$ | $0.2 \%$ | $6.7 \%$ | $0.8 \%$ |
| $16-39$ | 5,838 | 29.0 | 263.7 | $0.1 \%$ | $0.3 \%$ | $4.8 \%$ | $0.5 \%$ |
| $40-64$ | 15,563 | 55.1 | 252.9 | $0.2 \%$ | $0.8 \%$ | $3.8 \%$ | $0.6 \%$ |
| $65-$ | 19,091 | 73.3 | 228.0 | $0.3 \%$ | $2.2 \%$ | $1.4 \%$ | $0.3 \%$ |


| Platelet count $\left(10^{3} / \mu \mathrm{L}\right)($ male $)$ |  |  |  |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> platelet count | $89 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $129 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $370 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $450 \times 10^{3} / \mu \mathrm{L}$ <br> and above |
| $0-6$ | 1,676 | 3.8 | 330.9 | $0.1 \%$ | $0.3 \%$ | $27.1 \%$ | $7.0 \%$ |
| $7-15$ | 2,984 | 10.9 | 282.1 | $0.1 \%$ | $0.3 \%$ | $7.6 \%$ | $0.9 \%$ |
| $16-39$ | 2,166 | 28.0 | 255.3 | $0.1 \%$ | $0.4 \%$ | $2.4 \%$ | $0.3 \%$ |
| $40-64$ | 5,850 | 55.5 | 246.1 | $0.2 \%$ | $1.0 \%$ | $2.8 \%$ | $0.4 \%$ |
| $65-$ | 8,644 | 73.3 | 220.7 | $0.4 \%$ | $2.9 \%$ | $1.3 \%$ | $0.3 \%$ |


| Platelet count $\left(10^{3} / \mu \mathrm{L}\right)$ (female) |  |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> platelet count | $89 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $129 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $370 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $450 \times 10^{3} / \mu \mathrm{L}$ <br> and above |
| $0-6$ | 1,617 | 3.8 | 333.3 | $0.1 \%$ | $0.3 \%$ | $26.4 \%$ | $7.7 \%$ |
| $7-15$ | 2,848 | 10.8 | 279.4 | $0.1 \%$ | $0.2 \%$ | $5.9 \%$ | $0.6 \%$ |
| $16-39$ | 3,672 | 29.5 | 268.6 | $0.1 \%$ | $0.2 \%$ | $6.2 \%$ | $0.7 \%$ |
| $40-64$ | 9,713 | 54.9 | 257.0 | $0.2 \%$ | $0.6 \%$ | $4.4 \%$ | $0.8 \%$ |
| $65-$ | 10,447 | 73.3 | 234.0 | $0.3 \%$ | $1.6 \%$ | $1.5 \%$ | $0.3 \%$ |

## WBC

FY 2011

| WBC $\left(10^{3} / \mu \mathrm{L}\right)$ |  |  |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | :--- | :--- | ---: | ---: | ---: |
| Age (overall) |  |  |  |  |  |  |  |  |
| $0-6$ | 6,429 | 3.6 | 8.5 | $0.1 \%$ | $0.6 \%$ | $28.1 \%$ | $13.0 \%$ |  |
| $7-15$ | 11,475 | 11.0 | 6.5 | $0.2 \%$ | $3.7 \%$ | $5.8 \%$ | $2.0 \%$ |  |
| $16-39$ | 14,757 | 28.1 | 6.1 | $0.6 \%$ | $6.4 \%$ | $4.1 \%$ | $1.4 \%$ |  |
| $40-64$ | 23,649 | 54.0 | 5.9 | $0.8 \%$ | $8.2 \%$ | $3.0 \%$ | $1.0 \%$ |  |
| $65-$ | 16,723 | 73.7 | 5.9 | $0.6 \%$ | $6.8 \%$ | $2.3 \%$ | $0.7 \%$ |  |


| WBC |  |  |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | :--- | ---: | ---: | ---: | ---: |
| Age |  | Examinees | Average <br> age | Average <br> WBC | 2.9x10 <br> (male <br> and below | $3.9 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $9.6 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $11.1 \times 10^{3} / \mu \mathrm{L}$ <br> and above |
| $0-6$ | 3,253 | 3.6 | 8.5 | $0.1 \%$ | $0.7 \%$ | $28.3 \%$ | $12.9 \%$ |  |
| $7-15$ | 5,765 | 10.9 | 6.5 | $0.2 \%$ | $3.4 \%$ | $6.0 \%$ | $2.1 \%$ |  |
| $16-39$ | 5,966 | 27.7 | 6.3 | $0.3 \%$ | $4.6 \%$ | $4.6 \%$ | $1.6 \%$ |  |
| $40-64$ | 9,562 | 54.5 | 6.4 | $0.3 \%$ | $4.0 \%$ | $5.1 \%$ | $1.8 \%$ |  |
| $65-$ | 7,495 | 73.4 | 6.2 | $0.3 \%$ | $4.8 \%$ | $3.1 \%$ | $1.1 \%$ |  |


| WBC |  |  |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | :--- | ---: | ---: | ---: | ---: |
| Age |  | Examinees | Average <br> age | Average <br> WBC | 2.9x $10^{3} / \mu \mathrm{L}$ <br> and below | $3.9 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $9.6 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $11.1 \times 10^{3} / \mu \mathrm{L}$ <br> and above |
| $0-6$ | 3,176 | 3.6 | 8.5 | $0.1 \%$ | $0.4 \%$ | $27.9 \%$ | $13.0 \%$ |  |
| $7-15$ | 5,710 | 11.0 | 6.5 | $0.2 \%$ | $4.0 \%$ | $5.7 \%$ | $1.8 \%$ |  |
| $16-39$ | 8,791 | 28.3 | 6.0 | $0.9 \%$ | $7.6 \%$ | $3.8 \%$ | $1.3 \%$ |  |
| $40-64$ | 14,087 | 53.7 | 5.6 | $1.1 \%$ | $11.1 \%$ | $1.6 \%$ | $0.5 \%$ |  |
| $65-$ | 9,228 | 73.8 | 5.8 | $0.9 \%$ | $8.5 \%$ | $1.7 \%$ | $0.5 \%$ |  |

FY 2012

| WBC $\left(10^{3} / \mu \mathrm{L}\right) \quad$ (overall) |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average <br> WBC | $2.9 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $3.9 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $9.6 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $11.1 \times 10^{3} / \mu \mathrm{L}$ <br> and above |
| 0-6 | 4,342 | 3.6 | 8.6 | 0.1\% | 0.4\% | 29.1\% | 13.4\% |
| 7-15 | 7,435 | 10.9 | 6.5 | 0.2\% | 2.6\% | 6.0\% | 2.0\% |
| 16-39 | 8,480 | 28.6 | 6.0 | 0.7\% | 7.8\% | 3.6\% | 1.3\% |
| 40-64 | 19,551 | 55.0 | 5.8 | 0.9\% | 9.7\% | 2.6\% | 0.8\% |
| 65- | 18,637 | 73.5 | 5.7 | 0.8\% | 8.3\% | 1.7\% | 0.5\% |


| WBC $\left(10^{3} / \mu \mathrm{L}\right) \quad$ (male) |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average WBC | $2.9 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $3.9 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $9.6 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $11.1 \times 10^{3} / \mu \mathrm{L}$ <br> and above |
| 0-6 | 2,166 | 3.6 | 8.6 | 0.0\% | 0.3\% | 29.3\% | 13.2\% |
| 7-15 | 3,809 | 10.8 | 6.5 | 0.2\% | 2.7\% | 6.5\% | 2.2\% |
| 16-39 | 3,230 | 27.9 | 6.1 | 0.4\% | 5.3\% | 4.1\% | 1.6\% |
| 40-64 | 7,717 | 55.4 | 6.2 | 0.3\% | 5.1\% | 4.3\% | 1.4\% |
| 65- | 8,476 | 73.4 | 6.0 | 0.5\% | 6.1\% | 2.4\% | 0.7\% |


| WBC $\left(10^{3} / \mu \mathrm{L}\right) \quad$ (female) |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average <br> WBC | $2.9 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $3.9 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $9.6 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $11.1 \times 10^{3} / \mu \mathrm{L}$ <br> and above |
| 0-6 | 2,176 | 3.6 | 8.6 | 0.1\% | 0.5\% | 29.0\% | 13.5\% |
| 7-15 | 3,626 | 10.9 | 6.5 | 0.2\% | 2.5\% | 5.4\% | 1.8\% |
| 16-39 | 5,250 | 29.1 | 5.9 | 0.9\% | 9.4\% | 3.4\% | 1.1\% |
| 40-64 | 11,834 | 54.6 | 5.5 | 1.3\% | 12.6\% | 1.5\% | 0.4\% |
| 65- | 10,161 | 73.6 | 5.5 | 1.0\% | 10.2\% | 1.2\% | 0.4\% |

## WBC

FY 2013

| WBC $\left(10^{3} / \mu \mathrm{L}\right)$ (overall) |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> WBC | $2.9 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $3.9 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $9.6 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $11.1 \times 10^{3} / \mu \mathrm{L}$ <br> and above |
| 0-6 | 3,781 | 3.7 | 8.6 | - | 0.3\% | 30.0\% | 13.5\% |
| 7-15 | 6,421 | 10.8 | 6.6 | 0.1\% | 2.3\% | 6.6\% | 2.2\% |
| 16-39 | 6,536 | 29.0 | 6.1 | 0.4\% | 7.2\% | 3.6\% | 1.4\% |
| 40-64 | 16,920 | 55.3 | 5.8 | 0.8\% | 9.0\% | 2.8\% | 0.9\% |
| 65- | 18,955 | 73.5 | 5.8 | 0.7\% | 7.6\% | 2.0\% | 0.7\% |


| WBC ( $10^{3} / \mu \mathrm{L}$ ) (male) |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average <br> WBC | $2.9 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $3.9 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $9.6 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $11.1 \times 10^{3} / \mu \mathrm{L}$ <br> and above |
| 0-6 | 1,942 | 3.7 | 8.6 | - | 0.3\% | 30.1\% | 14.2\% |
| 7-15 | 3,287 | 10.9 | 6.6 | 0.0\% | 2.6\% | 7.0\% | 2.2\% |
| 16-39 | 2,480 | 28.3 | 6.2 | 0.2\% | 6.1\% | 3.5\% | 1.5\% |
| 40-64 | 6,510 | 55.7 | 6.3 | 0.3\% | 4.7\% | 4.8\% | 1.6\% |
| 65- | 8,637 | 73.4 | 6.0 | 0.4\% | 5.5\% | 2.6\% | 0.9\% |


| WBC $\left(10^{3} / \mu \mathrm{L}\right) \quad$ (female) |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> WBC | $2.9 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $3.9 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $9.6 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $11.1 \times 10^{3} / \mu \mathrm{L}$ <br> and above |
| 0-6 | 1,839 | 3.7 | 8.6 | - | 0.2\% | 30.0\% | 12.9\% |
| 7-15 | 3,134 | 10.8 | 6.7 | 0.2\% | 2.1\% | 6.2\% | 2.3\% |
| 16-39 | 4,056 | 29.5 | 6.0 | 0.5\% | 7.9\% | 3.6\% | 1.3\% |
| 40-64 | 10,410 | 55.0 | 5.5 | 1.0\% | 11.7\% | 1.5\% | 0.4\% |
| 65- | 10,318 | 73.5 | 5.6 | 1.0\% | 9.3\% | 1.4\% | 0.5\% |

FY 2014

| WBC $\left(10^{3} / \mu \mathrm{L}\right)$ (overall) |  |  |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> WBC | $2.9 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $3.9 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $9.6 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $11.1 \times 10^{3} / \mu \mathrm{L}$ <br> and above |  |
| $0-6$ | 3,295 | 3.8 | 8.6 | $0.0 \%$ | $0.3 \%$ | $30.0 \%$ | $14.4 \%$ |  |
| $7-15$ | 5,832 | 10.9 | 6.6 | $0.2 \%$ | $2.5 \%$ | $6.0 \%$ | $1.9 \%$ |  |
| $16-39$ | 5,843 | 29.0 | 6.0 | $0.8 \%$ | $7.8 \%$ | $4.1 \%$ | $1.3 \%$ |  |
| $40-64$ | 15,591 | 55.1 | 5.9 | $0.8 \%$ | $8.5 \%$ | $3.2 \%$ | $1.0 \%$ |  |
| $65-$ | 19,152 | 73.3 | 5.9 | $0.6 \%$ | $7.3 \%$ | $2.3 \%$ | $0.7 \%$ |  |


| WBC $\left(10^{3} / \mu \mathrm{L}\right)(\mathrm{male})$ |  |  |  |  |  |  |  |
| :---: | :---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> WBC | $2.9 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $3.9 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $9.6 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $11.1 \times 10^{3} / \mu \mathrm{L}$ <br> and above |
| $0-6$ | 1,677 | 3.8 | 8.7 | $0.1 \%$ | $0.3 \%$ | $30.9 \%$ | $14.3 \%$ |
| $7-15$ | 2,984 | 10.9 | 6.6 | $0.1 \%$ | $2.4 \%$ | $6.1 \%$ | $1.9 \%$ |
| $16-39$ | 2,168 | 28.0 | 6.1 | $0.3 \%$ | $6.4 \%$ | $4.2 \%$ | $1.4 \%$ |
| $40-64$ | 5,858 | 55.5 | 6.3 | $0.4 \%$ | $4.5 \%$ | $5.4 \%$ | $1.9 \%$ |
| $65-$ | 8,676 | 73.3 | 6.1 | $0.3 \%$ | $5.3 \%$ | $3.2 \%$ | $0.9 \%$ |


| WBC $\left(10^{3} / \mu \mathrm{L}\right)($ female |  |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> WBC | $2.9 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $3.9 \times 10^{3} / \mu \mathrm{L}$ <br> and below | $9.6 \times 10^{3} / \mu \mathrm{L}$ <br> and above | $11.1 \times 10^{3} / \mu \mathrm{L}$ <br> and above |
| $0-6$ | 1,618 | 3.8 | 8.6 | - | $0.3 \%$ | $29.2 \%$ | $14.5 \%$ |
| $7-15$ | 2,848 | 10.8 | 6.6 | $0.2 \%$ | $2.6 \%$ | $6.0 \%$ | $2.0 \%$ |
| $16-39$ | 3,675 | 29.5 | 6.0 | $1.1 \%$ | $8.6 \%$ | $4.1 \%$ | $1.2 \%$ |
| $40-64$ | 9,733 | 54.9 | 5.6 | $1.0 \%$ | $10.9 \%$ | $1.9 \%$ | $0.5 \%$ |
| $65-$ | 10,476 | 73.3 | 5.7 | $0.8 \%$ | $8.9 \%$ | $1.5 \%$ | $0.4 \%$ |

## Differential white blood count (neutrophil)

FY 2011

| Neutrophil (count/ $\mu \mathrm{L}$ ) (overall) |  |  |  |  |  |  |  |
| ---: | ---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees <br> Average <br> age |  | Average <br> neutrophil | Minimum <br> value | Maximum <br> value | $500 / \mu \mathrm{L}$ <br> below |  |
| $0-6$ | 6,418 | 3.6 | 3,666 | 198 | 16,770 | $0.0 \%$ |  |
| $7-15$ | 11,470 | 11.0 | 3,373 | 324 | 13,876 | $0.0 \%$ |  |
| $16-39$ | 14,746 | 28.1 | 3,465 | 531 | 17,313 | - |  |
| $40-64$ | 23,643 | 54.0 | 3,250 | 266 | 19,388 | $0.0 \%$ |  |
| $65-$ | 16,719 | 73.7 | 3,275 | 336 | 17,553 | $0.0 \%$ |  |


| Neutrophil (count/ $\mu \mathrm{L}) \quad(\mathrm{male})$ |  |  |  |  |  |  |
| ---: | ---: | :--- | ---: | :--- | :--- | :--- |
| Age | Examinees <br> Average <br> age |  | Average <br> neutrophil | Minimum <br> value | Maximum <br> value | $500 / \mu \mathrm{L}$ <br> below |
| $0-6$ | 3,247 | 3.6 | 3,683 | 558 | 15,566 | - |
| $7-15$ | 5,762 | 10.9 | 3,321 | 324 | 12,901 | $0.0 \%$ |
| $16-39$ | 5,962 | 27.7 | 3,428 | 531 | 14,977 | - |
| $40-64$ | 9,559 | 54.5 | 3,494 | 379 | 15,222 | $0.0 \%$ |
| $65-$ | 7,495 | 73.4 | 3,423 | 336 | 17,553 | $0.0 \%$ |


| Neutrophil (count/ $\mu \mathrm{L}$ ) (female) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average neutrophil | Minimum value | Maximum value | $500 / \mu \mathrm{L}$ and below |
| 0-6 | 3,171 | 3.6 | 3,649 | 198 | 16,770 | 0.1\% |
| 7-15 | 5,708 | 11.0 | 3,425 | 336 | 13,876 | 0.0\% |
| 16-39 | 8,784 | 28.3 | 3,490 | 581 | 17,313 | - |
| 40-64 | 14,084 | 53.7 | 3,085 | 266 | 19,388 | 0.0\% |
| 65- | 9,224 | 73.8 | 3,156 | 474 | 15,709 | 0.0\% |

FY 2012

| Neutrophil (count/ $\mu \mathrm{L}$ ) (overall) |  |  |  |  |  |  |
| ---: | ---: | ---: | ---: | :--- | :--- | :--- |
| Age | Examinees |  | Average <br> age |  | Average <br> neutrophil | Minimum <br> value |
| $0-6$ | 4,320 | 3.6 | 3,538 | Maximum <br> value | $500 / \mu \mathrm{L}$ <br> below |  |
| $7-15$ | 7,429 | 10.9 | 3,299 | 604 | 23,763 | $0.1 \%$ |
| $16-39$ | 8,455 | 28.6 | 3,437 | 637 | 17,052 | - |
| $40-64$ | 19,473 | 55.0 | 3,213 | 554 | 20,720 | - |
| $65-$ | 18,547 | 73.5 | 3,204 | 451 | 18,990 | $0.0 \%$ |


| Neutrophil (count/ $\mu \mathrm{L})$ (male) |  |  |  |  |  |  |
| ---: | ---: | ---: | ---: | :--- | :--- | :--- |
| Age | Examinees | Average <br> age |  | Average <br> neutrophil | Minimum <br> value | Maximum <br> value |
| $0-6$ | 2,158 | 3.6 | 3,555 | 204 | 14,164 | $0.1 \%$ |
| $7-15$ | 3,806 | 10.8 | 3,259 | 822 | 17,052 | - |
| $16-39$ | 3,219 | 27.9 | 3,397 | 805 | 12,797 | - |
| $40-64$ | 7,687 | 55.4 | 3,467 | 736 | 20,720 | - |
| $65-$ | 8,435 | 73.4 | 3,360 | 600 | 17,108 | - |


| Neutrophil (count/ $\mu \mathrm{L}$ ) (female) |  |  |  |  |  |  |  |
| ---: | ---: | ---: | ---: | :--- | :--- | :--- | :---: |
| Age | Examinees | Average <br> age |  | Average <br> neutrophil | Minimum <br> value | Maximum <br> value |  |
| $0-6$ | 2,162 | 3.6 | 3,521 | 315 | 23,763 | $0.0 \%$ |  |
| $7-15$ | 3,623 | 10.9 | 3,341 | 664 | 16,674 | - |  |
| $16-39$ | 5,236 | 29.1 | 3,461 | 637 | 28,578 | - |  |
| $40-64$ | 11,786 | 54.7 | 3,048 | 554 | 13,617 | - |  |
| $65-$ | 10,112 | 73.6 | 3,074 | 451 | 18,990 | $0.0 \%$ |  |

## Differential white blood count (neutrophil)

FY 2013

| Neutrophil (count/ $\mu \mathrm{L}$ ) (overall) |  |  |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :--- | :--- | :---: |
| Age | Examinees | Average <br> age | Average <br> neutrophil | Minimum <br> value | Maximum <br> value | 500/ $\mu \mathrm{L}$ and <br> below |  |
| $0-6$ | 3,777 | 3.7 | 3,476 | 525 | 14,067 | - |  |
| $7-15$ | 6,417 | 10.8 | 3,341 | 315 | 15,498 | $0.0 \%$ |  |
| $16-39$ | 6,526 | 29.0 | 3,482 | 702 | 16,789 | - |  |
| $40-64$ | 16,906 | 55.3 | 3,247 | 268 | 16,044 | $0.0 \%$ |  |
| $65-$ | 18,949 | 73.5 | 3,270 | 442 | 25,690 | $0.0 \%$ |  |


| Neutrophil (count/ $\mu \mathrm{L}$ ) (male) |  |  |  |  |  |  |  |
| ---: | :--- | ---: | ---: | ---: | :--- | :--- | :---: |
| Age | Examinees | Average <br> age | Average <br> neutrophil | Minimum <br> value | Maximum <br> value | $500 / \mu \mathrm{L}$ <br> below <br> $0-6$ |  |
| 7,941 | 3.7 | 3,472 | 525 | 14,067 | - |  |  |
| $16-39$ | 3,284 | 10.9 | 3,255 | 315 | 11,914 | $0.0 \%$ |  |
| $40-64$ | 2,476 | 28.3 | 3,421 | 736 | 16,789 | - |  |
| $65-$ | 8,605 | 55.7 | 3,499 | 603 | 14,328 | - |  |


| Neutrophil (count/ $\mu \mathrm{L}$ ) (female) |  |  |  |  |  |  |  |
| ---: | ---: | ---: | ---: | ---: | :--- | :--- | :---: |
| Age | Examinees | Average <br> age | Average <br> neutrophil | Minimum <br> value | Maximum <br> value | $500 / \mu \mathrm{L}$ <br> below <br> $0-6$ |  |
| $7-836$ | 3.7 | 3,480 | 526 | 12,243 | - |  |  |
| $16-39$ | 3,133 | 10.8 | 3,431 | 761 | 15,498 | - |  |
| $40-64$ | 4,050 | 29.5 | 3,520 | 702 | 13,513 | - |  |
| $65-$ | 10,401 | 55.0 | 3,089 | 268 | 16,044 | $0.0 \%$ |  |

FY 2014

| Neutrophil (count $/ \mu \mathrm{L})$ (overall) |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Age | Examinees | Average age | Average <br> neutrophil | Minimum <br> value | Maximum <br> value | $500 / \mu \mathrm{L}$ and <br> below |
| $0-6$ | 3,293 | 3.8 | 3,526 | 301 | 12,784 | $0.0 \%$ |
| $7-15$ | 5,831 | 10.9 | 3,279 | 493 | 13,655 | $0.0 \%$ |
| $16-39$ | 5,838 | 29.0 | 3,479 | 714 | 12,900 | - |
| $40-64$ | 15,583 | 55.1 | 3,282 | 450 | 17,777 | $0.0 \%$ |
| $65-$ | 19,151 | 73.3 | 3,314 | 81 | 23,197 | $0.0 \%$ |


| Neutrophil (count $/ \mu \mathrm{L})($ male $)$ |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> neutrophil | Minimum <br> value | Maximum <br> value | $500 / \mu \mathrm{L}$ and <br> below |
| $0-6$ | 1,677 | 3.8 | 3,579 | 862 | 12,784 | - |
| $7-15$ | 2,984 | 10.9 | 3,215 | 493 | 13,655 | $0.0 \%$ |
| $16-39$ | 2,167 | 28.0 | 3,401 | 952 | 12,900 | - |
| $40-64$ | 5,855 | 55.5 | 3,556 | 652 | 17,777 | - |
| $65-$ | 8,675 | 73.3 | 3,490 | 504 | 23,197 | - |


| Neutrophil (count $/ \mu \mathrm{L})($ female) |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> neutrophil | Minimum <br> value | Maximum <br> value | $500 / \mu \mathrm{L}$ and <br> below |
| $0-6$ | 1,616 | 3.8 | 3,471 | 301 | 11,692 | $0.1 \%$ |
| $7-15$ | 2,847 | 10.8 | 3,346 | 624 | 12,171 | - |
| $16-39$ | 3,671 | 29.5 | 3,526 | 714 | 12,316 | - |
| $40-64$ | 9,728 | 54.9 | 3,118 | 450 | 12,766 | $0.0 \%$ |
| $65-$ | 10,476 | 73.3 | 3,167 | 81 | 21,143 | $0.0 \%$ |

## Differential white blood count (lymphocyte)

FY 2011

| Lymphocyte (count/ $\mu \mathrm{L}$ ) (overall) |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | :--- | :--- | :--- |
| Age | Examinees | $\begin{array}{l}\text { Average } \\ \text { age }\end{array}$ |  | $\begin{array}{l}\text { Average } \\ \text { lymphocyte } \\ \text { count }\end{array}$ | $\begin{array}{l}\text { Minimum } \\ \text { value }\end{array}$ | $\begin{array}{l}\text { Maximum } \\ \text { value }\end{array}$ |
| $0-6$ | 6,418 | 3.6 | 4,134 | $500 / \mu \mathrm{L}$ and |  |  |
| below |  |  |  |  |  |  |$]$


| Lymphocyte (count/ $\mu \mathrm{L}$ ) (male) |  |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :--- | :--- |
| Age | Examinees | Average <br> age |  | Average <br> lymphocyte <br> count | Minimum <br> value | Maximum <br> value |
| $0-6$ | 3,247 | 3.6 | 4,055 | 500 | $500 / \mu \mathrm{L}$ and <br> below |  |
| $7-15$ | 5,762 | 10.9 | 2,533 | 210 | 6,890 | $0.1 \%$ |
| $16-39$ | 5,962 | 27.7 | 2,232 | 390 | 6,247 | $0.0 \%$ |
| $40-64$ | 9,559 | 54.5 | 2,278 | 535 | 6,598 | - |
| $65-$ | 7,495 | 73.4 | 2,172 | 468 | 14,380 | $0.0 \%$ |


| Lymphocyte (count/ $\mu \mathrm{L}$ ) (female) |  |  |  |  |  |  |
| :--- | ---: | ---: | :--- | :--- | :--- | :--- |
| Age | Examinees | Average <br> age |  | Average <br> lymphocyte <br> count | Minimum <br> value | Maximum <br> value |
| $0-6$ | 3,171 | 3.6 | 4,214 | 975 | 14,091 | 5elow <br> bel |
| $7-15$ | 5,708 | 11.0 | 2,514 | 322 | 6,879 | $0.1 \%$ |
| $16-39$ | 8,784 | 28.3 | 2,018 | 351 | 5,611 | $0.0 \%$ |
| $40-64$ | 14,084 | 53.7 | 2,021 | 350 | 35,322 | $0.0 \%$ |
| $65-$ | 9,224 | 73.8 | 2,137 | 377 | 10,009 | $0.0 \%$ |

FY 2012

| Lymphocyte (count/ $\mu \mathrm{L}$ ) (overall) |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | :--- | :--- | ---: |
| Age | Examinees | $\begin{array}{l}\text { Average } \\ \text { age }\end{array}$ |  | $\begin{array}{l}\text { Average } \\ \text { lymphocyte } \\ \text { count }\end{array}$ | $\begin{array}{l}\text { Minimum } \\ \text { value }\end{array}$ | $\begin{array}{l}\text { Maximum } \\ \text { value }\end{array}$ |
| $0-6$ | 4,320 | 3.6 | 4,261 | 418 | 16,188 | $0.0 \%$ and |
| below |  |  |  |  |  |  |$]$


| Lymphocyte (count $/ \mu \mathrm{L}$ ) (male) |  |  |  |  |  |  |
| ---: | ---: | :--- | :--- | :--- | :--- | :--- |
| Age | Examinees | Average <br> age |  | Average <br> lymphocyte <br> count | Minimum <br> value | Maximum <br> value |
| $0-6$ | 2,158 | 3.6 | 4,202 | $500 / \mu \mathrm{L}$ and <br> below |  |  |
| $7-15$ | 3,806 | 10.8 | 2,582 | 199 | 8,981 | $0.0 \%$ |
| $16-39$ | 3,219 | 27.9 | 2,136 | 723 | 6,354 | - |
| $40-64$ | 7,687 | 55.4 | 2,138 | 367 | 5,568 | $0.0 \%$ |
| $65-$ | 8,435 | 73.4 | 2,013 | 396 | 11,115 | $0.0 \%$ |


| Lymphocyte (count/ $\mu \mathrm{L}$ ) (female) |  |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :--- | ---: |
| Age | Examinees | Average <br> age |  | Average <br> lymphocyte <br> count | Minimum <br> value | Maximum <br> value |
| $0-6$ | 2,162 | 3.6 | 4,321 | 418 | 500/ $\mu \mathrm{L}$ and <br> below |  |
| $7-15$ | 3,623 | 10.9 | 2,569 | 418 | 8,526 | $0.0 \%$ |
| $16-39$ | 5,236 | 29.1 | 1,920 | 536 | 5,628 | - |
| $40-64$ | 11,786 | 54.7 | 1,949 | 396 | 13,909 | $0.1 \%$ |
| $65-$ | 10,112 | 73.6 | 1,994 | 332 | 41,569 | $0.0 \%$ |

## Differential white blood count (lymphocyte)

FY 2013

| Lymphocyte (count/ $\mu \mathrm{L}$ ) (overall) |  |  |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :--- | :--- | :---: |
| Age | Examinees | Average <br> age |  | Average <br> lymphocyte <br> count | Minimum <br> value | Maximum <br> value |  |
| $0-6$ | 3,777 | 3.7 | 4,330 | 945 | 15,912 | below <br> ben |  |
| $7-15$ | 6,417 | 10.8 | 2,633 | 687 | 7,425 | - |  |
| $16-39$ | 6,526 | 29.0 | 2,020 | 371 | 5,396 | $0.0 \%$ |  |
| $40-64$ | 16,906 | 55.3 | 2,042 | 210 | 7,391 | $0.0 \%$ |  |
| $65-$ | 18,949 | 73.5 | 2,017 | 124 | 12,381 | $0.0 \%$ |  |


| Lymphocyte (count/ $\mu \mathrm{L}$ ) (male) |  |  |  |  |  |  |
| :--- | ---: | ---: | :--- | :--- | :--- | :--- |
| Age | Examinees | Average <br> age |  | Average <br> lymphocyte <br> count | Minimum <br> value | Maximum <br> value |
| $0-6$ | 1,941 | 3.7 | 4,304 | $500 / \mu \mathrm{L}$ and <br> below |  |  |
| $7-15$ | 3,284 | 10.9 | 2,633 | 954 | 15,912 | - |
| $16-39$ | 2,476 | 28.3 | 2,122 | 371 | 5,375 | $0.1 \%$ |
| $40-64$ | 6,505 | 55.7 | 2,156 | 524 | 7,391 | - |
| $65-$ | 8,633 | 73.4 | 2,029 | 124 | 12,381 | $0.0 \%$ |


| Lymphocyte (count/ $\mu \mathrm{L}$ ) (female) |  |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :--- | :--- |
| Age | Examinees | Average <br> age |  | Average <br> lymphocyte <br> count | Minimum <br> value | Maximum <br> value |
| $0-6$ | 1,836 | 3.7 | 4,357 | 945 | 13,244 | $500 / \mu \mathrm{L}$ and <br> below |
| $7-15$ | 3,133 | 10.8 | 2,634 | 687 | 7,425 | - |
| $16-39$ | 4,050 | 29.5 | 1,958 | 452 | 5,396 | $0.0 \%$ |
| $40-64$ | 10,401 | 55.0 | 1,971 | 210 | 6,469 | $0.0 \%$ |
| $65-$ | 10,316 | 73.5 | 2,006 | 360 | 6,930 | $0.0 \%$ |

FY 2014

| Lymphocyte (count $/ \mu \mathrm{L}$ ) (overall) |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> lymphocyte <br> count | Minimum <br> value | Maximum <br> value | $500 / \mu \mathrm{L}$ and <br> below |
| $0-6$ | 3,293 | 3.8 | 4,299 | 620 | 13,600 | - |
| $7-15$ | 5,831 | 10.9 | 2,624 | 591 | 6,474 | - |
| $16-39$ | 5,838 | 29.0 | 2,018 | 574 | 6,390 | - |
| $40-64$ | 15,583 | 55.1 | 2,057 | 306 | 20,155 | $0.0 \%$ |
| $65-$ | 19,151 | 73.3 | 2,040 | 310 | 80,504 | $0.0 \%$ |


| Lymphocyte (count $/ \mu \mathrm{L}$ ) (male) |  |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> lymphocyte <br> count | Minimum <br> value | Maximum <br> value | $500 / \mu \mathrm{L}$ and <br> below |  |
| $0-6$ | 1,677 | 3.8 | 4,236 | 620 | 13,600 | - |  |
| $7-15$ | 2,984 | 10.9 | 2,630 | 591 | 6,474 | - |  |
| $16-39$ | 2,167 | 28.0 | 2,122 | 594 | 6,390 | - |  |
| $40-64$ | 5,855 | 55.5 | 2,158 | 470 | 7,760 | $0.0 \%$ |  |
| $65-$ | 8,675 | 73.3 | 2,042 | 310 | 9,257 | $0.1 \%$ |  |


| Lymphocyte (count $/ \mu \mathrm{L}$ ) (female) |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> lymphocyte <br> count | Minimum <br> value | Maximum <br> value | $500 / \mu \mathrm{L}$ and <br> below |
| $0-6$ | 1,616 | 3.8 | 4,364 | 1,015 | 12,403 | - |
| $7-15$ | 2,847 | 10.8 | 2,617 | 597 | 5,862 | - |
| $16-39$ | 3,671 | 29.5 | 1,957 | 574 | 4,949 | - |
| $40-64$ | 9,728 | 54.9 | 1,996 | 306 | 20,155 | $0.0 \%$ |
| $65-$ | 10,476 | 73.3 | 2,039 | 425 | 80,504 | $0.0 \%$ |

## Differential white blood count (monocyte)

FY 2011

| Monocyte (count/ $\mu \mathrm{L}$ ) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average monocyte count | Minimum value | Maximum value |
| 0-6 | 6,418 | 3.6 | 440 | 0 | 1,936 |
| 7-15 | 11,470 | 11.0 | 355 | 0 | 1,380 |
| 16-39 | 14,746 | 28.1 | 338 | 0 | 1,150 |
| 40-64 | 23,643 | 54.0 | 319 | 0 | 1,558 |
| 65- | 16,719 | 73.7 | 330 | 0 | 1,369 |


| Monocyte (count/ LL ) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average monocyte count | Minimum value | Maximum value |
| 0-6 | 3,247 | 3.6 | 454 | 0 | 1,683 |
| 7-15 | 5,762 | 10.9 | 366 | 0 | 1,380 |
| 16-39 | 5,962 | 27.7 | 361 | 0 | 1,150 |
| 40-64 | 9,559 | 54.5 | 363 | 0 | 1,558 |
| 65- | 7,495 | 73.4 | 366 | 19 | 1,369 |


| Monocyte (count/ $/ \mathrm{L}$ ) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average monocyte count | Minimum value | Maximum value |
| 0-6 | 3,171 | 3.6 | 426 | 0 | 1,936 |
| 7-15 | 5,708 | 11.0 | 343 | 0 | 1,242 |
| 16-39 | 8,784 | 28.3 | 322 | 0 | 1,120 |
| 40-64 | 14,084 | 53.7 | 289 | 26 | 986 |
| 65- | 9,224 | 73.8 | 301 | 0 | 1,293 |

FY 2012

| Monocyte (count/ $\mu \mathrm{L}$ ) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> monocyte <br> count | Minimum value | Maximum value |
| 0-6 | 4,320 | 3.6 | 445 | 0 | 2,580 |
| 7-15 | 7,429 | 10.9 | 350 | 0 | 1,455 |
| 16-39 | 8,455 | 28.6 | 329 | 0 | 1,017 |
| 40-64 | 19,473 | 55.0 | 317 | 0 | 1,729 |
| 65- | 18,547 | 73.5 | 332 | 38 | 3,913 |


| Monocyte (count/ $\mu \mathrm{L}$ ) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average monocyte count | Minimum value | Maximum value |
| 0-6 | 2,158 | 3.6 | 460 | 0 | 2,580 |
| 7-15 | 3,806 | 10.8 | 362 | 39 | 1,455 |
| 16-39 | 3,219 | 27.9 | 353 | 43 | 1,017 |
| 40-64 | 7,687 | 55.4 | 362 | 0 | 1,161 |
| 65- | 8,435 | 73.4 | 368 | 44 | 3,913 |


| Monocyte (count/ $\mu \mathrm{L}$ ) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average monocyte count | Minimum value | Maximum value |
| 0-6 | 2,162 | 3.6 | 431 | 30 | 1,708 |
| 7-15 | 3,623 | 10.9 | 337 | 0 | 1,372 |
| 16-39 | 5,236 | 29.1 | 314 | 0 | 988 |
| 40-64 | 11,786 | 54.7 | 289 | 29 | 1,729 |
| 65- | 10,112 | 73.6 | 303 | 38 | 3,128 |

## Differential white blood count (monocyte)

FY 2013

| Monocyte (count/ $\mu \mathrm{L}$ ) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average monocyte count | Minimum value | Maximum value |
| 0-6 | 3,777 | 3.7 | 450 | 0 | 1,611 |
| 7-15 | 6,417 | 10.8 | 357 | 0 | 1,180 |
| 16-39 | 6,526 | 29.0 | 332 | 38 | 1,092 |
| 40-64 | 16,906 | 55.3 | 318 | 21 | 1,273 |
| $65-$ | 18,949 | 73.5 | 334 | 58 | 1,989 |


| Monocyte (count/ $\mu \mathrm{L}$ ) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average monocyte count | Minimum value | Maximum value |
| 0-6 | 1,941 | 3.7 | 465 | 0 | 1,462 |
| 7-15 | 3,284 | 10.9 | 365 | 43 | 1,174 |
| 16-39 | 2,476 | 28.3 | 356 | 38 | 1,092 |
| 40-64 | 6,505 | 55.7 | 362 | 21 | 1,273 |
| 65- | 8,633 | 73.4 | 369 | 58 | 1,989 |


| Monocyte (count/ $\mu \mathrm{L}$ ) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average monocyte count | Minimum value | Maximum value |
| 0-6 | 1,836 | 3.7 | 435 | 0 | 1,611 |
| 7-15 | 3,133 | 10.8 | 349 | 0 | 1,180 |
| 16-39 | 4,050 | 29.5 | 317 | 42 | 997 |
| 40-64 | 10,401 | 55.0 | 290 | 55 | 1,258 |
| 65- | 10,316 | 73.5 | 304 | 79 | 1,827 |

FY 2014

| Monocyte (count $/ \mu \mathrm{L}$ ) (overall) |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> monocyte count | Minimum <br> value | Maximum <br> value |  |
| $0-6$ | 3,293 | 3.8 | 445 | 0 | 1,760 |  |
| $7-15$ | 5,831 | 10.9 | 350 | 0 | 1,430 |  |
| $16-39$ | 5,838 | 29.0 | 330 | 0 | 1,165 |  |
| $40-64$ | 15,583 | 55.1 | 322 | 22 | 10,417 |  |
| $65-$ | 19,151 | 73.3 | 341 | 55 | 2,803 |  |


| Monocyte (count $/ \mu \mathrm{L})($ male $)$ |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> monocyte count | Minimum <br> value | Maximum <br> value |  |
| $0-6$ | 1,677 | 3.8 | 462 | 0 | 1,663 |  |
| $7-15$ | 2,984 | 10.9 | 362 | 0 | 1,430 |  |
| $16-39$ | 2,167 | 28.0 | 354 | 51 | 1,165 |  |
| $40-64$ | 5,855 | 55.5 | 366 | 57 | 1,392 |  |
| $65-$ | 8,675 | 73.3 | 378 | 61 | 2,385 |  |


| Monocyte (count/ $\mu \mathrm{L}$ ) (female) |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> monocyte count | Minimum <br> value | Maximum <br> value |  |
| $0-6$ | 1,616 | 3.8 | 426 | 0 | 1,760 |  |
| $7-15$ | 2,847 | 10.8 | 338 | 54 | 1,127 |  |
| $16-39$ | 3,671 | 29.5 | 316 | 0 | 958 |  |
| $40-64$ | 9,728 | 54.9 | 295 | 22 | 10,417 |  |
| $65-$ | 10,476 | 73.3 | 311 | 55 | 2,803 |  |

## Differential white blood count (eosinophil)

FY 2011

| Eosinophil (count/ $\mu \mathrm{L}$ ) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average eosinophil count | Minimum value | Maximum value |
| 0-6 | 6,418 | 3.6 | 223 | 0 | 2,720 |
| 7-15 | 11,470 | 11.0 | 214 | 0 | 2,331 |
| 16-39 | 14,746 | 28.1 | 175 | 0 | 3,310 |
| 40-64 | 23,643 | 54.0 | 160 | 0 | 3,180 |
| 65- | 16,719 | 73.7 | 153 | 0 | 5,852 |


| Eosinophil (count/ $\mu \mathrm{L}$ ) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average eosinophil count | Minimum value | Maximum value |
| 0-6 | 3,247 | 3.6 | 250 | 0 | 1,980 |
| 7-15 | 5,762 | 10.9 | 244 | 0 | 2,135 |
| 16-39 | 5,962 | 27.7 | 201 | 0 | 3,141 |
| 40-64 | 9,559 | 54.5 | 190 | 0 | 3,180 |
| 65- | 7,495 | 73.4 | 179 | 0 | 5,852 |


| Eosinophil (count/ $\mu \mathrm{L}$ ) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average eosinophil count | Minimum value | Maximum value |
| 0-6 | 3,171 | 3.6 | 195 | 0 | 2,720 |
| 7-15 | 5,708 | 11.0 | 185 | 0 | 2,331 |
| 16-39 | 8,784 | 28.3 | 158 | 0 | 3,310 |
| 40-64 | 14,084 | 53.7 | 139 | 0 | 2,353 |
| 65- | 9,224 | 73.8 | 133 | 0 | 3,110 |

FY 2012

| Eosinophil (count $/ \mu \mathrm{L}$ ) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average eosinophil count | Minimum value | Maximum value |
| 0-6 | 4,320 | 3.6 | 288 | 0 | 2,317 |
| 7-15 | 7,429 | 10.9 | 266 | 0 | 2,402 |
| 16-39 | 8,455 | 28.6 | 180 | 0 | 3,457 |
| 40-64 | 19,473 | 55.0 | 158 | 0 | 3,438 |
| 65- | 18,547 | 73.5 | 150 | 0 | 6,024 |


| Eosinophil (count/ $\mu \mathrm{L}$ ) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average eosinophil count | Minimum value | Maximum value |
| 0-6 | 2,158 | 3.6 | 316 | 0 | 2,183 |
| 7-15 | 3,806 | 10.8 | 304 | 0 | 2,156 |
| 16-39 | 3,219 | 27.9 | 210 | 0 | 1,610 |
| 40-64 | 7,687 | 55.4 | 188 | 0 | 3,438 |
| 65- | 8,435 | 73.4 | 174 | 0 | 6,024 |


| Eosinophil (count $/ \mu \mathrm{L}$ ) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average eosinophil count | Minimum value | Maximum value |
| 0-6 | 2,162 | 3.6 | 261 | 0 | 2,317 |
| 7-15 | 3,623 | 10.9 | 226 | 0 | 2,402 |
| 16-39 | 5,236 | 29.1 | 162 | 0 | 3,457 |
| 40-64 | 11,786 | 54.7 | 139 | 0 | 3,394 |
| 65- | 10,112 | 73.6 | 131 | 0 | 1,808 |

## Differential white blood count (eosinophil)

FY 2013

| Eosinophil (count/ $\mu \mathrm{L}$ ) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average eosinophil count | Minimum value | Maximum value |
| 0-6 | 3,777 | 3.7 | 301 | 0 | 2,793 |
| 7-15 | 6,417 | 10.8 | 275 | 0 | 3,737 |
| 16-39 | 6,526 | 29.0 | 176 | 0 | 4,563 |
| 40-64 | 16,906 | 55.3 | 160 | 0 | 4,717 |
| 65- | 18,949 | 73.5 | 153 | 0 | 17,225 |


| Eosinophil (count/ $\mu \mathrm{L}$ ) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average eosinophil count | Minimum value | Maximum value |
| 0-6 | 1,941 | 3.7 | 333 | 0 | 2,793 |
| 7-15 | 3,284 | 10.9 | 314 | 0 | 3,737 |
| 16-39 | 2,476 | 28.3 | 206 | 0 | 4,563 |
| 40-64 | 6,505 | 55.7 | 190 | 0 | 4,618 |
| 65- | 8,633 | 73.4 | 178 | 0 | 3,885 |


| Eosinophil (count/ $\mu \mathrm{L}$ ) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average eosinophil count | Minimum value | Maximum value |
| 0-6 | 1,836 | 3.7 | 267 | 0 | 2,121 |
| 7-15 | 3,133 | 10.8 | 234 | 0 | 1,628 |
| 16-39 | 4,050 | 29.5 | 158 | 0 | 1,168 |
| 40-64 | 10,401 | 55.0 | 141 | 0 | 4,717 |
| 65- | 10,316 | 73.5 | 132 | 0 | 17,225 |

FY 2014

| Eosinophil (count/ $\mu \mathrm{L}$ ) (overall) |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> eosinophil <br> count | Minimum <br> value | Maximum <br> value |  |
| $0-6$ | 3,293 | 3.8 | 294 | 0 | 3,117 |  |
| $7-15$ | 5,831 | 10.9 | 277 | 0 | 3,132 |  |
| $16-39$ | 5,838 | 29.0 | 176 | 0 | 2,000 |  |
| $40-64$ | 15,583 | 55.1 | 161 | 0 | 2,215 |  |
| $65-$ | 19,151 | 73.3 | 154 | 0 | 2,312 |  |


| Eosinophil (count/ $\mu \mathrm{L})(\mathrm{male})$ |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> eosinophil <br> count | Minimum <br> value | Maximum <br> value |  |
| $0-6$ | 1,677 | 3.8 | 327 | 0 | 3,117 |  |
| $7-15$ | 2,984 | 10.9 | 325 | 0 | 3,132 |  |
| $16-39$ | 2,167 | 28.0 | 203 | 0 | 2,000 |  |
| $40-64$ | 5,855 | 55.5 | 192 | 0 | 1,840 |  |
| $65-$ | 8,675 | 73.3 | 179 | 0 | 2,312 |  |


| Eosinophil (count $/ \mu \mathrm{L})(\mathrm{female})$ |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> eosinophil <br> count | Minimum <br> value | Maximum <br> value |  |
| $0-6$ | 1,616 | 3.8 | 259 | 0 | 2,114 |  |
| $7-15$ | 2,847 | 10.8 | 228 | 0 | 1,875 |  |
| $16-39$ | 3,671 | 29.5 | 159 | 0 | 1,973 |  |
| $40-64$ | 9,728 | 54.9 | 143 | 0 | 2,215 |  |
| $65-$ | 10,476 | 73.3 | 133 | 0 | 2,035 |  |

## Differential white blood count (basophil)

FY 2011

| Basophil (count $/ \mu \mathrm{L}$ ) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average <br> age | Average basophil count | Minimum value | Maximum value |
| 0-6 | 6,418 | 3.6 | 36 | 0 | 378 |
| 7-15 | 11,470 | 11.0 | 31 | 0 | 703 |
| 16-39 | 14,746 | 28.1 | 30 | 0 | 390 |
| 40-64 | 23,643 | 54.0 | 30 | 0 | 463 |
| 65- | 16,719 | 73.7 | 28 | 0 | 1,286 |


| Basophil (count/ $\mu \mathrm{L}$ ) (male) |  |  |  |  |  |  |
| ---: | :--- | ---: | ---: | :--- | :--- | :---: |
| Age | Examinees | Average <br> age | Average <br> basophil <br> count | Minimum value | Maximum value |  |
| $0-6$ | 3,247 | 3.6 | 38 | 0 | 378 |  |
| $7-15$ | 5,762 | 10.9 | 33 | 0 | 703 |  |
| $16-39$ | 5,962 | 27.7 | 31 | 0 | 390 |  |
| $40-64$ | 9,559 | 54.5 | 32 | 0 | 463 |  |
| $65-$ | 7,495 | 73.4 | 29 | 0 | 1,286 |  |


| Basophil (count $/ \mu \mathrm{L})$ (female) |  |  |  |  |  |  |
| ---: | ---: | ---: | :--- | :--- | :--- | :---: |
| Age | Examinees | Average <br> age | Average <br> basophil <br> count | Minimum value | Maximum value |  |
| $0-6$ | 3,171 | 3.6 | 35 | 0 | 321 |  |
| $7-15$ | 5,708 | 11.0 | 29 | 0 | 338 |  |
| $16-39$ | 8,784 | 28.3 | 28 | 0 | 210 |  |
| $40-64$ | 14,084 | 53.7 | 28 | 0 | 190 |  |
| $65-$ | 9,224 | 73.8 | 27 | 0 | 636 |  |

FY 2012

| Basophil (count $/ \mu \mathrm{L}$ ) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> basophil <br> count | Minimum value | Maximum value |
| 0-6 | 4,320 | 3.6 | 39 | 0 | 471 |
| 7-15 | 7,429 | 10.9 | 33 | 0 | 440 |
| 16-39 | 8,455 | 28.6 | 38 | 0 | 306 |
| 40-64 | 19,473 | 55.0 | 40 | 0 | 542 |
| 65- | 18,547 | 73.5 | 38 | 0 | 2,021 |


| Basophil (count/ $\mu \mathrm{L}$ ) (male) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average basophil count | Minimum value | Maximum value |
| 0-6 | 2,158 | 3.6 | 40 | 0 | 471 |
| 7-15 | 3,806 | 10.8 | 36 | 0 | 440 |
| 16-39 | 3,219 | 27.9 | 40 | 0 | 273 |
| 40-64 | 7,687 | 55.4 | 43 | 0 | 542 |
| 65- | 8,435 | 73.4 | 41 | 0 | 2,021 |


| Basophil (count $/ \mu \mathrm{L}$ ) (female) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average basophil count | Minimum value | Maximum value |
| 0-6 | 2,162 | 3.6 | 37 | 0 | 426 |
| 7-15 | 3,623 | 10.9 | 30 | 0 | 408 |
| 16-39 | 5,236 | 29.1 | 37 | 0 | 306 |
| 40-64 | 11,786 | 54.7 | 37 | 0 | 216 |
| 65- | 10,112 | 73.6 | 36 | 0 | 395 |

## Differential white blood count (basophil)

FY 2013

| Basophil (count $/ \mu \mathrm{L}$ ) (overall) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age | Examinees | Average age | Average <br> basophil <br> count | Minimum value | Maximum value |
| 0-6 | 3,777 | 3.7 | 38 | 0 | 1,120 |
| 7-15 | 6,417 | 10.8 | 34 | 0 | 798 |
| 16-39 | 6,526 | 29.0 | 40 | 0 | 258 |
| 40-64 | 16,906 | 55.3 | 41 | 0 | 345 |
| 65- | 18,949 | 73.5 | 39 | 0 | 683 |


| Basophil (count/ $\mu \mathrm{L}$ ) (male) |  |  |  |  |  |  |
| ---: | :--- | :--- | :--- | :--- | :--- | :---: |
| Age | Examinees | Average <br> age | Average <br> basophil <br> count | Minimum value | Maximum value |  |
| $0-6$ | 1,941 | 3.7 | 40 | 0 | 1,120 |  |
| $7-15$ | 3,284 | 10.9 | 35 | 0 | 231 |  |
| $16-39$ | 2,476 | 28.3 | 42 | 0 | 192 |  |
| $40-64$ | 6,505 | 55.7 | 45 | 0 | 345 |  |
| $65-$ | 8,633 | 73.4 | 41 | 0 | 590 |  |


| Basophil (count $/ \mu \mathrm{L})$ (female) |  |  |  |  |  |  |
| ---: | :--- | :--- | :--- | :--- | :--- | :---: |
| Age | Examinees | Average <br> age | Average <br> basophil <br> count | Minimum value | Maximum value |  |
| $0-6$ | 1,836 | 3.7 | 36 | 0 | 340 |  |
| $7-15$ | 3,133 | 10.8 | 32 | 0 | 798 |  |
| $16-39$ | 4,050 | 29.5 | 39 | 0 | 258 |  |
| $40-64$ | 10,401 | 55.0 | 39 | 0 | 230 |  |
| $65-$ | 10,316 | 73.5 | 37 | 0 | 683 |  |

FY 2014

| Basophil (count/ $\mu \mathrm{L}$ ) (overall) |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> basophil count | Minimum <br> value | Maximum <br> value |  |
| $0-6$ | 3,293 | 3.8 | 37 | 0 | 326 |  |
| $7-15$ | 5,831 | 10.9 | 33 | 0 | 248 |  |
| $16-39$ | 5,838 | 29.0 | 39 | 0 | 239 |  |
| $40-64$ | 15,583 | 55.1 | 42 | 0 | 225 |  |
| $65-$ | 19,151 | 73.3 | 41 | 0 | 921 |  |


| Basophil (count $/ \mu \mathrm{L})(\mathrm{male})$ |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> basophil count | Minimum <br> value | Maximum <br> value |  |
| $0-6$ | 1,677 | 3.8 | 39 | 0 | 326 |  |
| $7-15$ | 2,984 | 10.9 | 35 | 0 | 248 |  |
| $16-39$ | 2,167 | 28.0 | 40 | 0 | 239 |  |
| $40-64$ | 5,855 | 55.5 | 46 | 0 | 200 |  |
| $65-$ | 8,675 | 73.3 | 43 | 0 | 921 |  |


| Basophil (count $/ \mu \mathrm{L}$ ) (female) |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Age | Examinees | Average age | Average <br> basophil count | Minimum <br> value | Maximum <br> value |  |
| $0-6$ | 1,616 | 3.8 | 34 | 0 | 320 |  |
| $7-15$ | 2,847 | 10.8 | 30 | 0 | 220 |  |
| $16-39$ | 3,671 | 29.5 | 38 | 0 | 190 |  |
| $40-64$ | 9,728 | 54.9 | 40 | 0 | 225 |  |
| $65-$ | 10,476 | 73.3 | 39 | 0 | 552 |  |

## 【Summary】

Although there are no significant changes in the survey population of FY 2012-2014 from FY 2011, the participants, the time of receiving their health exams and the medical organizations differ. Due to such modifying factors, this is not a strict comparison.

Exam schedule for participants aged 15 years old and under is the following: Jan-Mar 2012 for FY 2011, Jul-Dec 2012 for FY 2012, Jul-Dec 2013 for FY 2013, and Jul-Dec 2014 for FY 2014.

1) The average weight of participants decreased in every age group of 64 and younger in FY 2012 from FY 2011. Afterward, the average weight of those aged 16-64 years gradually decreased. In the age group of 65 years and older, the average weight slightly increased over time from FY 2011. The prevalence of males weighing 70 kg and above in the age group of 16-64 gradually decreased since FY 2012, whereas it successively increased in the age group of 65 years and older. The prevalence of females weighing 65 kg and above steadily increased in the age group of 16 and older.
2) Overweight individuals with a BMI of $25 \mathrm{~kg} / \mathrm{m}^{2}$ or above for FY 2011 increased with age ( $22.3 \%$ in the age group of $16-39$, and $37.1 \%$ in the age group of 65 and older). The prevalence of overweight individuals was higher among males in all age groups compared with females. The prevalence stayed almost the same from FY 2011 through FY 2013, but it decreased from FY 2013 through FY 2014 in every age group ( $21.8 \%$ in the age group of $16-39$, and $34.3 \%$ in the age group of 65 and older).
3) The prevalence of males with abdominal circumference (AC) above diagnostic criteria of metabolic syndrome ( 85 cm and above) in FY 2011 was $37.3 \%$ in the age group of 16-39, 56.0\% in the age group of $40-64,58.2 \%$ in the age group of 65 and older. It decreased respectively in FY 2014: 32.0\%; 55.3\%; $56.2 \%$. The prevalence of females with AC above diagnostic criteria of metabolic syndrome ( 90 cm and above) in FY 2011 was: $9.5 \%$ in the age group of $16-39,19.5 \%$ in the age group of $40-64,26.7 \%$ in the age group of 65 and older. In FY 2014, it decreased in the age group of 16-39 (8.5\%), and in the age group of 65 and older (26.4\%), but increased in the age group of 40-64 (20.7\%).
4) The prevalence of hypertensive individuals, with a systolic blood pressure of 140 mmHg and above or a diastolic pressure of 90 mmHg and above, decreased among both males and females aged 40 and older over the years in FY 2012-2014 compared with FY 2011. The prevalence was low in males and females aged 39 and younger, and even lower in FY 2012-2014 compared with FY 2011. The prevalence of hypertensive individuals was higher among males than females in all age groups.
5) The prevalence of individuals who test positive for urinary sugar (1+) and above decreased among males and females in every age group of 16 and older in FY 2014 compared with FY 2011.
6) The prevalence of urine protein (1+) and above continued to increase in the age group of 16-39 from 1.1\% in FY 2011 to 2.2\% (FY 2012), 2.4\% (FY 2013), and 2.5\% (FY 2014). In other age groups, the prevalence was almost the same as in FY 2011.
7) The prevalence of urine occult blood (1+) and above omitting the time period during menstruation in FY 2012-2014 was almost the same as FY 2011.
8) The prevalence of serum creatinine $1.15 \mathrm{mg} / \mathrm{dL}$ and above, an indicator of impaired renal function,
among males aged 65 and older increased over the years from $7.6 \%$ in FY 2011 to $8.3 \%$ in FY 2012, $9.0 \%$ in FY 2013, and $9.9 \%$ in FY 2014.
9) The prevalence of eGFR less than $60 \mathrm{ml} / \mathrm{min} / 1.73 \mathrm{~m}^{2}$, an indicator of impaired renal function, increased among males and females aged 40 and older over the years in FY 2012-2014 compared with FY 2011.
10) The prevalence of impaired glucose tolerance indicated by fasting plasma glucose of $110 \mathrm{mg} / \mathrm{dL}$ and above remained the same among males and females in the age groups of 16-39 and 40-64 from FY 2011 to FY 2014. In the age group of 65 and older, the prevalence decreased among males and females for FY 2014.
11) The prevalence of impaired glucose tolerance indicated by HbA1c $6.0 \%$ and above increased among males and females in age groups of 16 and older for FY 2014 compared with FY 2011. However, the prevalence of poor blood sugar control of HbA1c $7.0 \%$ and above decreased among males and females in age groups of 40 and older for FY 2014 compared with FY 2011.
12) The prevalence of abnormal lipid metabolism with an LDL cholesterol of $120 \mathrm{mg} / \mathrm{dL}$ and above, triglyceride of $150 \mathrm{mg} / \mathrm{dL}$ and above, and HDL-C less than $40 \mathrm{mg} / \mathrm{dL}$ increased with age in FY 2011: $13.2 \%, 7.0 \%$, and $2.9 \%$ respectively in the age group of $7-15$. The prevalence slightly decreased in the age group of 65 and older in FY 2012. In the age group of $7-15$, the prevalence of hypertriglyceridemia gradually increased in FY 2014.
13) The prevalence of hepatic dysfunction indicated by AST, ALT, or $\gamma$-GT above their reference intervals increased from FY 2011 to 2012, but it dropped to the level of FY 2011 in FY 2013. Moreover, it decreased from FY 2013 to FY 2014.
14) The prevalence of hyperuricemia with a uric acid level of $7.1 \mathrm{mg} / \mathrm{dL}$ and above among males in FY 2011 was: $4.7 \%$ in the age group of $7-15 ; 18.5 \%$ in the age group of $16-39$; and $18.1 \%$ in the age group of 40-64. The prevalence was markedly higher among males than females in all age groups. Compared with FY 2011, it increased in all age groups except for 65 and over in FY 2014: 5.0\% in the age group of $7-15 ; 22.0 \%$ in the age group of $16-39$; and $20.3 \%$ in the age group of $40-64$ among males.
15) RBC, hemoglobin, and hematocrit: There were no significant differences in the average value of each age group through FY 2011-2014.
16) Platelet count: There were no significant changes in the average value of each age group through FY 2011-2014.
17) There were no changes in the value of RBC, WBC, and platelet count among children in FY 2012, 2013, and 2014 compared with FY 2011.
18) WBC differential: There were no significant changes in the average value of each age group through FY 2011-2014. There was no increase in the prevalence of lymphocyte counts $500 / \mu \mathrm{L}$ and below.

There were no significant changes in the average absolute counts of neutrophils, lymphocytes, monocytes, eosinophils, or basophils in the age groups of 0-6 and 7-15 through FY 2011-2014.

# Fukushima Health Management Survey 

 Mental Health and Lifestyle Survey Questionnaire (For ages 0-3)```
〒963-0000
```

Room 302, Idai Apartment
1, Hikarigaoka, Fukushima city

## Mr. Taro Idai

Enter the required items in the fields below.
Please check $\checkmark$ in corresponding boxes $\square$.
Date of entry : MM/DD/2016

| Child's name : | Sex: ${ }_{1} \square \mathrm{M} \quad{ }_{2} \square \mathrm{~F}$ |
| :--- | :--- |
| Child's date of birth : MM/DD/YYYY |  |



Please check $\boldsymbol{\checkmark}$ in the corresponding small boxes $\square$ below.

Q1. Describe your child's current health condition.
$\square$ Very good
${ }_{2} \square$ Good
Normal
Bad
Very bad

Q2. Please enter your child's current height and weight.
Example : Height 89.9 cm weight 12.6 kg (enter values right justified)

$$
\text { Height:8:9. } 9 \mathrm{~cm} \text { Weight } 1: 2.6 \mathrm{~kg}
$$

Height


Q3. Is your child currently receiving treatment for (a) disease( $s$ ), etc.?
No Yes If so, please check $\checkmark$ in the corresponding boxes $\square$.


Q4. Has your child been hospitalized due to an illness within this year?
No Yes If so, please check $\checkmark$ the corresponding boxes $\square$


Q5. Below are questions regarding your child's sleeping habits.

1) When does your child regularly sleep or wake up?

Bedtime


Time to wake up
 $\min$
2) Does your child take naps?
${ }_{1} \square$ No
${ }_{2} \square$ Yes
$\longrightarrow$ About
h


Q6. Below are questions for guardians who have a child aged 2 years or younger. How much does your child exercise? (Running around indoors, kicking balls, riding tricycles, etc.)
${ }_{1} \square$ Almost every day ${ }_{2} \square$ Around 2-4 times per week
${ }_{3} \square$ Once a week $\quad{ }_{4} \square$ Almost never

Q7. Below are questions regarding your child's diet.

1) Does your child drink breast milk?
${ }_{1} \square$ Yes
${ }_{2} \square$ No
2) Below are questions for guardians who have a child aged 1 year old or more. Please check $\checkmark$ in corresponding boxes regarding your child's past month diet.
(1) Does your child eat seafood 3 days or more per week? $\cdots \cdots \cdots \cdots \omega_{1} \square$ Yes ${ }_{2} \square$ No
(2) Does your child eat food such as vegetables other than pickles, seaweed or mushrooms almost every day? $\cdots{ }_{1 \square} \square$ Yes ${ }_{2} \square$ No
(3) Does your child eat fruits almost every day?

Yes ${ }_{2} \square$ No
(4) Does your child eat soy products (Tofu, deep fried tofu, natto, boiled beans, etc.) almost every day? $\cdot{ }_{1} \square$ Yes ${ }_{2} \square$ No
(5) Does your child eat dairy products (milk, yogurt, etc.) almost every day?YesNo

Q8. Are there ever times when you doubt your ability to raise a child?Yes
${ }_{2} \square$ No
$0 \quad{ }_{3} \square$ Cannot say
※ If you have concerns regarding your child＇s health or comments regarding this survey，please describe them below．
Your comments will be used for references for future health management and surveys．


That is it for the questions．
Please enclose the questionnaire in a return envelope and send it by mail．
Thank you for your cooperation．

ふくしまから はじめよう。
［Contact〕
O Exclusively for the Mental Health and Lifestyle Survey Radiation Medical Science Center，Fukushima Medical University

Phone number：024－549－5170
（9：00－17：00 with the exception of Dec 29－Jan 3 and weekends／holidays）

# Fukushima Health Management Survey 

 Mental Health and Lifestyle Survey Questionnaire (For ages 4-6)〒963-0000<br>Room 302, Idai Apartment<br>1, Hikarigaoka, Fukushima city<br>\section*{Taro Idai}

Enter the required items in the fields below. Please check $\checkmark$ in corresponding boxesa.

| Child's name : | Sex: ${ }_{1} \square \mathrm{M} \quad{ }_{2} \square \mathrm{~F}$ |
| :--- | :--- |
| Child's DOB : MM/DD/YYYY |  |



Fukushima Prefecture, Fukushima Medical University

Please check $\checkmark$ in the corresponding small boxes $\square$ below.
Q1. Describe your child's current health condition.
${ }_{1} \square$ Very good $\quad{ }_{2} \square$ Good $\quad{ }_{3} \square$ Normal ${ }_{4} \square$ Bad
Very bad
Q2. Please enter your child's current height and weight.
Example : Height 89.9 cm , weight 12.6 kg (enter values right justified)

$$
\text { Height } 1: 1: 6.6 \mathrm{~cm} \text { Weight } \quad 2: 1.3 \mathrm{~kg}
$$



Q3. Is your child currently receiving treatment for (a) disease(s), etc.?
No Yes

If so, please check $\checkmark$ in the corresponding boxes $\square$.


Q4. Has your child been hospitalized due to an illness within this year?
No $\qquad$
If so, please check $\checkmark$ in the corresponding boxes $\square$.
Asthma (Infantile Asthmahronchial asthma) $\square$ Pneumonia (acute/bronchial pneumonia) Mycoplasma pneumoniaRespiratory syncytial virus infection (Respiratory syncytial virus pneumonia) ${ }_{5}$Common coldBronchitis (Acute bronchitis)InfluenzaGastroenteritis (acute
gastroenteritis)Rotavirus infection
${ }_{10} \square$ Febrile convulsion ${ }^{11} \square$ Kawasaki disease
hernia (hernia)
${ }_{13} \square$ Other (Specific diseases) $\square$
Q5. Below are questions regarding your child's sleeping habits.

1) When does your child regularly sleep or wake up?

$$
\left(\begin{array}{lllll}
\text { Enter right justified based on } & \text { 24-hour clock. } \\
(\mathrm{Ex}) 7: 10 \mathrm{PM} \rightarrow & 1: 9 & \square & 7: 10 \mathrm{AM} \rightarrow & \boxed{7} \\
\hline 10
\end{array}\right)
$$


2) Does your child take naps?No
$\square$ Yes
$\longrightarrow$ About $\quad \begin{aligned} & \text { h } \\ & \square\end{aligned}$


Q6. Below are questions for guardians who have a child aged 2 years or younger. How much does your child exercise? (Running around indoors, kicking balls, riding tricycles, etc.)
${ }_{\square}$ Almost every day ${ }_{\square} \square$ Around 2-4 times per week
${ }_{3} \square$ Once a week $\quad{ }_{4} \square$ Almost never

Q7. Please check $\checkmark$ in the corresponding boxes $\square$ below regarding your child's diet during the past month.

1) Does your child eat fast compared to others? $\cdots \cdots \cdots{ }_{1}$ Fast $\quad{ }_{2} \square$ Normal $\quad{ }_{3} \square$ Slow
2) Does your child drink beverages containing sugar (juice, soft drinks) every day? $\cdots$.. Yes $\quad \square$ No
3) Does your child eat seafood 3 days or more per week?Yes No
4) Does your child eat food such as vegetables other than pickles, seaweed or mushrooms almost every day? $\cdots \cdots{ }_{1} \square$ Yes ${ }_{2} \square$ No
5) Does your child eat fruits almost every day? $\qquad$
YesNo
6) Does your child eat soy products (Tofu, deep fried tofu, natto, boiled beans, etc.) almost every day? $\cdot{ }_{1} \square$ Yes ${ }_{2} \square$ No
7) Does your child eat dairy products (milk, yogurt, etc.) almost every day?
${ }_{1} \square$ Yes ${ }_{2} \square$ No
8) Does your child eat pre-cooked food such as side dishes and boxed meal (including instant

$$
\text { food) almost every day? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . } \quad{ }_{1} \square \text { Yes } \quad{ }_{2} \square \text { No }
$$

9) Does your child eat out (including fast food) almost every day?YesNo

## Q8. For each question item below, please check the box "Does not apply",

 "Somewhat applies" or "Applies" (Ex: $\begin{aligned} & \text { ). Even if you are unsure of your answer, }\end{aligned}$ or if you think the question is absurd, please make sure to answer all questions.1) Please describe your child's behavior in the past 6 months.

|  |  | Does not <br> apply | Some- <br> what <br> applies | Applies |
| :--- | :--- | :---: | :---: | :---: |
| 1 | My child is often considerate towards feelings of others. | $\square$ | $\square$ | $\square$ |
| 2 | My child is restless and can't stay put for a long period of time. | $\square$ | $\square$ | $\square$ |
| 3 | My child often complains of headaches, stomachaches and feeling | $\square$ | $\square$ | $\square$ |
|  | sick. |  |  |  |
| 4 | My child often shares things (snacks, toys, pencils, etc.) with other | $\square$ | $\square$ | $\square$ |
|  | children. |  |  |  |
| 5 | My child often gets angry or loses his/her temper. | $\square$ | $\square$ | $\square$ |
| 6 | My child likes being alone and often plays alone. | $\square$ | $\square$ | $\square$ |
| 7 | My child is obedient and usually listens to adults. | $\square$ | $\square$ | $\square$ |
| 8 | My child has many concerns and always seems nervous. | $\square$ | $\square$ | $\square$ |
| 9 | My child proactively helps others if somebody is hurt, depressed | $\square$ | $\square$ | $\square$ |
|  | or harassed. | $\square$ | $\square$ | $\square$ |
| 10 | My child is always restless and fidgets often. | $\square$ | $\square$ | $\square$ |
| 11 | My child has at least one close friend. | $\square$ | $\square$ | $\square$ |
| 12 | My child has fights with or bullies other children often. | $\square$ | $\square$ | $\square$ |
| 13 | My child often feels down or has tears in his/her eyes. | $\square$ | $\square$ | $\square$ |
| 14 | My child is mostly liked by other children. | $\square$ | $\square$ | $\square$ |
| 15 | My child has difficulty paying attention and cannot focus on one | $\square$ | $\square$ | $\square$ |
|  | thing. | $\square$ | $\square$ | $\square$ |
| 16 | My child easily loses confidence, gets nervous, and hangs on my | $\square$ | $\square$ |  |

17 My child is kind to younger children.
18 My child often covers up the truth or lies.
19 My child has been bullied or made fun of by other children.
20 My child often helps others (parents, teachers, other children, etc.) proactively.
21 My child thinks thoroughly before taking action.
22 My child often steals from home, school, and others.
23 My child seems more comfortable with adults than spending time with other children.
24 My child is a coward and gets scared easily.
2) Overall, do you think your child has any issues in one or more of the following areas: emotions, paying attention, behaviors or relationships with others?No ${ }_{2} \square$ Yes (small issues)
${ }_{3} \square$ Yes (clear issues)Yes (serious issues)

3) Below are questions for guardians who responded "yes" above. Does your child worry or become upset about these issues?
${ }_{1} \square$ Not at all $\quad{ }_{2} \square$ Just a little $\quad{ }_{3} \square$ Very $\quad{ }_{4} \square$ Greatly

Q9. Does your child ever refuse to go to nursery school or kindergarten?
${ }_{1} \square$ Yes $\quad{ }_{2} \square$ No
${ }_{3} \square$ My child is currently not enrolled in nursery school or kindergarten.
※ If you have any concerns regarding your child's health or comments regarding this survey, please describe them below.
Your comments will be used for references for future health management and surveys.


That is it for the questions.
Please enclose the questionnaire in a return envelope and sent it by mail.
Thank you for your cooperation.

Oxclusively for the Mental Health and Lifestyle Survey Radiation Medical Science Center，Fukushima Medical University
Phone number：024－549－5170
（9：00－17： 00 with the exception of Dec 29－Jan 3 and weekends／holidays）

# Fukushima Health Management Survey Mental Health and Lifestyle Survey 

## Questionnaire (For elementary school students)

```
〒963-0000
    Room 302, Idai Apartment
    1, Hikarigaoka, Fukushima city
    Taro Idai
    00XOX0X
```

Enter the required items in the fields below. Please check $\checkmark$ in corresponding boxesa.

Date of entry : MM/DD/2016

| Child's name : | Sex: ${ }_{1} \square \mathrm{M} \quad{ }_{2} \square \mathrm{~F}$ |
| :--- | :--- |
| Child's DOB : MM/DD/YYYY |  |



Fukushima Prefecture, Fukushima Medical University

Please check $\checkmark$ in the corresponding small boxes $\square$ below.
Q1. Describe your child's current health condition.

1. Very good
${ }_{2} \square$ Good
Dormal
Bad

Very bad
Q2. Please enter your child's current height and weight.
Example : Height 145.0 cm , weight 38.0 kg (enter values right justified)


Q3. Is your child currently receiving treatment for (a) disease(s), etc.?
${ }_{1} \square$ No $\quad{ }_{2}$ Yes
If so, please check $\checkmark$ in the corresponding boxes $\square$.

|  |  |
| :---: | :---: |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

Q4. Has your child been hospitalized due to an illness within this year?

If so, please check $\checkmark$ in the corresponding boxes $\square$.


Q5. When does your child regularly go to sleep and wake up?


Bedtime

$\min$

Q6. How much does your child exercise regularly aside from physical education classes (club activities, sport-related lessons, etc.)?

Almost every day ${ }_{2} \square$ Around 2-4 times per weekOnce a week ${ }_{4} \square$ Almost never

Q7. Please check $\checkmark$ in the corresponding boxes $\square$ below regarding your child's diet during the past month.

1) Does your child eat fast compared to others? $\cdots \ldots \ldots{ }_{1 \square} \square$ Fast $\quad{ }_{2} \square$ Normal $\quad{ }_{3} \square$ Slow

2) Does your child drink beverages containing sugar (juice, soft drinks) every day? ....
${ }_{1}$ Yes $\quad \square$ No
3) Does your child eat seafood 3 days or more per week? $\ldots \ldots \ldots \ldots \omega_{1} \square$ Yes $\quad \square$ No
4) Does your child eat food such as vegetables other than pickles, seaweed or mushrooms almost every day? $\cdots{ }_{\square} \square$ Yes $\quad{ }_{2} \square$ No
5) Does your child eat fruits almost every day?

Yes ${ }_{2} \square$ No
7) Does your child eat soy products (Tofu, deep fried tofu, natto, boiled beans, etc.) almost every day? $\cdot{ }_{1} \square$ Yes ${ }_{2} \square$ No
8) Does your child eat dairy products (milk, yogurt, etc.) almost every day?Yes $\quad \square$ No
9) Does your child eat pre-cooked food such as side dishes and boxed meal (including instant

10) Does your child eat out (including fast food) almost every day?

## Q8. For each question item below, please check the box "Does not apply", "Somewhat applies" or "Applies" (Ex: $\boxtimes$ ). Even if you are unsure of your answer, or if you think the question is absurd, please make sure to answer all questions.

1) Please describe your child's behavior in the past 6 months.

|  |  | Not apply | Some- <br> what <br> applies | Applies |
| :--- | :--- | :---: | :---: | :---: |
| 1 | My child is often considerate towards feelings of others. | $\square$ | $\square$ | $\square$ |
| 2 | My child is restless and can't stay put for a long period of time. | $\square$ | $\square$ | $\square$ |
| 3 | My child often complains of headaches, stomachaches and feeling | $\square$ | $\square$ | $\square$ |
|  | sick. |  |  |  |
| 4 | My child often shares things (snacks, toys, pencils, etc.) with other | $\square$ | $\square$ | $\square$ |
| $\quad$ children. |  |  |  |  |
| 5 | My child often gets angry or loses his/her temper. | $\square$ | $\square$ | $\square$ |
| 6 | My child likes being alone and often plays alone. | $\square$ | $\square$ | $\square$ |
| 7 | My child is obedient and usually listens to adults. | $\square$ | $\square$ | $\square$ |
| 8 | My child has many concerns and always seems nervous. | $\square$ | $\square$ | $\square$ |

9 My child proactively helps others if somebody is hurt, depressed or harassed.
10 My child is always restless and fidgets often.
11 My child has at least one close friend.
12 My child has fights with or bullies other children often.
13 My child often feels down or has tears in his/her eyes.
14 My child is mostly liked by other children.
15 My child has difficulty paying attention and cannot focus on one thing.

16 My child easily loses confidence, gets nervous, and hangs on my arm when he or she is confronted with a new situation.
17 My child is kind to younger children.
18 My child often covers up the truth or lies.
19 My child has been bullied or made fun of by other children.
20 My child often helps others (parents, teachers, other children, etc.) proactively.
21 My child thinks thoroughly before taking action.
22 My child often steals from home, school, and others.
23 My child seems more comfortable with adults than spending time with other children.
24 My child is a coward and gets scared easily.
2) Overall, do you think your child has any issues in one or more of the following areas: emotions, paying attention, behaviors or relationships with others?No ${ }_{2} \square$ Yes (small issues)Yes (clear issues)Yes (serious issues)
 become upset about these issues?Not at allJust a littleVery ${ }_{4} \square$ Greatly

Q9. Does your child ever refuse to go to school?YesNo
※ If you have any concerns regarding your child's health or comments regarding this survey, please describe them below. Your comments will be used for references for future health management and surveys.
$\int$

That is it for the questions.
Please enclose the questionnaire in a return envelope and send it by mail.

Thank you for your cooperation.

〔Contact〕
○ Exclusively for the Mental Health and Lifestyle Survey

Future
From
Fukushima．
ふくしまから はじめよう。 Radiation Medical Science Center，Fukushima Medical University

Phone number：024－549－5170 （9：00－17：00 with the exception of Dec 29－Jan 3 and weekends／holidays）

# Fukushima Health Management Survey 

 Mental Health and Lifestyle Survey Questionnaire (For middle school students)

Please check $\checkmark$ in the corresponding small boxes $\square$ below.

For questions 1-5, please have your child answer in person.
Respondent : $\square$ Self $\quad{ }_{2} \square$ On behalf(Relationship___

Q1. How is your current health condition?
Very good ${ }_{2} \square$ Good

Normal Bad
${ }_{5} \square$ Very bad

Q2. Please enter your current height and weight.
Example : Height 159.6 cm , weight 54.2 kg (enter values right justified)


Q3. Below are questions regarding your sleeping habits.

1) What are your usual average hours of sleep (including naps) per day?

Around $\square$ h $\square$
2) Do you think your daily hours of sleep are sufficient?SufficientNot quite sufficientNot sufficient

Q4. How much do you exercise aside from physical education classes?
(Including club activities, sport-related lessons, etc.)Almost every day ${ }_{2} \square 2-4$ times per weekOnce a weekAlmost never

Q5. Check $\checkmark$ in the boxes $\square$ below that correspond to your diet during the past month.

1) Do you eat fast compared to others? $\cdots \cdots \cdots \quad \square$ Fast $\quad{ }_{2} \square$ Normal $\quad{ }_{3} \square$ Slow

2) Do you go to sleep within $1-2$ hours after dinner? $\cdots \cdots \cdots \cdots{ }_{1} \quad$ Yes $\quad{ }_{2} \square$ No
3) Do you drink beverages that contain sugar (coffee, juice, soft drinks) almost every day?
${ }_{1} \square$ Yes $\quad{ }_{2}$ No
5)) Do you eat seafood 3 days or more per week? Yes $\quad{ }_{2}$ No
4) Do you eat foods such as vegetables other than pickles, seaweed, and mushrooms? $\cdots \cdots{ }_{\square} \square$ Yes $\quad \square$ No
5) Do you eat fruits almost every day? $\ldots \ldots \ldots \ldots \ldots \ldots \ldots \ldots{ }_{\square}$ Yes $\quad{ }_{2} \square$ No
6) Do you eat soy products (Tofu, deep fried tofu, natto, boiled beans, etc.) almost every day?.- ${ }_{1} \square$ Yes ${ }_{2} \square$ No
7) Do you eat dairy products (milk, yogurt, etc.) almost every day? $\cdots \cdots \omega_{1} \square$ Yes ${ }_{2} \square$ No
8) Do you eat pre-cooked food such as side dishes and boxed meal (including instant food) almost every day?
$\qquad$
9) Do you eat out (including fast food) almost every day? YesNo
※ If you have any concerns regarding your health or comments regarding this survey, please describe them below. Your comments will be used for references for future health management and surveys.

That is it for the questions to you. Please give this questionnaire to your guardian. Thank you for your cooperation.

For the questions below, the guardian must respond on the child's behalf.

Q6. Is your child currently receiving treatment for (a) disease(s), etc.?


Q7. Has your child been hospitalized due to an illness within this year?
No Yes
If so, please check $\checkmark$ in the corresponding boxes $\square$.
Asthma (Infartile Astmalburchial astma) $\quad{ }_{2} \square$ Pneumonia (acute/bronchial pneumonia) $\square$ Mycoplasma pneumonia


Q8. For each question item below, please check the box "Does not apply", "Somewhat applies" or "Applies" (Ex: $\nabla$ ). Even if you are unsure of your answer, or if you think the question is absurd, please make sure to answer all questions.

1) Please describe your child's behavior in the past 6 months.

|  | Does not apply | Somewhat applies | Applies |
| :---: | :---: | :---: | :---: |
| 1 My child is often considerate towards feelings of others. | $\square$ | $\square$ | $\square$ |
| 2 My child is restless and can't stay put for a long period of time. | $\square$ | $\square$ | $\square$ |
| 3 My child often complains of headaches, stomachaches and feeling sick. | $\square$ | $\square$ | $\square$ |
| 4 My child often shares things (snacks, toys, pencils, etc.) with other children. | $\square$ | $\square$ | $\square$ |
| 5 My child often gets angry or loses his/her temper. | $\square$ | $\square$ | $\square$ |
| 6 My child likes being alone and often plays alone. | $\square$ | $\square$ | $\square$ |
| 7 My child is obedient and usually listens to adults. | $\square$ | $\square$ | $\square$ |
| 8 My child has many concerns and always seems nervous. | $\square$ | $\square$ | $\square$ |
| 9 My child proactively helps others if somebody is hurt, depressed or harassed. | $\square$ | $\square$ | $\square$ |
| 10 My child is always restless and fidgets often. | $\square$ | $\square$ | $\square$ |
| 11 My child has at least one close friend. | $\square$ | $\square$ | $\square$ |
| 12 My child has fights with or bullies other children often. | $\square$ | $\square$ | $\square$ |
| 13 My child often feels down or has tears in his/her eyes. | $\square$ | $\square$ | $\square$ |
| 14 My child is mostly liked by other children. | $\square$ | $\square$ | $\square$ |
| 15 My child has difficulty paying attention and cannot focus on one thing. | $\square$ | $\square$ | $\square$ |
| 16 My child easily loses confidence, gets nervous, and hangs on my arm when he or she is confronted with a new situation. | $\square$ | $\square$ | $\square$ |

17 My child is kind to younger children.
18 My child often covers up the truth or lies.
19 My child has been bullied or made fun of by other children.
20 My child often helps others (parents, teachers, other children, etc.) proactively.
21 My child thinks thoroughly before taking action.
22 My child often steals from home, school, and others.
23 My child seems more comfortable with adults than spending time with other children.
24 My child is a coward and gets scared easily.
25 My child finishes tasks to the end and has good focus.
2) Overall, do you think your child has any issues in one or more of the following areas: emotions, paying attention, behaviors or relationships with others?

3) Below are questions for guardians who responded "yes" above. Does your child worry or become upset about these issues?
${ }_{1} \square$ Not at all $\quad{ }_{2} \square$ Just a little $\quad{ }_{3} \square$ Very $\quad{ }_{4} \square$ Greatly

Q9. Does your child ever refuse to go to school?YesNo
※ If you have any concerns regarding your child's health or comments regarding this survey, please describe them below.
Your comments will be used for references for future health management and surveys.

That is it for the questions. Please enclose the survey in a return envelope and send it by mail.
Thank you for your cooperation.
$\square$

〔Contact〕
O Exclusively for the Mental Health and Lifestyle Survey

Future
From
Fukushima．
ふくしまから はじめよう。

Radiation Medical Science Center，Fukushima Medical University

Phone number：024－549－5170
（9：00－17： 00 with the exception of Dec 29－Jan 3 and weekends／holidays）

# Fukushima Health Management Survey Mental Health and Lifestyle Survey Questionnaire (For the general public) 

## 〒 963-0000

Room 302, Idai Apartment
1, Hikarigaoka, Fukushima city

## Taro Idai

00x0x0x

Enter the required items in the fields below. Please check $\checkmark$ in corresponding boxesa.


## Fukushima Prefecture, Fukushima Medical University

Please check $\checkmark$ in the corresponding small boxes $\square$ below.

Q1. How is your current health condition?Very good
${ }_{2} \square$ Good
$\square$ Normal
${ }_{4} \square$ BadVery bad
Q2. Please enter your current height and weight.
Example : Height $171,7 \mathrm{~cm}$ Weight 70.0 kg
Height $1,7,1.7 \mathrm{~cm}$ Weight:7:0 0 kg

1) Please enter your current height and weight.


Height
cm
Weight
kg (Right justified)
2) Has there been any changes in your body weight compared to one year ago?
${ }_{1} \square$ Increased by 3 kg or more ${ }_{2} \square$ Almost no change (within $\pm 3 \mathrm{~kg}$ ) ${ }_{3} \square$ Decreased by 3 kg or more

Q3. Have you been diagnosed with any of the diseases below within the past year?

1) High blood pressure

2) Diabetes (high blood-sugar level)No ${ }_{2} \square$ Yes
Are you currently attending a hospital as outpatient? $\square$ YesNo
3) Hyperlipidaemia (or has high chölësteroll "or high' nëutral " fät)No ${ }_{2} \square$ Yes
Are you currently attending a hospital as outpatient? $\square$ Yes $\square$ No
4) Mental disorder (diagnosed by a doctor (Ex: depression, sleep disorder, panic disorder, schizophrenia))

5) Cancer (including leukemia and lymphoma)

6) Stroke

No
Yes
7) Fracture
No
Yes
8) Thyroid disease
${ }_{1} \square$ No ${ }_{2} \square$ Yes


Q4. Below are questions regarding your sleeping habits.

1) What are your usual average hours of sleep per day? (including naps)
 h

2) Are you satisfied with your quality of sleep (regardless of the length) during the past month?
YesNot quiteNo
Not at all, I didn't get any sleep
3) Have you experienced the items below at least 3 times a week?

|  | Yes |  |  |  | No |
| :---: | :--- | :---: | :---: | :---: | :---: |
| 1 | It takes time for me to fall asleep, even after I'm in bed | ${ }_{1} \square$ | ${ }_{2} \square$ |  |  |
| 2 | I wake up during the night in the middle of sleep | ${ }_{1} \square$ | ${ }_{2} \square$ |  |  |
| 3 | I wake up before the time I set and can't go back to <br> sleep. | ${ }_{1} \square$ | ${ }_{2} \square$ |  |  |
| 4 | I don't get enough total sleep. | ${ }_{1} \square$ | ${ }_{2} \square$ |  |  |
| 5 | I feel depressed during the day. | ${ }_{1} \square$ | ${ }_{2} \square$ |  |  |
| 6 | My daily physical and mental activity levels are low. | ${ }_{1} \square$ | ${ }_{2} \square$ |  |  |
| 7 | I feel sleepy during the day. | ${ }_{1} \square$ | ${ }_{2} \square$ |  |  |

Q5. Do you exercise regularly?
${ }_{1} \square$ Almost every day $\quad{ }_{2} \square 2-4$ times per week
Once a week ${ }_{4} \square$ Almost never
※ Questions 6 and 7 target adults only.
If you are a minor, proceed to Q8.
Q6. Do you smoke tobacco (cigarettes)? These do not include cigars or pipes.


For individuals who smoke:
Tell us the number of tobacco/cigarettes you regularly smoke.
※I smoke around per day.

Q7. The questions below are regarding alcohol.

1) Do you currently drink alcohol?

2) How often do you drink alcohol?

Around days per week
3) Please tell us your alcohol intake per day.

※Reference Japanese sake 1 go ( 0.18 liters) conversion chart

| Beer/Sparkling liquor <br> 1 middle bottle | About | 500 |
| :--- | :--- | ---: |
| 5 Shochu highballs |  | 500 |
| can |  | ml |
| $25 \%$ shochu | 1 cup | 100 |
|  |  | ml |
| Whisky | 2 singles | 60 ml |
| Wine | 2 glasses | 240 |
|  |  | ml |

4) The questions below are regarding your past 30 days.

|  |  | No | Yes |
| :---: | :--- | :---: | :---: |
| 1 | Have you ever felt you should cut down on your drinking? | $1 \square$ | ${ }_{2} \square$ |
| 2 | Have people annoyed you by criticizing your drinking? | $1 \square$ | ${ }_{2} \square$ |
| 3 | Have you ever felt bad or guilty about your drinking? | $1 \square$ | ${ }_{2} \square$ |
| 4 | Have you ever had a drink first thing in the morning to steady your <br> nerves or to get rid of a hangover (eye-opener)? | $1 \square$ | ${ }_{2} \square$ |

Q8. How frequently have you lost your appetite during the past two weeks?
Never ${ }_{2} \square$ Several days $\quad{ }_{3} \square$ At least half of the time $\quad{ }_{4} \square$ Almost every day

Q9. Check $\sqrt{ }$ in the boxes $\square$ below that correspond to your dietary habits during the past month.

1) Do you eat fast compared to others? $\cdots \cdots \cdots{ }_{1} \square$ Fast ${ }_{2} \square$ Normal ${ }_{3} \square$ Slow
2) Do you skip breakfast often?...................................... ${ }_{1} \square$ Yes ${ }_{2} \square$ No
3) Do you eat snacks during the day or night almost every day? $\cdots \cdots \cdots \cdots{ }_{1} \square$ Yes $\quad{ }_{2} \square$ No
4) Do you eat within 2 hours of bedtime 3 or more days per week?Yes
5) Do you eat pre-cooked food such as side dishes and boxed meals (including instant food) almost every day? ${ }_{1} \square$ Yes ${ }_{2} \square$ No

Q10. For the past 30 days, how often did you experience the items below?
Please circle the corresponding numbers.

|  |  | Never | A little | Some- <br> times | Most <br> of the <br> time | Always |
| :--- | :--- | :---: | :---: | :---: | :---: | :---: |
| 1 | How often did you feel nervous? | 0 | 1 | 2 | 3 | 4 |
| 2 | How often did you feel hopeless? | 0 | 1 | 2 | 3 | 4 |
| 3 | How often did you feel restless or fidgety? | 0 | 1 | 2 | 3 | 4 |
| 4 | How often did you feel so depressed that <br> nothing could cheer you up? | 0 | 1 | 2 | 3 | 4 |
| 5 | How often did you feel that everything was <br> an effort? | 0 | 1 | 2 | 3 | 4 |


| 6 | How often did you feel worthless? | 0 | 1 | 2 | 3 | 4 |
| :---: | :--- | :--- | :--- | :--- | :--- | :--- |
| 7 | Due to such conditions, have you even <br> experienced inconveniences in your daily <br> life? | 0 | 1 | 2 | 3 | 4 |

Q11. Below are questions regarding your daily living conditions.

1) Are you currently living away from your family because of the earthquake disaster?Yes

2) Please indicate the number of people you are currently living with (including yourself).

Before the earthquake disaster ( ) At present ( )
3) Where do you currently live? Check $\sqrt{ }$ in the corresponding boxes below.
${ }_{1} \square$ Municipally subsidized rental housing $\quad{ }_{2} \square$ Temporary housing $\quad{ }_{3} \square$ Restoration public housing ${ }_{4} \square$ Rented house/Apartment $\quad{ }_{5} \square$ Relative's house ${ }_{6} \square$ Owned house $\quad{ }_{7} \square$ Other (
4) Please tell us your current working hours.

## Full-time/self-employed <br> Part-time <br> Unemployed (Including students

 and housewives)5) How do you feel about your current living condition economically?Tough ${ }_{2} \square$ Slightly toughNormal Slightly comfortable Comfortable
6) Were you (or your spouse) pregnant before the earthquake disaster? Also, were you living together with your child who is underage? (Multiple answers possible)
NoYes
$\square$ I (or my spouse) was pregnant.
I was living with my pre-school or younger child. I was living with my elementary school child. I was living with my middle school child.
I was living with my underage child who has at least graduated from middle school.
7) Are you (or your spouse) currently pregnant? Or are you currently living with your child who is underage? (Multiple answers possible)
1 路 1 I am (or my spouse) is currently pregnant. I live with my preschool or younger child. I live with my elementary school child. I live with my middle school child. I live with my underage child who has at least graduated from middle school.

Q12. Below are questions regarding radiation.
In a disaster caused by something we cannot sense such as ionizing radiation, perceptions of health risk are considered to have an impact on one's mental health.

1) Below are questions regarding your awareness or opinion on the health effects of radiation.

Please circle the corresponding number.

|  |  | The <br> possibilities <br> are very low |  | The <br> possibilities <br> are very <br> high |  |
| :--- | :--- | :---: | :---: | :---: | :---: |
| 1 | How much health disorders (For example, <br> cancer, etc.) do you expect to occur in the future <br> due to the current radiation exposure? | 1 | 2 | 3 | 4 |
|  | How much health effects do you think the <br> current radiation exposure will have on the <br> future generations (your future children or <br> grandchildren)? | 1 | 2 | 3 | 4 |

2) For the past month, how frequently did you experience inconveniences in your daily life due to your anxieties about radiation?

Frequently ${ }_{2} \square$ Sometimes $\quad{ }_{3} \square$ Rarely ${ }_{4} \square$ Never

Q13. Do you know anyone or any organization that you can consult regarding mental or physical issues that were caused by the Great East Japan Earthquake?
$\square$ No

If you do, check $\checkmark$ for all corresponding items below.Family/relatives
${ }_{2} \square$ Friends/acquaintances
${ }_{3} \square$ Colleagues/superiors
${ }_{4} \square$ Municipal consultation service (City public health bureau, health center, etc.)Prefectural consultation service (Prefectural public health bureau/public health and welfare office, etc.)Mental health and welfare centerFukushima Kokoro no Care Center (Fukushima mental care center)Visiting care/nursing care service organizationsMedical institutions such as psychosomatic medicine/psychiatry/neurology/mental clinicsMedical institutions other than the above (general internal medicine, surgical department, ophthalmology, otorhinology, orthopedics, obstetrics and gynecology, etc.Facilities related to religion such as temples, shrines, churches, etc.Other (
※ If you have any concerns regarding your health or comments regarding this survey，please describe them below．Your comments will be used for references for future health management and surveys．

$[$
That is it for the questions．Please enclose the survey in a return envelope and send it by mail．Thank you for your cooperation．

〔Contact〕
－Exclusively for the Mental Health and Lifestyle Survey
Radiation Medical Science Center，
Fukushima Medical University
Phone number：024－549－5170
（9：00－17：00 with the exception of Dec 29－Jan 3 and weekends／holidays）


[^0]:    Including Yamakiya of Kawamata, Namie and litate.

[^1]:    Percentages have been rounded and may not total to $100 \%$.

[^2]:    * See Appendix 6 for details.

[^3]:    Estimates are based on effective external radiation doses.

[^4]:    h) Excluding participants who have not receive the test results.

